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ABSTRACT 
 
Molecular genetics has transformed our understanding of disease and is 
gradually changing the way medicine is practiced. Genetic mapping provides a 
powerful approach to discover genes and biological processes underlying 
human disorders. Recent advances in DNA microarray and sequencing 
technology have significantly increased the power of genetic mapping studies 
and have ushered in a new era for biomedicine. In this thesis, linkage analysis 
(including homozygosity mapping), exome sequencing and candidate gene 
sequencing have been utilised to genetically dissect autosomal recessive 
retinal disease. Subsequently, clinical findings from patients found to be 
similar in terms of molecular pathology have been pooled. DNA and basic 
phenotypic data from over 500 unrelated individuals were available for the 
project. Disease-causing variants in three genes that have not been previously 
associated with human recessive disorders are reported: (a) biallelic mutations 
in TRPM1 abrogate ON bipolar cell function and cause complete congenital 
stationary night blindness; (b) biallelic mutations in KCNJ13, a gene encoding 
an inwardly rectifying potassium channel subunit cause Leber congenital 
amaurosis; (c) biallelic mutations in PLA2G5, a gene encoding group V 
phospholipase A2, cause benign fleck retina. The consequences of mutations 
in these and other disease-related genes (RDH5, GRM6, KCNV2, OAT and 
SAG) on retinal structure (spectral domain optical coherence tomography, 
fundus autofluorescence imaging) and visual function (electrophysiology, 
perimetry testing) have been studied; features that may have mechanistic 
relevance have been identified. Additionally, DNA sequence variation of a 
highly polymorphic gene (C2ORF71), recently associated with photoreceptor 
degeneration, has been studied and quantified in patient and control samples. 
Basic bioinformatics tools to analyse genomic data have been developed 
(bash, perl, python and R programming languages). Overall, results presented 
in this thesis contribute to an understanding of Mendelian retinal disease that 
is not only observational but also mechanistic. 
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1 INTRODUCTION  
 
1.1 Genetics 
 
1.1.1 A Brief History of Genes and Linkage  
 
1.1.1.1 Chromosomes carry genes 
 
The term “gene” along with the terms “genotype” and “phenotype”, were 
introduced by the Danish plant physiologist and geneticist Wilhelm Johannsen 
in 1909 [1-2]. Johannsen was born in Copenhagen in 1857, two years before 
the publication of the Origin of Species and a decade before The Variation of 
Animals and Plants under Domestication, Darwin’s first attempt to explain 
heredity. In the concluding remarks of this book, Darwin proposed that 
organisms throw off tiny particles which he called gemmules introducing his 
theory of pangenesis [3]. Meanwhile, in St Thomas's Abbey in Brno, Gregor 
Mendel has started cultivating and testing pea plants (Pisum sativum) [4]. 
Mendel published the results of his over 10-year long experiment in 1866, 
implicating the existence of genes and laying the foundation of genetics [5], a 
discipline to be baptised 40 years later in a personal letter dated April 18, 1905 
by the British geneticist William Bateson [6-7]. 
 
Despite the fact that Darwin had put heredity at the heart of his theory of 
evolution, Mendel’s work had little impact and was referenced only four times 
before 1900 [2]. The birth of classical modern genetics is usually dated at 
1900 when Hugo de Vries in Holland [8-9], Erich von Tschermak in Austria 
[10] and Carl Correns in Germany [11] rediscovered the laws of heredity. De 
Vries also coined the term “mutation” as the driving force of evolution [12-13] 
and the term “pangens” as "the smallest particles, of which each represents 
one hereditary characteristic” [14]. This term was abbreviated to “genes” two 
decades later in Wilhelm Johannsen’s book Elemente der exakten 
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Erblichkeitslehre [1]. In the same book a conceptual distinction between 
genotype and phenotype, the foundation stones of genetics, is drawn and the 
basic principles of the statistical analysis, which is essential to render genetics 
an exact and quantitative science, are laid out [15-16]. 
 
At around the same time, 
Thomas Morgan, an American 
embryologist, turned from 
Mendel's plants to the study of 
animals, particularly the fruit fly 
(Drosophila melanogaster), soon 
to become a major model 
organism in genetics. The initial 
purpose of his study was to find 
an occasional fly that had 
undergone a “mutation” (defined 
as a sudden change in body 
form) [18]. This phenomenon 
had been previously described 
in plants by de Vries [12]. In 
1910, after two years of 
breeding, a spontaneous 
mutation occurred with Morgan 
noticing a white-eyed mutant 
male among the red-eyed wild-
types and naming the mutated 
gene "white”. Further 
experiments and observations proved that each character resides on a 
particular chromosome with “white” being carried with the sex chromosome 
[19-20]. This findings confirmed and elaborated the, independently developed 
in 1902 by Boveri [21-22] and Sutton [23], chromosomal theory of heredity with 
Morgan proposing that “each chromosome contains a collection of small units 
called genes” [24]. In the same paper and in more detail in his seminal book 
The Mechanism of Mendelian Heredity [25], after the study of over a hundred 
 
Figure 1-1. Genetic map published in 1921 from 
Morgan’s laboratory showing the distribution of 
mutant loci in the four chromosomes of Drosophila 
melanogaster [17]. 
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mutant Drosophila characters and their interactions, Morgan and his 
colleagues inferred the process of chromosome recombination and 
hypothesised the phenomenon of crossing over, soon to be elaborated in a 
thesis by Muller [26]. They proposed that the frequency of a recombination 
event between two genes is associated with their distance on the 
chromosome. This led Alfred Sturtevant, Morgan's student, to develop the first 
genetic maps [27-28]. Haldane, in 1919 introduced the centiMorgan as a unit 
for measuring the distance between genes on a chromosome [29]. 
 
Fifty years after Mendel's discovery, the abstract idea of hypothetical factors 
was shaped into the physical reality of specific genes residing at specific 
locations along a chromosome. During the following years, by correlating 
cytological observations of chromosomes under the binocular microscope [30-
31] with breeding results, the role of genes and chromosomes in inheritance 
would be firmly established [32]. 
 
It was a matter of time until Beadle and Tatum would discover in 1941 that 
enzymes are encoded by genes, linking genetics and biochemistry [33-35] and 
Avery, MacLeod and McCarty would demonstrate in 1944 genes to be the 
chemical substance DNA, revealing it as the genetic material [36-37]. 
 
1.1.1.2 Genes can be linked 
 
Another important contribution of Morgan’s group was the expansion of the 
understanding of gene linkage, the tendency of certain characters to be 
inherited together breaking Mendel’s law of independent assortment. The term 
“linkage” in the sense that it is used today is attributed to Morgan and Lynch 
and their phrase: “the linkage of two factors in Drosophila that are not sex-
linked” [38-39]. 
 
The first report of linkage was by Correns in 1900. It was a case of complete 
linkage, without recombination, between the characters of flower colour and 
leaf type in stocks [11]. Incomplete linkage (with demonstrated recombination) 
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was first reported in 1905 by Punnett and Bateson in sweet pea for the 
characters of flower colour and grain shape with the authors concluding that: 
“‘there is, therefore, some coupling of pollen-shape and colours“ [2, 40]. In 
man, linkage was first implied in 1911 for colour-blindness gene and the X 
chromosome [41] although this “peculiar mode of inheritance had of course 
long been noted (and from 1820 sometimes called Nasse’s Law after C.F. 
Nasse who studied the inheritance pattern of haemophilia)” [39]. The first 
successful attempt to explain linkage, was by Lock in 1906, a few years before 
Morgan and Sturtevant set up their “fly room” [2, 42]. After the observation and 
explanation of linked traits, the next challenge was the quantification and 
statistical estimation of linkage (recombination fraction). According to 
Edwards, “in 1914 the first statistical estimate proper was made by Yule & 
Engledow” but “unfortunately this path-breaking paper (...) has never entered 
the linkage-estimation literature, which is commonly taken to start with 
Haldane (1919), who did not refer to it” [43]. Indeed Engledow and Yule’s 
paper introduces the method of minimum x2 and has only been referenced 
once before Edwards’ paper [44-45]. Linkage estimation literature was 
enriched with the contribution of Muller [26], Haldane [29, 46] and Fisher; 
notably, the latter introduced the method of maximum likelihood, opening a 
new era in linkage analysis [47]. 
 
By 1930, the statistical problems of recombination fraction estimation in 
experimental organisms have been solved and linkage estimation in humans, 
where mating cannot be arranged as we wish and loci are scattered across 23 
chromosomes, was the question.  
 
A major problem was that disease-disease mapping was hard or even not 
possible in humans. The development of human genetic markers provided the 
solution and made disease-marker mapping feasible. Marker genetic maps, 
prerequisite for the latter, had been constructed and evolved from the 
approximately 20 blood group markers (1910-1960) to the over 40 million 
SNPs of the NCBI dbSNP Build 135.  
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Table 1-1. Development of human linkage analysis between loci over the 20
th
 century 
y-score First analysis of linkage in human Bernstein (1931) 
Sib-Pair 
Method 
First autosomal human linkage between 
Lewis and Lutheran blood groups [48] 
Penrose (1935) 
Maximum 
Likelihood 
Method 
First ad hoc method; accurate estimate 
of recombination fraction (θ) between 
protan and haemophilia loci [49-51] 
Fisher (1922), Bell 
and Haldane (1937), 
Smith and Haldane 
(1947) 
μ-score Link between y-score and z-score Fisher (1935) 
LOD 
score  
(Z-score) 
Most efficient statistic way of evaluating 
pedigrees for linkage. Formulae for Z(θ) 
described [52] 
Morton (1955) 
Peeling 
methods 
Fast and exact calculation of LOD score 
in large pedigrees for few markers [53] 
Elston and Stewart 
(1971) 
Calculation of LOD score for 
simultaneous study of any number of loci 
provided not too large a pedigree [54] 
Lander and Green 
(1987) 
 
With the increasing availability of genetic markers and the main 
methodological and statistical problems worked out (mainly by Morton [55]; 
table 1-1) attention started to shift towards the computational challenges. In 
1958, Simpson described a computer program written for the Elliott 401 at 
Rothamsted (Harpenden, UK) [56], making the first attempt to compute 
recombination fraction (θ) using a computer (flow diagram of calculation is 
presented in figure 1-2) [49]. The Elston-Stewart algorithm, developed in 1971 
[53], is the basis for programs performing linkage analysis such as LIPED [57], 
LINKAGE [58] and VITESSE [59], while the 1987 Lander-Green algorithm is 
implemented in GENEHUNTER [60-61], ALLEGRO [62] and MERLIN [63]. 
 
Linkage analysis has had a pivotal role in the evolution of genetics. Since first 
conceived in Drosophila by Sturtevant in 1913 [28], it has been extensively 
used to elucidate biological processes underlying heritable traits. Its 
tremendous impact on human genetics is discussed in the next pages. 
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Figure 1-2. Flow diagram of calculations performed in Simpson’s first computer program for 
linkage analysis (modified from [56]). 
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1.1.1.3 Linkage analysis  
 
Genetic mapping allows localisation of genes associated with phenotypes by 
demonstrating co-segregation of the trait locus with genetic markers, without 
the need for prior hypotheses about biological function [64]. Linkage analysis, 
the simplest form of genetic mapping, uses observations of related individuals 
to map loci [65-66]. Despite having merits for the identification of genes 
underlying complex traits, it has been predominantly used to genetically 
dissect Mendelian disorders; these are characters in which a particular 
genotype is both necessary and sufficient for the disease phenotype to be 
expressed. 
 
1.1.1.3.1 Human genetic mapping of Mendelian characters 
 
Although many conditions have been considered by the medical profession 
since ancient times to be influenced by heredity, it was after the rediscovery of 
Mendel’s laws when physicians started to propose the mode of inheritance for 
human disease; this was the necessary first step in the search for the 
chromosomal location of trait loci. 
 
Recessive inheritance was initially suggested for alkaptonuria (1902) [67], 
arguably the first example of human genetic disease [68], and albinism (1903) 
[69]. In 1906, at a talk before the Neurological Society of London, Bateson 
would propose dominant inheritance in a family, originally described by 
Farabee, with bone deformity in fingers and toes as well as in two families with 
congenital cataract brought to his attention by Nettleship. In the same talk, 
Bateson would also discuss X-linked red-green colour blindness, in cases 
again by Nettleship, and haemophilia; these were the first human traits to be 
mapped to a chromosome [70]. 
 
In 1968, Donahue et al. reported the “first assignment of a specific gene locus 
to a specific autosome in man” providing evidence that “the Duffy blood group 
locus, already believed to be linked to a congenital cataract locus, is close to 
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this uncoiler element Un, and that all three are probably on chromosome no. 
1” [71]. 
 
For most of the 20th century, position-independent methods (functional cloning, 
candidate gene cloning) were employed to identify disease-associated genes 
and candidates were suggested by knowledge of the underlying biochemical 
or cell biology defect (phenylketonuria, haemophilia A, sickle cell disease). 
Nevertheless, to date, the majority of human disease-related genes have been 
detected through position-dependent methods using genetic mapping. 
 
The breakthrough in genetic mapping came in the 1980s following the 
advances in recombinant DNA technology that provided a source of 
polymorphic markers (restriction fragment length polymorphisms or RFLPs). 
The groundwork was set in a 1980 paper by Botstein et al. [72] and by 1983, 
the first disease-associated genes mapped using RFLP linkage analysis were 
reported [73-75]. In 1986, three years after the development of PCR, based on 
genetic linkage data, chromosome walking within a defined region and 
hybridization with an enriched cDNA probe, Royer-Prokora et al. have 
identified a 379-amino-acid protein as the cause of chronic granulomatous 
disease [76]. This is considered the first success for the positional cloning 
scheme of gene identification (reviewed in [77] and [78]). Over the next 
decades, this approach would play an important role in gene identification both 
in isolation (as in the case of retinoblastoma [79] and cystic fibrosis [80-82]) or, 
more often, combined with the candidate gene approach to avoid amplifying 
the full length of the interval refined by genetic mapping (as in the case of 
rhodopsin RP [83]). 
 
A quarter of a century after, studies of Mendelian disease utilising linkage 
analysis have both enhanced our understanding of the molecular pathology of 
heritable disorders and altered our perception of disease transmission [64]. 
Some important lessons have emerged including: 
(a) The candidate gene approach method of gene identification [84-85] is 
inadequate; most disease-associated genes were unsuspected on the basis of 
previous knowledge. 
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(b) Compartmentalising genetic disorders into “monogenic/Mendelian, simple 
and rare” and “multifactorial, complex and common” is an oversimplification. 
The concept of a monogenic disorder in its strict sense was inaccurate and our 
view of diseases as monogenic has often been a conceptual artefact [86-87]. 
A greater complexity was revealed (locus heterogeneity, variable expressivity, 
incomplete penetrance) and important clues to understanding common 
disease were provided [88-89]. 
(c) Linkage analysis has led to many notable successes in mapping variants 
that confer susceptibility to common diseases [65] (BRCA1 and BRCA2 genes 
with breast cancer [90-91], INS with diabetes [92], APOE with Alzheimer’s 
disease [93-94]); this was possible mainly through studying rare Mendelian 
subtypes of such disorders. Nevertheless, linkage studies have low power and 
resolution for variants of modest effect [95] and can only explain a small 
proportion of the familial clustering observed in common diseases. 
(d) A large number of Mendelian disorders remain for which no disease-
related gene has been identified. Furthermore, striking genetic heterogeneity 
has been observed in several Mendelian conditions and, for many disorders, 
mutations in previously identified disease-associated genes explain only a 
fraction of cases. Elucidation of further pathogenic loci calls for the 
development of alternative strategies and tools [89, 96]. 
 
1.1.1.3.2 Present and future of linkage analysis 
 
Over the past few years, linkage analysis has lost its predominance in favour 
of association or linkage equilibrium association mapping (comparison of 
frequencies of genetic variants among affected and unaffected individuals) 
[65]. Although genetic association analysis is based on an old idea (the 
principle was applied in 1954 to reveal correlation between blood group and 
peptic ulceration [84]), the tools for reproducible studies on a genome-wide 
basis only became available over the past decade [97]. GWA studies have 
detected a large number of genetic variants robustly associated with common 
human diseases, providing valuable insights into their genetic architecture. 
However, for any particular complex trait, the identified sequence alterations 
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explain only a fraction of total genetic variance calculated from family studies; 
this gap has been termed “missing heritability” [98-99]. The search for this 
missing heritability has recently led to a renewed interest in family-based 
methods and linkage analysis (reviewed in [65]). 
 
Despite the profound success of linkage in mapping Mendelian disease, allelic 
variants underlying fewer than half of all known or suspected Mendelian 
disorders have been discovered [100-101]; limiting factors include availability 
of families, reduced penetrance, locus heterogeneity and reduced reproductive 
fitness [102]. An alternative, more efficient, approach has emerged over the 
last few years as sequencing complete human genomes is becoming 
increasingly feasible and affordable [103]. The first demonstration of a method 
coupling targeted capture with high-throughput sequencing to genetically 
dissect Mendelian disease in 2009 [102], can be probably regarded as the 
beginning of a new era in human genetics. This powerful novel approach 
(exome sequencing, sequencing the protein coding subset of the genome; 
section 2.4.17) can both identify disease-related variants in circumstances in 
which conventional approaches would fail and provide a means for 
accelerating discovery [101]. However, a key challenge has emerged: how to 
identify disease-causing alleles among the background of nonpathogenic 
genomic variation and sequencing errors [101, 104]. The use of family-based 
filtering strategies (linkage approaches) can substantially narrow the genomic 
search space for candidate causal alleles. In this study, homozygosity 
mapping [105], a subtype of parametric linkage analysis, combined with either 
biological candidate gene or exome sequencing has been utilised to identify 
novel Mendelian retinal disease-associated genes. 
 
1.1.1.4 Genes in pedigrees and populations (quantitative genetics) 
 
Reginald Punnett was a British geneticist who created the Punnett square, a 
tool used to predict the probability of an offspring having a particular genotype. 
Moreover, he had a minor role in the formulation of an important principle of 
population genetics. In 1908, Punnett was asked at a lecture to explain why in 
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a random-mating population the dominants did not in the course of time drive 
out the recessives. Punnett could not answer the question and in turn asked 
the mathematician G.H. Hardy. Out of this conversation came the Hardy-
Weinberg law stating that gene frequencies and genotype ratios in a randomly 
breeding population remain constant from generation to generation [106-108]. 
Wilhelm Weinberg a German geneticist and physician, reached and published 
the same conclusion simultaneously [109]. 
 
During the first two decades of the 20th century a huge debate raged around 
the relevance of Mendelism to evolution. In the Stanford Encyclopedia of 
Philosophy we read that: “many of the early Mendelians did not accept 
Darwin's ‘gradualist’ account of evolution, believing instead that novel 
adaptations must arise in a single mutational step” (saltationism); conversely, 
“many of the early Darwinians did not believe in Mendelian inheritance, often 
because of the erroneous belief that it was incompatible with the process of 
evolutionary modification as described by Darwin” (biometric school) [110]. 
 
The development of population genetics in the 1920s provided the synthesis 
between those two schools of thought. In the next few decades, Ronald A 
Fisher, J.B.S. Haldane and Sewall Wright would weld Mendelism and 
Darwinism together to create what is known as the “evolutionary synthesis” 
proving that natural selection was compatible with Mendel’s laws and shifting 
the level at which evolution works from organisms and individuals (Darwinism) 
to genes, phenotypes and populations. 
 
It was R.A. Fisher, a British statistician and geneticist who in 1918 first 
interpreted biostatistic results in accordance with Mendelian inheritance [111]. 
Part of the Mendelian-Darwinian controversy was due to the belief that 
discrete inherited factors (genes) did not conform to the Darwinian concept of 
continuously varying evolution [112]. How could small variations and gradual 
selective pressure account for the vast differences observed among species? 
In Fisher’s 1918 paper the question is answered by demonstrating that if a 
continuous trait is associated with a large number of overall minimally 
contributing Mendelian factors (genes), then the trait would show an 
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approximately normal distribution in the population. In the same paper, the 
term “variance” as the square of the standard deviation, is coined for the first 
time [111]. In 1922 Fisher introduced a theoretical approach based on the 
method of maximum likelihood, an important tool for statistical estimation [47]. 
Finally, Fisher’s 1930 textbook The Genetical Theory of Natural Selection 
brought genetics together with evolution and set the foundations of population 
genetics [113]. 
 
Fisher’s analysis was confirmed and applied to real world paradigms by J.B.S. 
Haldane, a British biologist and keen experimenter, in his series of papers A 
Mathematical Theory of Natural and Artificial Selection (1924-1934).  
 
Sewall Wright, an American geneticist, conducted pioneering work in 
quantitative genetics, animal breeding and path analysis. In the 1921 series on 
Systems of Mating Wright defined inbreeding coefficient and explored the 
methods to compute it in pedigrees and populations [114-119]. This work had 
a major and lasting effect on the theory and application of genetics. 
 
 
 
Figure 1-3. History of early Mendelian genetics (modified from [120]). 
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1.1.2 Molecular Medicine: from Phenotype to Genomic Variation 
 
Understanding the relationship between genotype and phenotype is a central 
task for biology and medicine. This can be split into two main goals: 
elucidating the genetic basis of human phenotypes (disease to genes) and 
computing the Bayesian predictive power of a genotype (genes to disease). 
This thesis focused on genetic mapping, whose primary value is “not risk 
prediction but providing novel insights about mechanisms of disease” [64]. A 
prerequisite to this is the precise delineation of variants and alleles associated 
with hereditary disorders. 
 
1.1.2.1 Hereditary disease 
 
Hereditary diseases are characterised by familial aggregation, i.e. tendency of 
relatives to be more phenotypically similar than unrelated individuals. 
Importantly, familial aggregation does not a priori suggest genetic involvement 
as environmental factors may be partially or wholly explanatory [121]. 
Understanding phenotypic clustering within families is the first step in 
determining whether and to what extent a genetic aetiology exists for a 
specific trait. Trying to address this issue, Sewall Wright and R.A. Fisher 
introduced the concept of heritability, a term used to describe the proportion of 
phenotypic variance in a population that is due to genetic variation [122-123]. 
Although essentially a population parameter, heritability significantly 
determines statistical power in genetic mapping studies and holds a key role 
within the gene discovery hierarchy (figure 1-4). Once a strong correlation 
between phenotype and genotype is established (large heritability), 
subsequent segregation and DNA analysis can be undertaken to elucidate the 
underlying genetic component [121].  
 
Hereditary disorders are often viewed as either Mendelian or multifactorial. 
This traditional distinction is most of the time blurred although purely 
Mendelian traits have been identified. Despite the main genetic contribution to 
morbidity and mortality being through the genetic component of common 
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multifactorial disease, Mendelian disorders are the focus of this thesis. Five 
basic Mendelian pedigree patterns are observed: autosomal dominant, 
autosomal recessive, X-linked recessive, X-linked dominant and Y-linked. 
These patterns are subject to basic complications including nonpenetrance 
(e.g. RP [124]), pseudodominant inheritance (e.g. Stargardt disease [125]), 
variable expressivity (e.g. FEVR [126]), anticipation and uniparental isodisomy 
(e.g. LCA/RP [127]). Some atypical modes of inheritance that can be viewed 
as an expansion of Mendelian concepts include mitochondrial (e.g. Leber 
hereditary optic neuropathy [128]) and digenic (e.g. RP [129]) [130].  
 
Figure 1-4. Flowchart illustrating the role of heritability within the gene discovery framework 
[121]. 
 
This study is detailing retinal disease exhibiting known or suspected 
autosomal recessive inheritance. It is noteworthy that one to one genotype-
phenotype correspondence is the exception rather than the rule in these 
disorders. This is mainly due to three types of heterogeneity: locus 
heterogeneity (e.g. complete CSNB, sections 3.1.6 and 3.2.3), allelic 
heterogeneity (e.g. gyrate atrophy, section 3.1.7) and clinical heterogeneity 
(e.g. SAG retinopathy, section 3.1.3).  
INTRODUCTION 
 
28 
 
1.1.2.2 Human genomic variation 
 
Inherited information regarding disease risk, anthropometric characteristics 
and response to environment can be associated with several, often interacting, 
mechanisms; these include genetic, epigenetic, ecological and cultural 
inheritance as well as parental effects [131]. Despite increasing awareness 
that nongenetic information can be inherited, genetic variation is still 
considered to be responsible for nearly all the heritable aspects of human 
individuality. Human genetic variation is common (on average two copies of 
the human genome are expected to differ by 0.5% of the DNA sequence [132]) 
and occurs on many different scales, ranging from gross karyotype alterations 
to single nucleotide changes [133]. While most sequence alterations exert no 
direct effect on phenotype or gene/protein function, a subset of them has 
functional consequences (ranging from beneficial to highly deleterious). 
Consequently, an individual may carry alleles that produce no product (null), 
reduced amount or activity of product (hypomorphic), increased amount or 
activity of product (hypermorphic), a novel activity or product (neomorphic) or 
an antagonistic to the normal protein activity or product (antimorphic) [134]. 
Variants that form such alleles often cause or predispose to disease and 
pinpointing them among the background of nonpathogenic variation is the 
ultimate goal of genetic mapping.  
 
With the advent of high-throughput sequencing, whittling down a list of 
candidate variants to those that are causal became increasingly challenging, 
so that currently, the main obstacle is interpretation rather than data collection 
[104]. This interpretation challenge is in fact a multiple hypothesis testing 
problem with the prior probability of any given genetic variation being causal, 
tending to zero. A number of approaches, computational or experimental 
(summarised in [104]), can be utilised to more accurately estimate this prior 
probability. Genetic mapping can significantly contribute to this Bayesian 
predictive model (a priori or a posteriori) despite both linkage analysis and 
GWA studies often being insufficiently powered to solely delineate 
phenotypically important genetic variation.  
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In Mendelian autosomal recessive disorders, the allelic spectrum of loci tends 
to be moderately diverse [135] and disease-causing variants tend to be rare 
and highly penetrant; thus amenable to linkage analysis. However, presumed 
recessive disease in a number of phenotypes characterised by simplex cases 
could result from inheriting a de novo autosomal dominant or X-linked 
germline mutation [136] or be caused by a “total mutational load” (epistasis 
[137]) rather than straightforward autosomal recessive alleles. 
 
1.1.3 Hereditary Disease and the Eye 
 
Looking back at the century passed after the assignment of colour blindness to 
the X chromosome [41, 70, 138], the pivotal role of ophthalmology and retinal 
disease in the evolution of human genetics is omnipresent (see [139] and 
figure 1-5 for a timeline of historic discoveries). The main reason is that both 
structural defects and functional abnormalities related to the eye, the most 
important of the sense organs, have been well documented over the centuries 
from the Pre-Hippocrates and Galen to Dalton, Cuniers and Stargardt. 
Therefore, the hereditary nature of many eye conditions was brought to the 
attention of geneticists from the early days (as the above mentioned 
collaboration between Nettleship and Bateson in 1906). 
 
 
Figure 1-5. Timeline of landmarks in ophthalmic genetics (modified from [140]). 
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1.2 The Retina 
 
“If you are going to study how the brain works, it is a good idea to start with the 
simplest part.” 
Jeremy Nathans 
 
The retina is the most accessible part of the central nervous system and can 
be characterised as an outpost of the brain. It is the first level of vision and a 
major source of sensory input.  
 
The term retina comes indirectly from Greek through Latin and Arabic, to 
Medieval Latin réte, meaning net [141]. It was introduced by Galen to describe 
the mesh of blood vessels at the back of the eye. The modern retina is defined 
as the innermost layer of the eye that captures the light and converts it into a 
neural response. It is derived from the neuroectoderm (optic cup) and is 
composed of two laminar structures: an outer RPE and an inner neurosensory 
retina. The central region of highest visual acuity is known as the fovea.  
 
1.2.1 The Retinal Pigment Epithelium 
 
The RPE consists of a single layer of hexagonal melanin-containing epithelial 
cells. Like the whole retina, the RPE exhibits regional differences with its 
diameter varying from 10 to 60 μm (taller and thinner in the fovea) and its cell 
density decreasing from the fovea to the periphery [142]. Like other epithelial 
cells, the RPE is polarised. The basal end is folded and attached to a basal 
lamina that forms the inner layer of Bruch’s membrane of the choroid. The 
apical region has multiple villous processes, 5 to 7 μm long, that are 
embedded in a glycosaminoglycan matrix (interphotoreceptor matrix) and 
surround the photoreceptor outer segments. These microvilli increase the 
photoreceptor-RPE surface of contact, optimizing metabolic efficiency. 
Adjacent RPE cell membranes are firmly attached to each other in the basal 
region by the zonula adherens and in the apical region by the zonula 
occludens. These intercellular junctional complexes provide structural stability 
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and maintain a selective blood-retinal barrier. 
 
The RPE nuclei occupy the basal aspect of the cytoplasm, whereas the apical 
part and microvilli contain numerous melanin granules (figure 1-6). These 
granules, called melanosomes, are synthesised in utero and remain virtually 
unchanged thereafter [143]. This is not the case with the other main class of 
pigment found in the RPE, lipofuscin, which accumulates during life [144]. To 
prevent the toxic effects of accumulated photooxidative products, 
photoreceptor cells undergo a daily renewal process wherein ~10% of their 
volume is shed and subsequently phagocytosed by RPE cells. Lipofuscin 
granules are the products of incomplete lysosomal activity on the phagosomes 
containing phagocytosed photoreceptor outer segment debris [145]. Lipofuscin 
is a heterogeneous material containing a mixture of different compounds, 
predominantly byproducts of light-related vitamin A cycling [146]. These 
compounds contain an extended system of conjugated double bonds that 
allow the absorption of light with subsequent emission of fluorescence; 
therefore, in vivo visualization with fluorescence microscopy is enabled. The 
excitation wavelength ranges from 300 to 600 nm and the emission spectrum 
from 480 to 800 nm (maximum around 620 nm) [147]. 
 
The RPE has numerous functions. These include absorption of light energy 
focused by the lens onto the retina (reduction of scatter), bidirectional 
transport of metabolites between photoreceptors and the choriocapillaris, 
phagocytosis of shed photoreceptor membranes and uptake, storage and 
metabolism of vitamin A [148]. 
 
Many RPE expressed genes are involved in retinoid metabolism, ion transport 
or extracellular matrix maintenance and, when mutated, lead to retinal 
dystrophies. For example, mutations in the RPE genes encoding 11-cis retinol 
dehydrogenase (RDH5) and retinaldehyde-binding protein (RLPB1), both 
essential components in rhodopsin regeneration, cause autosomal recessive 
retinal disease [149-150]. Importantly, retinal disease due to mutation in the 
RPE expressed gene RPE65 has been shown to respond to gene-
replacement therapy in patients [151-153]. 
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Figure 1-6. Sensory retina and RPE. 
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1.2.2 The Neurosensory Retina 
 
The neurosensory retina is a laminated structure composed of mainly neuronal 
but also glial and vascular elements, ranging in thickness from 100 μm (ora 
serata) to 400 μm (near the optic disc). Six major neuronal cell classes that 
can be further divided into many subtypes for a total of over 60 different 
neurons are found in this highly specialised tissue. 
 
Three zones of clustered nuclei separated by two layers called the plexiform or 
synaptic layers can be seen in an unstained vertical section. 
 
Table 1-2. Major neuronal cell types in the human retina [141, 154] 
Cell classes Characteristic Cell Types Number 
Photoreceptors Rod; L-cone; M-cone; S-cone     4 
Bipolar cells Diffuse (ON-OFF); midget (ON-OFF) ; S-
cone; giant 
  13 
Horizontal cells HI; HII     2 
Ganglion cells Parasol (on-off); midget (on-off); small 
bistratified; biplexiform; photosensitive; 
projecting to the LGN 
>20 
Amacrine cells A2, AII, A8, A13, A17, A18, A19, A20, A22, 
starburst 
~30 
Interplexiform cells 
 
The neurosensory retina can be divided into an outer photoreceptive, 
glutamatergic sensory retina where phototransduction takes place and an 
inner neural retina where the first steps of visual processing are carried out. 
 
1.2.2.1 The Sensory Retina 
 
The sensory retina contains rod and cone photoreceptors, long, narrow cells 
whose names describe the shape of their free ends (figure 1-6). Each 
photoreceptor cell consists of an outer and an inner segment connected 
through a nonmotile “9+0” primary cilium (connecting cilium), a cell body 
(nucleus) and a synaptic terminal. The outer segment contains multiple 
laminated lipid bilayer discs and envelops the visual pigments responsible for 
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photon absorption. Rod outer segments are made up of a stack of discrete 
discs unattached to the ciliary plasma membrane, whereas cone outer 
segments differ by having a series of invaginations continuously connected to 
the membrane. The connecting cilium originates from the inner segment basal 
body. In addition to its structural role, it plays a critical role in molecular 
transport; it transfers disc membrane lipids and phototransduction proteins to 
the outer segment that is incapable of protein synthesis. The inner segment, in 
which the protein synthesis occurs, consists of the ellipsoid (outer part) and 
the myoid (inner part). The ellipsoid contains the basal body and mitochondria 
and the myoid the endoplasmatic reticulum, ribosomes and a Golgi apparatus. 
The myoid is continuous with the main cell body. The innermost part of the 
photoreceptor contains the synaptic terminal. The rod synaptic terminal is 
termed a spherule and is formed by a single invagination that accommodates 
two horizontal cell processes and one ON bipolar cell dendrite. The cone 
synaptic terminals, the pedicles, are located inner to the rod spherules, are 
larger and contain a number of invaginations. Each invagination contains the 
processes of two horizontal cells and the processes of two or more ON bipolar 
cells. Additionally, mainly OFF, bipolar cell processes lie near the 
invaginations. Just posteriorly to each spherule or pedicle invagination lays a 
synaptic ribbon, a structure allowing photoreceptors to sustain continuous 
release of synaptic vesicles. 
 
The human retina possesses a single rod type and three cone types (L-, M- 
and S-cones). Rods account for 95% of all photoreceptors and are exquisitely 
sensitive to light but have a low photon saturation threshold. They function 
optimally in low light settings and are sensitive to contrast, brightness and 
motion. Cones account for 5% of photoreceptors, have a high saturation 
threshold, a fast photoresponse but relatively low sensitivity. The different 
types of cones provide high acuity and discern colour differences. Colour 
vision is based on differences in the photon catch rate of the three different 
cone types. Maximum sensitivity and absorbance for S-cones is 420 nm, for L-
cones 534 nm and for M-cones 564 nm; for rods it is 498 nm [141, 155]. 
 
Cone and rod photoreceptor density varies throughout the retina. The 
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periphery is rod-dominated whereas the macula contains a cone-dominated 
fovea surrounded by a parafoveal ring at 5 mm containing maximum rod 
spatial density [156]. 
 
Photoreceptors convert the energy of absorbed photons to an electrical neural 
signal, the receptor potential. This is achieved by opsins, cell membrane 
proteins that bind a light absorbing chromophore. The chromophore, 11-cis 
retinal, is a derivative of β-carotene, a vitamin A analogue entirely derived from 
the diet. Light transforms 11-cis retinal to its isomer all-trans retinal, changing 
the opsin to its catalytically active form; consequently, the exchange of GTP to 
GDP on a membrane bound G-protein (transducin) is catalysed. 
Subsequently, one of the activated transducin subunits binds to and activates 
a phosphodiesterase. Through a number of intermediate steps, the 
photoreceptor membrane hyperpolarises. This, following the general rule for 
all neurons in all species, leads to a decrease in the rate of neurotransmitter 
(glutamate) release at the photoreceptor terminal synapse. Numerous proteins 
are involved in photoactivation and photorecovery in cone and rod 
photoreceptors with mutations in the genes encoding them often leading to 
retinal disease (table 1-3). 
 
1.2.2.2 The Neural Retina 
 
The neural retina includes an inner nuclear layer containing the cell bodies of 
horizontal, bipolar and amacrine cells and a ganglion cell layer containing 
ganglion cells and displaced amacrine cells. In the neural retina, signals from 
the rods and cones undergo complex processing. The output takes the form of 
action potentials in ganglion cells whose axons converge at the optic nerve.  
 
The most direct pathway from the photoreceptors to ganglion cells is through 
bipolar cells (vertical pathway). All types of bipolar cells respond to changes in 
photoreceptor glutamate release rate by forming graded potentials. However, 
different bipolar types express different glutamate receptors at subsynaptic 
sites and can react to a certain stimulus either by hyperpolarizing or 
INTRODUCTION 
 
36 
 
depolarizing their plasma membranes. These different, glutamate-gated, 
bipolar cell responses are associated with expression of either ionotropic 
(sign-conserving; OFF bipolar cells) or metabotropic (sign-inverting; ON 
bipolar cells) glutamate receptors on bipolar cell dendrites. Importantly, 
mutations in the ON bipolar metabotropic glutamate receptor (mGluR6) cause 
CSNB [157]. The full mGluR6 cascade has not been resolved.  
 
Ganglion cells form the innermost nuclear layer and are the final output 
neurons of the human retina. There are over 20 distinct types of ganglion cells, 
all firing action potentials (sign-conserving to glutamate). Each type carries 
different channel of visual information and specialises for coding some 
particular aspect of the visual world (contrast, colour, movement and others). 
Ganglion cell axons are partially myelinated with the myelinated parts being 
outside the eye. 
 
1.2.3 Non-neuronal Elements 
 
In addition to the three major classes of neurons, the retina is also populated 
by three types of glia: Müller cells, microglia, and astrocytes. Müller cells are 
the predominant retinal glial cells. Their cell bodies are located in the inner 
nuclear layer, extending vertically and their processes form the outer and the 
inner limiting membrane. Other processes of the Müller cells make extensive 
contacts with the basal lamina of the retinal blood vessels. These vessels 
contain nonfenestrated endothelial cells whose tight junctions maintain the 
inner blood-retinal barrier. A basal lamina covers the outer surface of the 
endothelium and is covered by an interrupted layer of pericytes surrounded by 
their basement membrane. Astrocytes provide many of the same functions as 
Müller glia, but are restricted almost entirely to the nerve fiber layer of the 
retina. Unlike astrocytes and Müller cells, the third glial subtype, microglia, 
may arise from myeloid tissue. Microglia play a central role in the elimination 
of neuronal debris and in the initiation of immunological signaling through the 
release of chemokines, cytokines or neurotoxic factors [158]. 
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1.3 Inherited Retinal Disease 
 
The term inherited retinal disease denotes a group of genetically determined 
conditions that differ from one another in mode of inheritance, pattern of visual 
loss and fundus appearance. Most of these conditions share an important 
feature: the loss or dysfunction of photoreceptor cells as a primary or 
secondary event [159]. Both clinical and genetic heterogeneity is observed; 
over 170 genes have been implicated and at least another 40 chromosomal 
loci have been determined (RetNet; figure 1-7). Notably, mutations in genes 
previously associated with retinal degenerations explain the disease in only a 
fraction of patients [160]. Due 
to the complicated and 
intricate structure and 
function of the retina, an even 
higher degree of genetic 
heterogeneity is expected 
with more genes remaining to 
be identified. 
 
In the past, retinal dystrophies have been diagnosed and subdivided into 
several groups on the basis of clinical features (e.g. RP, Stargardt disease). It 
is clear, however, that entities like RP are sole clinical manifestations of many 
genetically determined disorders. In the presence of molecular genetic 
information a more accurate diagnosis and classification is possible (e.g. 
ABCA4 retinopathy, rhodopsin RP, ciliopathies). Nevertheless, genetic testing 
has traditionally been limited by availability, cost and time requirements. With 
molecular diagnosis unavailable in most cases, age of onset, mode of 
inheritance and correlation of electrophysiology with retinal morphology are 
key to the diagnosis and classification of retinal disease.  
 
A brief overview of genes associated with relatively common forms of inherited 
retinal disease is found in table 1-3. 
 
 
Figure 1-7. Number of genes associated with retinal 
disease over time (modified from www.sph.uth.tmc.edu/retnet/). 
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Table 1-3. Summary of main monogenic inherited retinal disorders 
Nonsyndromic inherited retinal disease 
Rod or rod 
cone 
dysfunction;  
RP 
Progressive 
disease 
Childhood-
or adult- 
onset 
Autosomal 
recessive 
ABCA4, BEST1, C2ORF71, CDHR1, CERKL, 
CNGA1, CNGB1, CRB1, DHDDS, EYS, 
FAM161A, IDH3B, IMPG2, LRAT, MERTK, MFRP, 
NPHP5, NR2E3, NRL, OAT, PDE6A, PDE6B, 
PDE6G, PRCD, PROM1, RBP3, RBP4, RDH12, 
RGR, RHO, RLBP1, RP1, RPE65, SAG, SPATA7, 
TTC8, TULP1, USH2A 
Autosomal 
dominant 
CA4, CRB1, CRX, FSCN2, GUCA1B, IMPDH1, 
KLHL7, NR2E3, NRL, PRPF3, PRPF6, PRPF8, 
PRPF31, RDH12, RDS, RHO, ROM1, RP1, RP9, 
RPE65, RGR, SEMA4A, SNRNP200, TEAD1, 
TOPORS 
X-linked REP1, RP2,  RPGR, RS1 
Infantile-
onset; 
LCA 
Autosomal 
recessive 
AIPL1, CABP4, CEP290, CRB1, CRX, GUCY2D, 
IQCB1, KCNJ13, LCA5, LRAT, RD3, RDH12, 
RPE65, RPGRIP1, SPATA7, TULP1 
Autosomal 
dominant 
CRX, IMPDH1, OTX2 
Stationary 
disease; 
CSNB 
Autosomal 
recessive 
With fundus 
abnormalities 
RDH5, RHOK, SAG 
Complete GPR179, GRM6, TRPM1 
Incomplete CABP4, CACNA2D4 
Other (Riggs-
like type) 
SLC24A1 
Autosomal dominant  
(Riggs or Nougaret type) 
GNAT1, PDE6B, RHO 
X-linked 
Complete NYX 
Incomplete CACNA1F 
Maculopathy 
Autosomal recessive ABCA4, CFH, BEST1 
Autosomal dominant 
BEST1, C1QTNF5, EFEMP1, ELOVL4, FSCN2, 
GUCA1A, GUCA1B, GUCY2D, HMCN1, PROM1, 
RDS, RIMS1, RP1L1, TIMP3 
X-linked RS1, RPGR 
Cone or 
cone rod 
dysfunction 
Autosomal 
recessive 
Rod monochromacy CNGA3, CNGB3, GNAT2, PDE6C, PDE6H 
Other 
ABCA4, ADAM9, CACNA2D4, C2ORF71, 
C8ORF37, CDHR1, CERKL, KCNV2, R9AP, 
RAX2, RGS9, RPGRIP1 
Autosomal dominant 
AIPL1, CRX, GUCA1A, GUCY2D, OPN1SW, 
PITPNM3, PROM1, RDS, RIMS1, SEMA4A, 
UNC119 
X-linked CACNA1F, RPGR, OPN1LW/OPN1MW 
Optic nerve 
disease 
Autosomal recessive TMEM126A 
Autosomal dominant OPA1 
Mitochondrial LHON 
FEVR, 
Norrie 
disease 
Autosomal recessive LRP5, TSPAN12 
Autosomal dominant FZD4, LRP5, TSPAN12 
X-linked NDP 
Retinoblastoma Autosomal dominant germline or somatic RB1 
Syndromic inherited retinal disease 
Usher 
Syndrome 
Autosomal recessive 
CDH23, CLRN1, DFNB31, GPR98, MYO7A, 
PCDH15, USH1C, USH1G, USH2A 
Albinism 
Autosomal recessive OCA2, SLC45A2, TYR, TYRP1  
X-linked GPR143 
Bardet-Biedl 
syndrome 
Autosomal recessive 
ARL6, BBS1, BBS2, BBS4, BBS5, BBS7, BBS9, 
BBS10, BBS12, INPP5E, MKKS, MKS1, TRIM32, 
TTC8 
Other 
syndromic 
retinal disease 
Autosomal recessive 
ABCC6, AHI1, ALMS1, CC2D2A, CDH3, CEP290, 
CLN3, CNNM4, COL9A1, INPP5E, INVS, IQCB1, 
MTTP, NPHP1, NPHP3, NPHP4, OPA3, PANK2, 
PEX1, PEX7, PHYH, PXMP3, RPGRIP1L, 
SDCCAG8, TTPA, WFS1 
Autosomal dominant 
ATXN7, COL11A1, COL2A1, JAG1, KCNJ13, 
PAX2, TREX1, VCAN 
X-linked OFD1, PGK1, TIMM8A 
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1.3.1 Clinical Diagnosis 
 
The invention of the ophthalmoscope by Babbage in 1847 [161] helped 
ophthalmologists to describe and classify familial forms of retinal disease. 
Some of the most frequently used terms to characterise genetic conditions of 
the retina were introduced by ophthalmologists in the 19th century. 
 
Detailed history, visual field and colour vision assessment as well as dilated 
fundoscopy, with examination including not only the affected individual but 
also potential carriers and other family members, usually allow a specific 
nosological entity (e.g. RP or Usher syndrome) to be diagnosed. On rare 
occasions (e.g. choroideremia, Best and Sorsby disease, familial dominant 
drusen), those investigations will point to a specific gene or even a specific 
mutation.  
 
Thorough structural and functional assessment of the retina can be performed 
with the use of electrophysiology (section 1.3.2), psychophysics (static and 
kinetic perimetry), fundus autofluorescence imaging (section 1.3.3.2), OCT 
(section 1.3.3.3) and fluorescein angiography.  
 
1.3.2 Electrophysiology 
 
Electrophysiology is the gold standard for investigating neuronal signalling. In 
the early 19th century, Luigi Galvani was the first to discover that the function 
of the nervous system is intrinsically linked to electrical activity [162]. Changes 
in the light flux on animal eyes were first reported to produce electrical signals 
by the Swedish physiologist Frithiof Holmgren in 1865 [163-164]. The first 
human subject was tested with success by Dewar in 1877 [165]. However, it 
was the work of Finnish Ragnar Granit and American Haldan K Hartline, two of 
the three winners of the 1967 Nobel in Medicine, that provided the basis for 
understanding retinal electrophysiology [166-167]. 
 
Electrophysiology is critical to the accurate diagnosis and appropriate 
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management of individuals with inherited retinal disease. The main tests are 
the EOG, which assesses the function of the RPE; the full field ERG, which 
reflects the function of the photoreceptors and inner nuclear layers of the 
retina; the pERG, which examines the function of the macular photoreceptors 
and ganglion cells; the VEP which examines the intracranial visual pathways. 
Other tests include multifocal ERG that spatially evaluates macular function 
and dark adaptometry that quantitatively determines the kinetics of rod and 
cone recovery following a bright flash [168]. The ISCEV, has published 
recommendations and minimum standards relating to the performance of 
these tests [169-174].  
 
 
Figure 1-8. Normal examples of ISCEV full field and pERGs. The bright flash was 0.6 log units 
brighter than the ISCEV standard flash to better demonstrate the a-wave (courtesy of Dr 
Anthony G Robson). 
 
Some electrophysiological phenotypes are highly suggestive of specific 
inherited retinal diseases. For example: reduced EOG light rise and normal full 
field ERGs are usually associated with Best disease; severely reduced light-
adapted and preserved dark-adapted ERGs in a young child are commonly 
associated with rod monochromacy (or other stationary cone dysfunction); 
undetectable ERGs in a young child imply LCA; electronegative ERG with 
normal a-wave is associated with X-linked retinoschisis, X-linked or recessive 
CSNB and some acquired diseases; VEP interhemispheric amplitude/latency 
difference is a feature of albinism. On two occasions of inherited retinal 
disease, ERGs can be “pathognomonic”. Those are: cone dystrophy with 
supernormal rod ERG (KCNV2 retinopathy) [175-176] and enhanced S-cone 
syndrome (NR2E3 retinopathy) [177-178]. The unique ability of 
electrophysiology to localise dysfunction in the visual system is summarised in 
table 1-4 [179-180]. 
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Table 1-4. Correlation between electrophysiological findings and visual pathway level of 
dysfunction 
Electrophysiological findings Site of dysfunction 
Abnormal EOG light rise, normal full field ERGs RPE dysfunction 
Abnormal dark-adapted 0.01 ERG b-wave and 
11.0 ERG a-wave 
Rod photoreceptor 
dysfunction 
Abnormal dark-adapted 0.01 ERG b-wave, 
normal a-wave and markedly subnormal b-wave 
in dark-adapted 11.0 ERG (electronegative) 
Postreceptoral disease 
Normal dark-adapted 11.0 ERG, abnormal light-
adapted responses 
Cone dysfunction 
Normal full field ERG, abnormal pERG P50 or 
multifocal ERG 
Macular dysfunction 
Normal full field ERG, preserved pERG P50, 
abnormal pERG N95 
Ganglion cell dysfunction 
Normal pERG, abnormal VEP Optic nerve dysfunction 
Asymmetrical VEP, crossed asymmetry Chiasmal dysfunction or 
misrouting 
Asymmetrical VEP, uncrossed asymmetry Retrochiasmal dysfunction 
 
1.3.3 Retinal Imaging 
 
It appears that the interior of the human eye was first observed by Purkinje 
who wrote in his 1823 thesis that when light was thrown back “the whole pupil 
lit up in a beautiful orange colour” [181-182]. Over the next decades, 
researchers realised that the observer had to stand in the path of the emerging 
rays in order to view the fundus. An English mathematician, Charles Babbage 
solved the problem in 1847 by using a mirror but his prototype 
ophthalmoscope was rejected by an ophthalmologist and laid aside [183]. 
Helmholtz is claimed to note that the instrument would have worked if a 
concave lens of four or five dioptres had been inserted to correct the 
convergent rays [184]. Hermann von Helmholtz is generally credited with the 
invention of the ophthalmoscope. His instrument was published in 1851 [185] 
and he was lucky to see it quickly accepted by prominent ophthalmologists like 
Donders and von Graefe [186]. Soon there was a flood of publications 
describing both observations and technical variations of the instrument. In 
1852 Christian Theodor Georg Ruete established indirect fundoscopy [187-
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188] and in 1911 Allvar Gullstrand, one of the few Ophthalmologists to receive 
a Nobel prize [189], developed the slit lamp [190]. Fundoscopic appearance of 
inherited retinal disease was reported early with Ernst Coccius describing RP 
in 1853 [191]. Since these early days ophthalmic imaging has played an 
important role in the documentation and diagnosis of inherited retinal disease. 
 
1.3.3.1 Fundus photography 
 
Photography as a practical procedure draws its origin in the 1830s. The 
challenges of imaging the fundus have been addressed early; the first 
technique for photographing the retina of a living human subject was proposed 
in 1886 [192] and the first commercial camera was produced in 1926 by Carl 
Zeiss Company. Nowadays, the high resolution digital fundus CCD cameras 
work on the principle of indirect ophthalmoscopy, except that the image is 
stored as electronic data. They are placed 2 to 3 cm from the subject and 
image an angle of 30° creating an imaging plane 2.5 times life size [193]. An 
imaging mode frequently supplementing colour photography is infrared 
imaging. It enables enhanced detail through poor media and more comfort for 
the patient (no flash). In inherited retinal disease, retinal photography is widely 
used to document fundus abnormalities, create illustrations for publication and 
education and track disease progression through serial photography. 
 
1.3.3.2 Fundus autofluorescence imaging 
 
The first use of a confocal scanning laser ophthalmoscope to produce 
autofluorescence signal from the retinoid fluorophores in a clinical setting was 
done in 1995 in the UCL Institute of Ophthalmology, London, UK [194]. 
Autofluorescent phenomena of the human fundus have been described in the 
early days of fluorescein angiography, mainly before the injection of the 
fluorescent dye, and were initially treated as a problem in fluorescein 
angiogram interpretation [195]. The use of a regular fundus camera posed two 
important limitations: the low intensity of the emitted autofluorescence and the 
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significant fluorescence deriving from tissues anterior to the retina, particularly 
the lens. The first problem was resolved with the use of a scanning laser 
ophthalmoscope. This device was developed in 1980 [196] and uses a 
different approach to imaging from the fundus camera: a spatially coherent, 
low-divergence, narrow beam from a laser rather than irregular cathode ray 
tube illumination is swept over the retina, delivering its energy to a very small 
spot for a very short time. Light returned from that spot is detected and 
decoded to form an image [197-198]. The problem associated with high noise 
from anterior structures was resolved with the introduction of confocal optics. 
Confocal imaging mode uses a small aperture size (2 mm) in order to 
suppress light scattered from layers other than the point of illumination and 
ensures that reflectance is collected from the same optical plane [199-200]. 
Several images are recorded, aligned and used to compute a mean image. 
 
One of the few commercially available confocal scanning laser 
ophthalmoscope devices for fundus autofluorescence imaging is the HRA 
(Heidelberg Engineering, Heidelberg, Germany). It uses an excitation 
wavelength of 488 nm and a 500 nm short wavelength cutoff filter. Two 
different lenses allow 35° or 55° field of view. One limitation is posed by the 
fact that the mean image’s pixel values are normalised; therefore the absolute 
amount of fundus autofluorescence cannot be assessed. 
 
The concept of using naturally occurring fluorescence to provide an indicator 
of RPE health makes fundus autofluorescence imaging an invaluable tool for 
the assessment of retinal dystrophies. It not only discloses information above 
and beyond those obtained by fundoscopy, but also specific fundus 
autofluorescence patterns seem to correlate with distinct patterns of 
dysfunction [201-202]. In short, it facilitates diagnosis and phenotype-genotype 
correlations and allows more sensitive assessment of disease progression. 
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Figure 1-9. Normal fundus autofluorescence image: the optic nerve head typically appears 
black due to abscence of RPE. At the fovea, autofluorescence is reduced due to absorption 
mainly from the foveal “blue light filter” (peaking at 460 nm), the macular pigment and 
secondarily due to increased melanin deposition. The macular pigment (lutein and 
zeaxanthin) concentration is highest in the prereceptoral axon layer of the fovea and its 
density can be assessed by subtracting the 514 nm fundus autofluorescence image from the 
regular 488 nm one. This is a result of the minimal absorpion of over 500 nm wavelengths by 
macular pigment [203-204]. 
 
1.3.3.3 Optical coherence tomography 
 
OCT generates cross sectional or three-dimensional images by measuring 
time delay and magnitude of backscattered or reflected light [205]. It is 
analogous to a radar or an ultrasound except that it measures reflectivity to an 
infrared signal (around 820 nm) rather than radio waves (1 mm to 100 m for 
radars; FM radio around 3 m, TV around 5 m, AM radio around 400 m) or 
“higher frequency than normal hearing” sound waves (in air: 0.1 mm to 1.5 mm 
for diagnostic ultrasound; audible sound wavelengths: 17 mm to 17 m). The 
optical signal that OCT uses is much shorter in wavelength to ultrasound; 
therefore, resolution is much higher (one to two orders of magnitude higher 
than conventional ultrasound) and probe-tissue contact is not necessary.  
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Two dimensional OCT was developed in 1991 [206] and became fast enough 
for in vivo studies two years later [207]. The first OCT instrument became 
commercially available in 1995 and over the next 15 years almost all 
technological OCT parameters have significantly improved. Every imaging 
modality is characterised by five main technological parameters: axial 
resolution, transverse (lateral) resolution, measurement (data acquisition) 
time, detection sensitivity, image penetration depth in tissue and image 
contrast [205]. Axial resolution, perhaps the most significant parameter of 
OCT, has reduced from 20 μm [207] to 2 μm [208-209] enabling 
comprehensive visualisation of the intraretinal morphology. Application of the 
Fourier transform, a mathematical formula, to signal processing in order to 
extract the frequency spectrum of a signal, has considerably improved image 
acquisition speed and resolution [210]. The first generation of instruments 
(time domain) was comparing echo delays of light from different retinal layers 
while the novel frequency domain technology, using Fourier transformation, 
measures all echoes of light simultaneously rather than sequentially. The 
common feature of both technologies is a Michelson interferometer measuring 
the effect of combining two light waves from the sample and a reference arm 
[211]. The first demonstration of Fourier domain OCT was in 2002 [212]. The 
consequent dramatic increase in imaging speed has led to an increased “line 
rate” (up to 312,000 A-scan per second) making three-dimensional 
reconstructions feasible [213-217]. 
 
Several studies have focused on the interpretation of OCT images and their 
correlation with retinal morphology. We are close to establishing a precise 
interpretation of OCT layers although one to one correspondence with 
histology cannot be expected [205, 209, 218-220]. Notably, the OCT contrast 
may often not be sufficient to visualise structures like ganglion cell layer or 
Bruch’s membrane. Advances in technology as well as observational studies 
have increased our understanding of the, crucial for the assessment of retinal 
dystrophies, outer retinal OCT appearance in health and disease [221-223]. 
Throughout this study outer retina morphology interpretation would be as 
suggested by Srinivasan et al.[221]. 
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In inherited retinal disease the introduction of OCT has clearly changed clinical 
practice enabling early diagnosis and accurate assessment of disease 
progression or response to treatment. The role of OCT imaging in research is 
also key and the overall impact of this technology on our understanding of the 
pathology of retinal dystrophies has ushered in a new exciting era, turning the 
page that Babbage and Helmholtz have opened 150 years ago. 
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1.4 Aims of this Thesis 
 
(a) To identify novel genes and loci associated with human retinal phenotypes. 
 
(b) To characterize the clinical consequences of mutations in genes associated 
with human retinal disease. 
(i)i To determine the structural and functional effects of mutation in the retina. 
(ii) To determine the variability within and between families. 
 
More specifically, this thesis focuses on  
 screening genes previously associated with retinal disorders,  
 combining linkage analysis (including homozygosity mapping), exome 
sequencing and candidate gene sequencing to identify novel genetic 
determinants of autosomal recessive retinal disease and 
 characterising the consequences of mutations identified on retinal 
structure and visual function. 
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2 MATERIALS AND METHODS 
 
2.1 Study Subjects 
 
2.1.1 Ethical Approval and Consent 
 
Approval for this study was obtained from the MEH Research Ethics Committee 
(project number MOOA1005) and from the Moorfields & Whittington Hospitals 
Research Ethics Committee (WEBA1006; 05/Q0504/38). All individuals involved 
in this study provided fully informed written consent. 
 
2.1.2 Control Panels 
 
Two control panels were used: 
(a) a control population of 192 anonymised, randomly selected, unrelated, UK 
Caucasian blood donors (HRC-1 and HRC-2, Health Protection Agency 
Culture Collections, Salisbury, UK),  
(b) a panel of 50 DNA samples from unrelated patients of South Asian origin 
and no history of eye disease (as part of a collaboration with Professor 
Eamonn R Maher and Birmingham University Women’s Hospital, Birmingham, 
UK). 
 
2.1.3 Linkage Study 
 
Experiments conducted prior to this study had generated genotyping data for 
162 individuals from 48 families; genome-wide genotyping microarray 
technologies (Human Mapping 10K, 50K and 250K Arrays, Affymetrix, Santa 
Clara, CA, USA) had been utilised. The molecular diagnosis had been 
determined in 22 families. In the remaining 26 (table 2-1), pedigree and 
phenotyping information were collected and genotyping data were 
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reprocessed and reanalyzed. Regions identified in families with similar clinical 
phenotypes were examined for overlap. 
 
Table 2-1. Families genotyped prior to this study  in which the molecular diagnosis was unclear 
Autosomal Recessive 
Condition 
Number of previously genotyped families 
with unclear molecular diagnosis 
LCA / RP/ EARLY-ONSET RETINAL DYSTROPHY 11 
CSNB 2 
MACULAR DYSTROPHY 4 
SYNDROMIC EYE DISEASE 4 
ROD MONOCHROMACY 3 
FLECK RETINA SYDROMES 2 
TOTAL 26 
 
Additional 21 individuals from 14 families were genotyped using a SNP array 
containing over 50,000 markers of genetic variation (GeneChip Human 
Mapping 50K Array Xba, Affymetrix, Santa Clara, CA, USA; section 
2.4.18.2.1). Genomic DNA ethanol precipitation, restriction enzyme digestion, 
ligation, PCR, PCR purification, fragmentation and labelling steps were 
performed in the laboratory as part of this study (sections 2.4.5, 2.4.6, 2.4.7, 
2.4.9 and 2.4.14). Hybridisation, staining and scanning steps were performed 
at the Wolfson Institute, UCL, London, UK as part of the UCL Genomics 
Microarray Facility genotyping support services. 
 
After the first year of this study, more powerful genotyping solutions became 
available. Genotyping using denser arrays (Genome-Wide Human SNP Array 
6.0, Affymetrix; section 2.4.18.2.2) was performed in 63 individuals from 49 
families. Genomic DNA preparation (sections 2.4.4, 2.4.5 and 2.4.8) was 
performed in the laboratory with all other steps conducted by Drs Jill Urquhart 
and Sarah Daly in the St. Mary's Hospital Academic Medicine Department, 
Manchester Academic Health Sciences Centre, University of Manchester, 
Manchester, UK as a service. 
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2.1.4 Exome Sequencing Study 
 
High-throughput sequencing platforms have become increasingly available 
and the cost of sequencing during the course of this study has dropped 40x 
(http://www.genome.gov/sequencingcosts/). A grant application was prepared 
(principal applicants Dr Donna S Mackay, PS and Dr Alice E Davidson; 
collaboration with Dr Vincent Plagnol, UCL Genetics Institute, London, UK) 
and funding was secured to perform exome sequencing in individuals affected 
with retinal disease (October 2010).  
 
Twelve unrelated patients, members of families previously studied using SNP 
genotyping arrays, were selected. Individuals were affected with: RP (3), LCA 
(1), rod monochromacy (3), cone-rod dystrophy (1), syndromic RP and 
cataract (1), FEVR (1), macular dystrophy (1) and benign fleck retina (1). 
 
Quantification using a microvolume spectrophotometer (NanoDrop 2000, 
Thermo Fisher Scientific, Wilmington, DE, USA; section 2.4.4) and inspection 
of genomic DNA on a 1% w/v agarose gel (section 2.4.8) were performed in 
the laboratory. Subsequently, 5 to 10 μg of high molecular weight DNA were 
sent to Beijing Genomics Institute, Shenzhen, China through UCL Genomics 
Whole Genome Sequencing support services. 
 
2.1.5 Mutation Detection Study 
 
A panel of 288 unrelated patients diagnosed with recessive adult-onset rod 
cone or cone rod dystrophy was collected using an SQL query in the MEH and 
UCL Institute of Ophthalmology Inherited Eye Disease Database. The 
genomic DNA extracted from peripheral blood leukocytes of the donated blood 
samples was quantified (sections 2.4.3 and 2.4.4) and samples with sample 
purity (260:280 ratio) over 1.80 and two consistent concentration 
measurements over 50 ng/µL were diluted to 50 ng/µL and added to 96-well 
plates. 
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A second panel with 192 unrelated probands diagnosed with autosomal 
recessive LCA or childhood-onset retinal dystrophy was also available for the 
study (courtesy of Drs Donna S Mackay and Louise Ocaka). The majority of 
patients were recruited in Professor Anthony T Moore’s clinics by Drs Robert 
H Henderson, Philip Moradi and Arundhati Dev Borman. The panel is enriched 
for novel mutations as patient DNA had been screened and excluded for 
previously identified LCA-related variants through an APEX genotyping 
microarray (LCA Chip, Asper Biotech, Tartu, Estonia; section 2.4.18.1). 
 
On the basis of suggestive phenotypic features, smaller panels were collected 
for the following recessive retinal disease-associated genes: CRB1, NR2E3, 
KCNV2, MERTK, GRM6, RDH5, RLBP1, CLRN1, ADAM9, OAT, PDE6C. In a 
similar fashion, panels were collected for disorders such as benign fleck retina, 
occult maculopathy, rod monochromacy, oligocone trichromacy, foveal 
hypoplasia and FEVR. 
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2.2 Phenotyping 
 
As part of this study, over 250 individuals with retinal dystrophy have been 
examined in the Genetic Clinic, MEH Medical Retina Department under Dr 
Andrew R Webster. Phenotyping information of further patients was collected 
retrospectively from the MEH electronic databases and patient clinical and 
genetic notes. 
 
A detailed clinical history covering age of onset and symptoms at presentation 
(e.g. central vision loss, night blindness, photophobia, colour blindness, 
peripheral vision problems), age at diagnosis, progression of symptoms and 
current symptoms (in light, in dark, visual acuity, colour vision, peripheral 
vision) was taken. 
 
A careful past medical history was enquired after. Patients were directly 
questioned for suggestion of exposure to retinotoxic medication (chloroquine, 
hydroxychloroquine, thioridazine, quinine, deferoxamine) or syndromic 
associations. Questions were asked regarding hearing (for Usher syndrome), 
anosmia and neuropathy (for Refsum disease), digit abnormalities and 
polydactyly (for Bardet-Biedl syndrome and Refsum disease), urinary tract 
abnormalities and amenorrhea (for Bardet-Biedl syndrome) as well as renal 
failure (for Senior-Loken syndrome). 
 
Family history was taken including detailed pedigree, ethnicity background 
information and history of consanguinity (or origin from a small gene pool 
resulting in high coefficient of inbreeding) in parents and the patient’s 
marriage. 
 
Best corrected Snellen visual acuity was obtained by an ophthalmic nurse 
prior to the instillation of dilating drops. As part of the clinical examination, 
confrontation visual fields to pick up gross defects were examined and colour 
vision testing with HRR plates (American Optical Company, New York, NY, 
MATERIALS AND METHODS 
 
53 
 
USA) and/or 24-plate Ishihara colour vision test (Kanehara and Co. Ltd, 
Tokyo, Japan) was conducted. 
 
General ophthalmic examination including slit lamp biomicroscopy was 
performed on all subjects. Most patients underwent retinal imaging including 
fundus photography (section 1.3.3.1), fundus autofluorescence imaging 
(section 1.3.3.2) and SD OCT (HRA2 and Spectralis HRA+OCT, Heidelberg 
Engineering; section 1.3.3.3). In the majority of cases, imaging was performed 
by medical photographers (MEH Medical Illustration Department). Fundus 
autofluorescence and SD OCT images were obtained in over 80 subjects as 
part of this study. 
 
Electrophysiological testing (section 1.3.2) was performed in the MEH 
Electrophysiology Department and the results were interpreted and reported 
by Professor Graham E Holder or Dr Anthony G Robson. 
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2.3 Bacteriological Procedures 
 
2.3.1 Bacterial Strain 
 
High efficiency (at >108 cfu/μg) E.coli competent cells (JM109 strain; Promega, 
Madison, WI, USA) were used. The JM109 strain [224] is sensitive to all 
common antibiotics and deficient in β-galactosidase activity; its genotype is: 
endA1, recA1, gyrA96, thi, hsdR17(rK-,
 mK+), relA1, supE44, Δ(lac-proAB), [F', 
traD36, proAB, lacIqZΔM15]. 
 
2.3.2 Transformation of Chemically Competent Cells 
 
After thawing and gently flicking the tubes of frozen E.coli competent cells 
(JM109 strain; Promega), 50 µl were transferred into chilled tubes containing 
DNA solution; the latter was either 2 µl (approximately 200 ng) of each 
cloning/ligation reaction (sections 2.4.7 and 2.4.13) or 0.1 ng of uncut plasmid 
(to determine transformation efficiency). Subsequently the tubes were placed 
on ice for 30 minutes followed by heat shock at 42 °C for 50 seconds and 
incubation on ice for a further minute. Finally, transformation reactions were 
diluted to 1 ml by addition of 900 to 950 µl of SOC medium prior to an 
incubation period of 2 hours at 37 ºC and with shaking at 225 rpm. 
 
2.3.3 Preparation of Growth Medium for Blue/White Screen 
 
LB Agar was prepared (7.5 g of LB Broth and 4.5 g of LB Agar powders were 
suspended in 0.5 litres of dH2O) and sterilised by autoclaving for 15 minutes at 
15 psi (around 103,400 Pascal). After air-cooling to 50 °C, agar was prepared 
for blue-white screening and antibiotic resistance selection. Ampicillin (final 
concentration 50 μg/ml), X-gal in dimethylformamide (20 mg/ml; final 
concentration 50 μg/ml) and IPTG (final concentration 0.1 mM) were added. 
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Using aseptic techniques, the solution was poured into sterile Petri dishes and 
allowed to harden at room temperature. 
 
2.3.4 Screening Bacterial Colonies and Bacterial Culture Growth  
 
Plates containing the aforementioned growth medium (section 2.3.3) were 
inoculated with 100 to 200 µl of each transformation culture (section 2.3.2) and 
once the inoculum had been absorbed, incubated at 37 °C in an inverted 
position for 12 to 16 hours. After removing the plates from the incubator and 
allowing the blue colour to develop (at 4 °C), colonies carrying recombinant 
plasmids (white) were identified. Single colonies were isolated, transferred to a 
sterile tube containing LB Broth and ampicillin (final concentration of 100 
μg/ml) and incubated for 12 to 16 hours at 37 °C in a shaker incubator (250 
rpm). Finally, the bacterial cells were harvested by centrifugation at 3,500 rpm 
for five minutes at room temperature and removal of the supernatant. 
 
All reagents used for growth media preparation and selection of recombinants 
were purchased from Sigma-Aldrich, Poole, UK. 
 
2.4 Nucleic Acid Procedures 
 
Understanding information macromolecules, DNA and RNA, is a primary 
concern of molecular genetics. As RNA is unstable and can easily be 
converted into DNA with reverse transcription, nucleic acid research has 
focused on how to study DNA sequence. Amplifying and detecting the target 
sequence are the necessary steps. The general approaches used in this study 
are summarised in figure 2-1. 
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Figure 2-1. Overview of basic nucleic acid procedures performed in the course of this study. 
 
2.4.1 RNA Electrophoresis 
 
Total RNA integrity and purity prior to RT PCR was assessed using 
microfluidic separation technology (Experion Automated Electrophoresis 
System and Experion RNA StdSens Analysis Kit, Bio-Rad, Hercules, CA, 
USA) according to the manufacturer’s instructions. After the automated steps 
(including electrophoresis, separation, staining, imaging, band detection and 
basic data analysis), electropherogram and simulated gel views of separation 
were inspected. 
 
To assess mRNA integrity the assumption that rRNA quality reflects that of the 
underlying mRNA population was made. This is because mRNA represents 
only 1 to 3% of total RNA samples and is not readily detectable while rRNA 
makes up over 80% of total RNA samples. The majority of rRNA is comprised 
by the 28S and 18S rRNA species with eukaryotic 28S and 18S rRNA size in 
kb ratio being relatively constant. In case of contamination or degradation, the 
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28S:18S ratio is decreased [225-226]. In 2006, the RNA integrity number 
(RIN) was introduced as an alternative predictor of RNA integrity [227]. 
 
2.4.2 Reverse Transcription 
 
Reverse transcription reactions were carried out using 20 U/μl of SuperScript 
III reverse transcriptase (Invitrogen, Carlsbad, CA, USA) with 1 µg of total 
RNA and 2 μM of gene-specific primer according to the manufacturer’s 
instructions. All resultant cDNA was stored at 4 °C and used within five days of 
synthesis. 
 
The reaction was performed to produce cDNA of various TRPM1 transcripts in 
skin and retina (section 3.2.3). After the integrity of total RNA samples from 
retina (Clontech, Mountain View, CA, USA) and skin (Stratagene, La Jolla, CA, 
USA) was assessed (section 2.4.1), a 3' end TRPM1-specific primer (in exon 
27; 5' CCTGTCCATGTATCACATCTGTTTTAT 3') was used for first-strand 
cDNA synthesis. The cDNA was utilised as template for the ensuing PCRs. 
 
As part of the RACE protocol (GeneRacer Kit, Invitrogen; section 2.4.12), 
reverse transcription was performed using two different modules: SuperScript 
III RT Module for both 5' and 3' RACE; Cloned AMV RT Module for 3' RACE. 
The aforementioned gene-specific primer for 5' RACE and an oligo-dT primer 
(different dT tail for each module) for 3' RACE were used to prime the first-
strand cDNA synthesis according to the manufacturer’s instructions. 
 
2.4.3 DNA Extraction 
 
Peripheral venous blood samples were collected in 10 ml tubes containing 
sodium EDTA as an anticoagulant and stored at 4 °C for less than five days to 
avoid DNA degradation. Extraction was carried out using either the BACC-2 
Kit (Tepnel Life Sciences, Manchester, UK) or the Gentra Puregene Blood Kit 
(Qiagen, Hilden, Germany). After extraction, DNA was stored at 4 °C if for 
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immediate use or at -20 °C if for longer term storage. The majority of blood 
samples were collected by Ms Genevieve Wright and Mrs Sophie Devery 
while most of DNA extraction was performed by Ms Bev Scott and Dr Naushin 
Waseem. 
 
2.4.4 Quantification of DNA 
 
DNA samples were quantified using a UV-Vis spectrophotometer (NanoDrop 
2000, Thermo Fisher Scientific). Analysis of 0.5 to 2.0 µl of stock sample was 
performed by measuring ultraviolet light absorbance at wavelengths of 260 nm 
and 280 nm. Using the Beer-Lambert law the amount of light absorbed was 
related to the concentration of the absorbing molecule. Double-stranded DNA 
absorbs maximally at 260 nm while proteins absorb maximally at 280 nm 
[225]. The concentration (ng/μl) of each DNA sample was calculated using the 
absorbance value obtained at 260 nm (Absorbance
260nm = 1 is equivalent to 50 
μg/ml of DNA); the Absorbance
260nm:Absorbance
280nm ratio was used as a marker of 
sample purity. Pure DNA has a ratio of approximately 1.80 and a ratio of less 
than 1.50 indicates that the sample has significant protein contamination.  
 
2.4.5 Ethanol Precipitation of DNA 
 
Ethanol precipitation was performed in order to concentrate and purify DNA 
samples. This procedure allows charged phosphate groups present on DNA 
backbones to form stable ionic bonds and precipitate out of aqueous solutions.  
 
In general, 95% v/v ethanol (2.5x sample volume) and 3 M sodium acetate (pH 
5.3; 0.1x sample volume) were added to each sample and the mix was stored 
overnight at -20 °C. Subsequently, precipitated DNA was collected by 
centrifugation in a microcentrifuge tube at 12,000 rpm for 20 minutes in a 4 °C 
environment. After centrifugation the supernatant solution was removed and 1 
ml of 70% v/v cold ethanol was added to the pellet (salt removal step). The 
suspension was centrifuged again at 12,000 rpm for 10 minutes to once again 
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pellet DNA. After the supernatant solution had been removed, the pellet was 
air-dried for 10 minutes. Finally, DNA was resuspended in 10 mM Tris-Cl, pH 
8.5 (Buffer EB, QIAgen Spin Kits, Qiagen).  
 
2.4.6 Digestion of DNA 
 
Restriction enzyme digestion [228-229] of genomic DNA was performed in this 
study as part of and according to the Affymetrix GeneChip Mapping 50K Xba 
Assay Kit protocol (section 2.4.18.2.1). The assay utilises a strategy that 
reduces the complexity of genomic DNA up to 10-fold by first digesting it. The 
Xba I restriction enzyme (New England Biolabs, Ipswich, MA, USA) was used 
and BSA (New England Biolabs) was added to enhance enzymatic activity.  
 
Restriction enzyme digestion of PCR products was utilised to assay the 
prevalence of c.352C>A, p.Arg118Ser variant in GRM6 within control 
populations (section 3.1.6.1.3). The enzyme SacII (New England Biolabs) was 
chosen on the basis of its ability to differentiate wild-type and mutant alleles 
(assessed by http://tools.neb.com/NEBcutter2/). Initially, 5.0 μl of PCR product 
for each individual were incubated with 1x NEBuffer 4 (New England Biolabs), 
3.5 μl dH2O and 0.1 U/μl of enzyme for one hour at 37
 °C. Subsequently, 5.0 
μl of digested product were run on a 2% w/v agarose gel with a 25 to 500 
separation range DNA ladder (HyperLadder V, Bioline, London, UK). 
 
EcoR I (New England Biolabs), whose recognition sites flank the insert 
position of the PCR product in the plasmid sequence of both pCR4-TOPO 
(Invitrogen) and pGEM-T easy (Promega) vectors, was used to digest eluted 
plasmid DNA. After fractionating the restricted DNA by agarose gel 
electrophoresis, band sizes were measured confirming the identity of the 
cloned fragment. 
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2.4.7 Ligation of DNA 
 
In the Affymetrix GeneChip Mapping 50K Xba Assay Kit protocol, the digestion 
of genomic DNA step is followed by a universal adapter ligation step (section 
2.4.18.2.1). In general, 0.25 μM of adapter (GeneChip Human Mapping 50K 
Xba Adaptor, Affymetrix), 10 U/μl of T4 DNA Ligase and 1x T4 DNA Ligase 
Buffer Ligase (New England Biolabs) were added to the digested DNA and 
incubated according to the assay protocol. 
 
A ligation reaction was also performed as part of the MLPA DNA 
detection/quantification protocol (section 2.4.11). This reaction involved two 
probe oligonucleotides and was followed by PCR. 
 
T4 DNA Ligase was the first DNA ligase to be characterised [230] and 
originates from the T4 bacteriophage. In addition to the aforementioned 
protocols, this enzyme was also used to allow PCR inserts to ligate efficiently 
with pGEM-T Easy Vectors (Promega; reaction was performed according to 
the manufacturer’s instructions). One example was the use of DNA inserts 
from the genomic region around PLA2G5 exon 3 (insert size 343 base pairs) 
in a benign fleck retina patient carrying two PLA2G5 variants (c.145G>A, 
p.Gly49Ser and c.157C>T, p.Arg53X; section 3.2.5). Insert to vector molar 
ratios ranging between 3:1 and 1:3 were used for ligation reactions. A vector-
only ligation was employed as a negative control every time ligation reactions 
were performed. 
 
2.4.8 Agarose Gel Electrophoresis 
 
Electrophoresis through agarose gel, a technique having its roots in the mid-
1960s [231], was used to separate, identify and purify DNA fragments. PCR 
products and restriction enzyme digests were analysed using this technique. 
Gels were prepared by adding the appropriate amount of agarose (typically 
2% w/v for 100 to 2,000 base pair product size; Bio-Rad Laboratories, 
Berkeley, CA, USA) in 1x TBE buffer (Eppendorf, Hamburg, Germany). After 
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dissolving the agarose, ethidium bromide [232] to 0.5 μg/ml final concentration 
was added and the gel was allowed to set. DNA was mixed with 1x DNA 
loading dye (Bioline), loaded into wells next to a standard size marker (Bioline) 
and run until desired separation was achieved, typically 150 mV for 30 minutes 
in 1x TBE buffer. The DNA was visualised on a transilluminator (UV light of 
wavelength 210 nm) and photographed using a camera with orange filter 
(BioDoc-It 210, UVP, Upland, CA, USA).  
 
2.4.9 PCR 
 
PCR [233-234] was usually performed using either MolTaq (Molzym, Bremen, 
Germany) or BioTaq (Bioline) DNA polymerase. Two of the protocols used are 
described in table 2-2. 
 
 
Occasionally, extra MgCl2 or DMSO up to 10% v/v were added to PCR 
reactions to enhance efficiency. For difficult/problematic PCR applications 
different polymerases were used including: Bio-X-Act long DNA Polymerase 
(Bioline), GC-RICH PCR System (Roche, Mannheim, Germany), Platinum Taq 
DNA Polymerase High Fidelity (Invitrogen) and Platinum Pfx DNA Polymerase 
(Invitrogen), all according to the manufacturers’ instructions. 
 
Table 2-2. Standard protocols for PCR 
Components MolTaq protocol BioTaq protocol 
Volume Final 
Concentration 
Volume Final 
Concentration 
Buffer 3 μl of Buffer; 
0.3 μl of 
Enhancer 
(Molzym) 
1x 2.5 μl of NH4 
Buffer (Bioline) 
1x 
MgCl2 1.5 mM 0.75 μl of 50mM 
MgCl2 (Bioline) 
1.5 mM  
dNTP mixture 0.24 μl (Promega) 0.2 mM each 0.2 μl 
(Promega) 
0.2 mM each 
10 μM 
Primer 
Forward 1 μl 0.33 μM 0.5 μl 0.2 μM 
Reverse 1 μl 0.33 μM 0.5 μl 0.2 μM 
Taq 
Polymerase 
0.2 to 0.3 μl of 
MolTaq (5 U/μl; 
Molzym) 
0.03 to 0.05 
U/μl 
0.1 μl of BioTaq 
(5 U/μl; Bioline) 
0.02 U/μl 
DNA Template 1 μl 10 to 50 ng/μl 2 μl 100 to 200 ng/μl 
dH2O 23.16 to 23.26 μl - 18.15 μl - 
Total Volume 30 μl - 25 μl - 
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The standard PCR cycling parameters used are stated below in table 2-3. 
 
Table 2-3. PCR cycling parameters 
Cycling stage Temperature (°C) Time  Cycles 
Initial denaturation 94 to 95 °C 3 to 5 minutes x 1  
Denaturation 94 to 95 °C  30 to 45 seconds  
 x 35 Annealing 50 to 70 °C  30 seconds 
Extension 72 °C 1 minute·kb-1 
Final Extension 72 °C  5 to 7 minutes x 1  
Hold 4 °C hold x 1 
 
2.4.10 Amplification Refractory Mutation System 
 
ARMS is an amplification strategy in which a PCR primer is designed in such a 
way that it is able to discriminate among templates that differ by a single 
nucleotide residue [235]. In ARMS, the primer pair is designed so that the 
terminal 3' nucleotide of one primer coincides with a DNA variant in the target 
sequence. When the primer mismatches, the amplification is not allowed to 
proceed to the same degree as under optimal hybridisation. A DNA 
polymerase possessing no 3'-5' exonuclease (proofreading; like Taq [236-
237], unlike Pfu [238] polymerase) activity was used. 
 
An ARMS test was used to assess the presence of a heterozygous mutation, 
c.2991+1655A>G, p.Cys998Stop, in CEP290 in two siblings affected with 
retinal dystrophy, their mother and a control DNA (section 3.1.1). DNA 
templates were amplified using  
 5' ACCGCACCTGGCCCCAGTTGTAATTGTGGG 3' as forward primer and 
 5' AGTAAGGAGGATGTAAGACTGGAGATAGAG 3' as reverse primer. 
This primer pair was designed to mismatch with the wild-type and match with 
the mutant DNA template sequence. Annealing temperature was 67 °C and 
product size was 137 base pairs. 0.25 U of Taq DNA polymerase (Bioline) per 
20 μl reaction was used. The protocol was optimised by Dr Donna S Mackay. 
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2.4.11 Multiplex Ligation-dependent Probe Amplification 
 
MLPA is a PCR based method permitting multiple targets to be amplified with 
a single primer pair. It is mainly used to test genomic DNA sequences for 
abnormal copy numbers. Notably, in MLPA, it is not target sequences that are 
amplified, but MLPA probes that hybridise to the target sequence. An MLPA 
probe consists of two probe oligonucleotides each containing one of the PCR 
primer sequences. In case both the oligonucleotides’ immediately adjacent 
target sequences are present in the sample, the probes hybridize next to each 
other allowing connection by ligation. Only ligated probe pairs will be 
exponentially amplified during the subsequent PCR reaction and the amount 
of PCR product is a measure for the number of target sequences [239]. 
 
The SALSA MLPA P221 LCA probemix-1 (MRC-Holland, Amsterdam, 
Netherlands) containing probes for AIPL1, CRB1, CRX and RPE65 genes was 
used according to the manufacturer’s instructions in order to identify 
duplications or deletions in five unrelated patients with a single heterozygous 
CRB1 mutation (section 3.1.1). 
 
2.4.12 Rapid Amplification of 5' and 3' cDNA Ends 
 
RACE is a PCR-based technique which was developed to facilitate the cloning 
of full length cDNA 5' and 3' ends [240]. RACE, also called one-sided [241] or 
anchored PCR [242], differs from conventional PCR in that it requires 
knowledge of only a small region of sequence within the target cDNA. 
Therefore, only one sequence-specific primer is used with the second primer 
being complementary to a general feature of the target. In general, 3' RACE 
takes advantage of the natural poly-A tail in mRNA as a generic priming site 
for PCR amplification. In the case of 5' RACE, protocols tend to slightly vary. 
The first experimental step of the GeneRacer Kit (Invitrogen) protocol that was 
used in this study involves RNA dephosphorylation and mRNA 5' cap structure 
removal. Subsequently, an RNA oligonucleotide that supplies a known 5' end 
priming site is ligated to the decapped mRNA. After reverse transcription 
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(section 2.4.2), cDNA is amplified and cloned into a vector. The flowchart in 
figure 2-2 outlines the RACE experiment. 
 
To investigate the full-length TRPM1 transcripts in retina and skin, 5′ and 3′ 
RACE were performed (section 3.2.3). After assessment of RNA integrity, 
ligation of RNA oligonucleotide and cDNA synthesis (sections 2.4.1 and 2.4.2), 
amplification was performed. For 5' RACE, a TRPM1-specific reverse primer 
was used together with the GeneRacer 5' primer. PCR reactions were setup 
according to the manufacturer’s instructions with an annealing temperature of 
68 °C. Subsequent nested PCR was also performed at 65 °C. In a similar 
fashion, two rounds of PCR for 3' RACE were setup (a TRPM1-specific 
forward primer and a nested TRPM1-specific forward primer with 
corresponding primers in the kit) using the same conditions as in the 5' RACE. 
The experiments were optimised and conducted with the assistance and 
supervision of Dr Zheng Li.  
 
 
 
 
 
 
Table 2-4. Rapid Amplification of 5' and 3' cDNA Ends primer sequences 
GeneRacer 5' primer CGACTGGAGCACGAGGACACTGA 
TRPM1 5' GSP-reverse GGAGCAGTGAGTCTGGCTTGGTGTCATA 
GeneRacer 5' nested primer GGACACTGACATGGACTGAAGGAGTA 
TRRM1 5' GSP-nested GGCAGAGGGGGGATATGCTGGTTGGTGAA 
GeneRacer 3' primer GCTGTCAACGATACGCTACGTAACG 
TRPM1 3' GSP-forward CCCAGATGGCAGTCACCTTGCAGTAGAT 
GeneRacer 3' nested primer CGCTACGTAACGGCATGACAGTG 
TRPM1 3' GSP-nested CCTCGAATCCCTCGCTTGTCCCTAA 
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Figure 2-2. Flow chart showing the RACE experiment outline as presented in the Invitrogen 
GeneRacer Kit instruction manual. 
 
2.4.13 Cloning PCR Products into T Vectors 
 
Taq polymerase generated PCR products were cloned into a vector (T vector) 
containing a complementary unpaired 3' thymidyl residue [243]. After PCR 
products were purified from an agarose gel, they were inserted to either a 
linearised pCR4-TOPO (Invitrogen) or a pGEM-T easy (Promega) vector. The 
main difference between these two cloning kits is that the first does not require 
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DNA ligase and uses topoisomerase I [244-245] while the second one is a 
typical, ligase based, T vector system (section 2.4.7).  
 
2.4.14 Purification of PCR Products and Plasmid DNA 
 
Typically, PCR fragments were purified using vacuum-based, size exclusion 
separation with a small volume, 96-well filter device (Montage PCR96 cleanup 
kit, Millipore, Watford, UK) according to the manufacturer’s instructions. 
 
On some occasions, the QIAquick gel extraction kit (Qiagen) was used to 
isolate the amplified DNA contained in excised bands from agarose gels. The 
manufacturer’s instructions were followed in order to bind the amplified DNA to 
the anionic silica membrane of appropriate columns after centrifugation. 
 
As part of the Affymetrix GeneChip Mapping 50K Xba Assay Kit protocol 
(section 2.4.18.2.1), pooled PCR products were purified with a MinElute 96 UF 
PCR Purification kit (Qiagen). 
 
For purification of high copy plasmid DNA from E.coli cultures, a QIAprep spin 
(Qiagen) or a Genelute plasmid (Sigma-Aldrich) miniprep kit were used 
according to the manufacturer’s instructions; a microcentrifuge was utilised. 
 
2.4.15 High Resolution Melting Analysis 
 
HRM is a rapid and cost effective method for targeted genotyping and 
mutation screening [246]. It is based on the analysis of the melting profile of 
amplified DNA and uses saturating fluorescent dye to monitor the transition 
from unmelted to melted polynucleotide. The approach was first introduced in 
1997 [247-248] and recent advances in instrumentation and DNA binding dyes 
have increased its sensitivity, accuracy and clinical utility. 
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HRM analysis was performed using the LightScanner System (Idaho 
Technology, Salt Lake City, UT, USA), which allows DNA sequence variation 
scanning in two steps: amplification (with a fluorescent dye) and amplimer 
melting. 
 
Amplification was performed either using the 2.5x LightScanner High 
Sensitivity Master Mix (Idaho Technology) or the following mix (final reaction 
volume 10 μl):  
1x reaction buffer, 0.2x of enhancer (Molzym),  
0.125 mM of each dNTP,  
1 μM of forward and reverse primer,  
10 to 50 ng of genomic DNA,  
10 U of Taq polymerase (MolTaq, Molzym) and  
1x of LCGreen Plus DNA dye (Idaho Technology). 
 
Each reagent concentration in this mix was titrated and optimised by 
comparing the agarose gel band appearance of control DNA amplified with 
this method to the one amplified with 2.5x LightScanner High Sensitivity 
Master Mix (Idaho Technology). 15 μl of mineral oil (Sigma-Aldrich) were 
added in each well before starting the reaction to avoid evaporation. 
 
PCR cycling parameters were used as described in the manufacturer’s 
instructions with annealing temperature ranging from 67.5 to 70 °C. 
 
Following PCR, amplimer melting was performed in 96-well plates. The 
LightScanner System (Idaho Technology) collected data from 77 to 95 °C at a 
ramp rate of 0.10 °C per second. Images of DNA melting were captured by 
CCD camera and sample-to-sample comparisons of these images were used 
to interrogate the sequences of the amplified DNA.  
 
Interpretation of data was performed using the Lightscanner Instrument and 
Analysis software with Call-IT function version 2.0 (Idaho Technology). After 
defining the negative control, raw melting data of different samples were 
normalised; lower temperature ranged between 83 and 93 °C and upper 
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temperature ranged between 90 and 95 °C. The default value of 5% was 
chosen for the melting temperature curve shift function. Samples were 
clustered into groups using various curve shape matching algorithms. Different 
sensitivity levels were tried (all over 0.25) and both normalised melting curve 
and difference plots were inspected. Samples with significant differences in 
fluorescence were selected, purified and sequenced bidirectionally. 
 
2.4.16 DNA Sequencing Using Sanger Method 
 
Nucleotide sequence of PCR fragments and plasmid DNA was determined 
using Sanger’s dideoxy mediated chain termination method [249-250]; the 
BigDye terminator v3.1 (>500 base pairs) cycle sequencing kit (ABI, Foster 
City, California, USA) was utilised. The sequencing reaction consisted of the 
following components: 10 to 50 ng of purified amplified DNA, 1 μM sequencing 
primer, 1x BigDye sequencing buffer, 0.5 µl of BigDye terminator and dH20 (up 
to 10 µl). 
 
The standard cycle sequencing conditions used were: 96 °C for 1 minute 
followed by 25 cycles of 96 °C for 10 seconds, 50 °C for 5 seconds and 60 °C 
for 4 minutes. Extension products were purified using a vacuum-based 
protocol with size-exclusion filter plates (Montage SEQ96 Sequencing Reaction 
cleanup kit, Millipore). Automated capillary electrophoresis was performed on 
a multi-colour fluorescence-based DNA analysis system with 48 capillaries 
operating in parallel (ABI PRISM 3730 Genetic Analyser). As a result, 
electropherogram files (AB1 files using the ABIF binary file format) were 
generated.  
 
2.4.17 Targeted Capture and High-throughput DNA Sequencing 
 
Sanger’s method has provided the backbone technology for genome analysis 
for the past 30 years. There has recently been a shift away from this approach 
[251]; in 2005, the beginning of a new era characterised by a “dizzying free-fall 
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in sequencing costs” [252] was heralded by two publications [253-254] 
introducing massively parallel, high-throughput DNA sequencing (figures 2-3 
and 2-4). Nevertheless, six years after and despite the cost of DNA 
sequencing dropping by approximately four orders of magnitude 
(http://www.genome.gov/sequencingcosts/), sequencing a human genome in 
its entity is still an expensive endeavour. Additionally, the costs associated 
with downstream data handling often match or surpass the data acquisition 
costs [251]. As an interim solution, target-enrichment methods in which 
specific genomic regions are selectively captured from a DNA sample prior 
sequencing, have been developed [255-257]. Such strategies often target the 
protein coding subset of the genome, i.e. the exome. Over the past couple of 
years “whole exome sequencing by high-throughput sequencing of target-
enriched genomic DNA” (exome sequencing) has been widely used to cost-
effectively interrogate this interpretable subset of the genome. 
 
 
Figure 2-3. Overview of commercially available high-throughput sequencing technologies and 
the combination of different protocols used. The methods included are diverse and can be 
broadly grouped as template preparation and sequencing. 
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Figure 2-4. Illumina reversible terminator-based sequencing method (modified from [251] and 
http://genome.wellcome.ac.uk/doc_WTX056439.html). 
[A] Random fragmentation of genomic DNA into small sizes (~100 to 300 base pairs; 
ultrasound technology is typically used) is followed by end-repair (converts the overhangs 
resulting from fragmentation into blunt ends), adenylation of 3' ends (to prevent fragments 
from ligating to one another during the adapter ligation reaction and allow efficient ligation to 
the complementary overhang-containing adapter) and adapter ligation. 
[B] The next step (amplification) is performed on an optically transparent surface similar to a 
microscope slide called the flow cell. The flow cell is partitioned into eight lanes/channels and 
high-density forward and reverse primers are bound to the its surface; these anchored 
oligonucleotides are complimentary to the adaptors used in the previous step. Adapted single-
stranded DNAs are randomly bound to the flow cell and amplified by solid-phase PCR (bridge-
amplification). In each PCR cycle, priming occurs by arching of the template molecule such 
that the adapter at its free end hybridizes to and is primed by a free oligonucleotide in the near 
vicinity on the flow cell surface. This process results in randomly distributed (“raindrop 
pattern”), clonally amplified clusters from fragment templates on a glass surface [251, 258-
259]. 
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[C] A cyclic reversible termination method utilising fluorescently modified nucleotides is used 
for sequencing. Initially, labelled terminators (3'-blocked nucleotides; each of A, T, C and G is 
bound to a different fluorophore), primer and DNA polymerase are applied to the flow cell. 
Subsequently, a three-step cycle which includes nucleotide incorporation, imaging and 
cleavage is repeated a number of times. In the first step, a dye-labelled modified nucleotide, 
complementary to the template base, is incorporated; this leads to termination of DNA 
synthesis. In the second step, remaining unincorporated nucleotides are washed away and the 
fluorescent signal at each cluster is recorded. Following imaging, a cleavage step removes the 
fluorophore from each incorporated base, unblocking the 3'-OH group. Washing is performed 
before starting the next incorporation step [251, 258-259]. 
 
As part of this study, solution-phase hybrid capture with biotinylated RNA baits 
was used to target 38 Mb (SureSelect Human All Exon Kit, Agilent, Santa 
Clara, CA, USA [256]) of genome sequencing from each of 12 patient DNA 
samples (sections 2.1.4 and 3.2.2). The enriched library was amplified and 
then sequenced on a HiSeq2000 (100 base pair paired-end mode; Illumina, 
San Diego, CA, USA). All experimental procedures were carried out according 
to the manufacturers’ protocols in BGI Shenzhen, China. Data were returned 
as two FASTQ files [260] per patient sample. 
 
2.4.18 DNA Microarrays 
 
Microarrays utilise a reverse hybridization assay to test for sequence variation 
in known target sequences, or to monitor for RNA expression levels. The idea 
that labelled nucleic acid molecules could be used to interrogate DNA 
attached to a solid support dates back to 1975 when Southern blot, the first 
DNA array, was introduced [261]. Key innovations in miniaturization, 
fluorescence-based detection [262-263], genome amplification [264-265] and 
oligonucleotide high density chemical synthesis [266-268] during the 1990s 
have provided a scale-up in hybridization assay technology, introducing 
oligonucleotide microarrays. Currently, microarrays are a standard tool of 
biomedical research and clinical diagnostics [269-270]. 
 
In this study different types of arrays have been used to identify and genotype 
mutations and polymorphisms. 
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2.4.18.1 Arrayed Primer Extension Microarray 
 
APEX technology was first introduced as a novel method for DNA analysis in 
1996 [271-272]. The APEX reaction involves several simultaneous mini-
sequencing reactions on a solid support (figure 2-5). Numerous 5′ modified, 
sequence specific oligonucleotides (probes) are arrayed on a glass surface 
with their 3′ end designed immediately adjacent to a variable site. PCR 
amplified and fragmented DNA from target samples is hybridised to the array. 
DNA polymerase-driven extension of the immobilised probes’ 3′ ends with 
ddNTPs is performed. The pattern of binding at different spots gives a visual 
record of the genotype. 
 
A number of patient samples were sent to Asper Ophthalmics, Tartu, Estonia 
for analysis with the LCA [273], recessive RP or ABCA4 chip [274] (Asper 
Biotech, Tartu, Estonia).  
 
                 A                                    B                                  C                                       D           
 
Figure 2-5. Overview of APEX technology.  
[A] Oligonucleotide probes are arrayed on a glass slide. 
[B] Complementary fragments of PCR amplified target sample DNA are annealed to the 
probes.  
[C] DNA polymerase-mediated, sequence-specific single nucleotide extension of the 3′ ends 
of the probe with fluorescent ddNTPs. 
[D] DNA fragments and unused ddNTPs are washed off followed by signal detection 
(modified from [274]). 
 
2.4.18.2 Genome-Wide Genotyping SNP Arrays 
 
Affymetrix GeneChip arrays were used in order to perform large scale, 
genome-wide linkage analysis. GeneChip probe arrays are high density, solid-
phase arrays (quartz chips), containing up to a million of different 
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oligonucleotide sequences on their glass surface. The different DNA probes 
are constructed by in situ, light-directed synthesis in sequential steps as 
opposed to being prepared in advance and then spotted onto the surface (e.g. 
APEX chips). 
 
2.4.18.2.1 Affymetrix GeneChip Human Mapping 50K Array Xba 
 
DNA samples from 21 individuals (section 2.1.3) have been processed with 
the Affymetrix GeneChip Mapping 50K Xba Assay Kit, enabling genotyping of 
over 50,000 SNPs per sample. Genomic DNA was digested with Xba I and 
ligated to adaptors that recognised the cohesive overhangs (sections 2.4.6 
and 2.4.7). A universal primer annealing to the adapter sequence was then 
used to amplify the adaptor-ligated fragments in a PCR reaction. The amplified 
DNA was then fragmented to a size range of 250 to 2,000 base pairs. 
Fragmented PCR products were then labelled and transferred to the Wolfson 
Institute, UCL, London, UK for hybridisation to the Affymetrix GeneChip 
Human Mapping 50K Array Xba. All steps were performed according to the 
manufacturer’s instructions. 
 
2.4.18.2.2 Affymetrix Genome-Wide Human SNP Array 6.0 
 
During the course of this study, as the array information capacity increased 
and the array price dropped, a decision to switch from the Affymetrix 
GeneChip Human Mapping 50K Array Xba to the Affymetrix Genome-Wide 
Human SNP Array 6.0 was made. The former features 1,800,000 genetic 
markers, including more than 906,600 SNPs and more than 946,000 probes 
for the detection of copy number variants (figure 2-6). 
 
For each subject (section 2.1.3), 500 ng of genomic DNA were sent to St. 
Mary's Hospital Academic Medicine Department, University of Manchester. 
Subsequently, ARR (array attribute), CEL (probe results) and GQC (genotype 
quality control) files were received and analysed.  
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Figure 2-6. Overview of the Affymetrix Genome-Wide Human SNP Nsp/Sty Assay 6.0 (from 
the Affymetrix datasheet). A similar principal applies to the Affymetrix GeneChip Mapping 50K 
Xba Assay although digestion with one (Xba I) rather than two restriction enzymes is 
performed. 
 
2.4.19 Microsatellite Markers 
 
Microsatellites are short runs (usually less than 100 base pairs) of tandem 
repeats of a very simple DNA sequence, usually 1 to 4 base pairs [134]. 
Genotyping with microsatellite markers was introduced in 1989 [275] and due 
to their abundance and high degree of polymorphism they became the primary 
tool for genetic mapping during the 1990s. 
 
Markers on 19p were chosen from the Généthon map [276] and fluorescently 
labelled microsatellite primers were ordered (ABI PRISM Linkage Mapping Set 
version 2.5). Microsatellite PCR reactions were performed according to the 
manufacturer’s instructions with an annealing temperature of 55 °C. The PCR 
products were diluted and (either multiplexed or alone) loaded onto an ABI 
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PRISM 3730 Genetic Analyser. Raw sample files (FSA files using the ABIF 
binary file format) were generated and fragment genotyping analysis was 
performed with the ABI GeneMapper Software (version 4.1). 
 
To further refine the candidate region, additional microsatellite primers were 
designed and labelled using a different approach, first described by Schuelke 
[277]. A sequence-specific forward primer with an M13(-21) tail at its 5′ end 
was designed. This oligonucleotide was subsequently added to the PCR mix 
together with a sequence-specific reverse primer and a FAM-labelled universal 
M13(-21) primer; amplification was carried out as previously described [277]. 
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2.5 Bioinformatics 
 
Despite the fact that computers were important tools in molecular biology a 
decade before DNA sequencing became feasible [278], the term 
bioinformatics was not used until 1978 when Dutch biologist Paulien Hogeweg 
coined the term as “the study of information processes in biotic systems” [279-
281]. Today, bioinformatics is used to describe the application of 
computational tools and techniques to capture, manage and analyse biological 
data (figure 2-7). Bioinformatics main aims are [282-285]:  
(a) To organise data in a way that allows researchers to access existing 
information and submit new entries. 
(b) To develop tools and resources that aid in the analysis of data and 
interpretation of the results in a biologically meaningful manner. 
 
Publically available bioinformatics databases and tools used in this study are 
summarised in table 2-5. 
 
Table 2-5. Publically available bioinformatics databases and tools used in this study 
Bioinformatics method: Link 
primer designing software http://www.basic.northwestern.edu/biotools/oligocalc.html 
http://frodo.wi.mit.edu/primer3/ 
genomic databases and 
genome browsers 
http://www.ensembl.org/ 
http://genome.ucsc.edu/ 
http://www.ncbi.nlm.nih.gov/sites/entrez?db=genome 
DNA variation databases 
(accessed 20/11/2011 
unless otherwise stated) 
http://browser.1000genomes.org/index.html 
http://snp.gs.washington.edu/EVS/ 
http://www.ncbi.nlm.nih.gov/projects/SNP/ 
http://www.hgmd.cf.ac.uk/ac/ 
http://hapmap.ncbi.nlm.nih.gov/ 
tools for sequence 
alignment 
http://www.ebi.ac.uk/Tools/clustalw2/ 
http://www.tcoffee.org/ 
http://genome.ucsc.edu/cgi-bin/hgBlat/ 
tools predicting impact of 
DNA variants on the 
structure and function of 
a protein 
http://genetics.bwh.harvard.edu/pph2/ 
http://genetics.bwh.harvard.edu/pph/ 
http://sift.bii.a-star.edu.sg/ 
http://bg.upf.edu/group/projects/condel.php 
http://mmb2.pcb.ub.es:8080/PMut/ 
http://www.ncbi.nlm.nih.gov/Class/FieldGuide/BLOSUM62.txt  
http://www.fruitfly.org/seq_tools/splice.html 
http://www.cbs.dtu.dk/services/NetGene2/ 
http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi 
http://cubweb.biology.columbia.edu/pesx/ 
http://genes.mit.edu/burgelab/rescue-ese/ 
expression databases 
and software modelling 
http://www.genenetwork.org/ 
http://www.ncbi.nlm.nih.gov/dbEST/ 
MATERIALS AND METHODS 
 
77 
 
gene regulatory dynamics
 
and networks 
http://www.ncbi.nlm.nih.gov/unigene 
http://neibank.nei.nih.gov/EyeSAGE/ 
http://omicspace.riken.jp/PosMed/ 
http://bioinfo.wilmer.jhu.edu/morenet/ 
tools for prediction
 
of 
gene and protein 
structure and function 
http://swissmodel.expasy.org/ 
http://www.pymol.org/ 
http://www.umass.edu/microbio/rasmol/ 
http://opm.phar.umich.edu/ 
http://www.ebi.ac.uk/Tools/InterProScan/ 
http://www.ebi.ac.uk/pdbsum/ 
http://www.pdb.org/pdb/home/home.do 
http://www.psipred.net/ 
http://pfam.sanger.ac.uk/ 
http://smart.embl-heidelberg.de/ 
tools for analysis of 
genome-wide genotyping 
data 
http://bioinf.wehi.edu.au/software/linkdatagen/ 
http://www.sph.umich.edu/csg/abecasis/merlin/ 
http://pngu.mgh.harvard.edu/~purcell/plink/ 
http://dna.leeds.ac.uk/autosnpa/ 
http://www.affymetrix.com/estore/browse/level_seven_software_pr
oducts_only.jsp?productId=131535&categoryId=35625#1_1 
http://www.affymetrix.com/estore/browse/level_seven_software_pr
oducts_only.jsp?productId=131408&categoryId=cat40006#1_1 
tools for analyzing exome 
sequencing data 
http://www.novocraft.com/main/page.php?s=novoalign 
http://bio-bwa.sourceforge.net/ 
http://samtools.sourceforge.net/ 
http://picard.sourceforge.net/index.shtml 
http://code.google.com/p/bedtools/ 
http://samtools.sourceforge.net/tabix.shtml 
http://vcftools.sourceforge.net/ 
http://www.openbioinformatics.org/annovar/ 
http://snp.gs.washington.edu/SeattleSeqAnnotation131/ 
http://www.broadinstitute.org/software/igv/ 
http://genomesavant.com/ 
http://compbio.charite.de/index.php/ibd2.html 
http://main.g2.bx.psu.edu/ 
ftp://ftp.ensembl.org/pub/current_fasta/homo_sapiens/dna/ 
http://www.ncbi.nlm.nih.gov/nuccore/251831106/ 
http://bzip.org/ 
http://www.r-project.org/ 
http://www.gnu.org/software/bash/ 
other http://www.omim.org/ 
http://www.uniprot.org/ 
http://www.ensembl.org/biomart/ 
http://www.sph.uth.tmc.edu/retnet/ 
http://www.hgvs.org/mutnomen/ 
http://phenome.jax.org/ 
http://www.sanger.ac.uk/mouseportal/ 
http://www.komp.org/ 
http://www.proteinatlas.org/ 
https://putt.eng.uiowa.edu/ 
http://bioweb.pasteur.fr/phylogeny/intro-en.html 
http://www.open-bio.org/ 
http://www.bioconductor.org/ 
http://tools.neb.com/NEBcutter2/ 
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Figure 2-7. Disciplines 
related to bioinformatics. In 
the past bioinformatics 
focused on practical 
applications of informatics to 
genomics. As data-driven is 
replaced by principle-driven 
biology, bioinformatics will 
become a more fundamental 
discipline encompassing other 
fields of basic science 
(concept from [286]). 
 
 
2.5.1 Primer Design 
 
Primers were designed to avoid the known polymorphisms; their properties 
were evaluated with OligoCalc [287]. Typically, PCR primers (a) between 18 
and 28 nucleotides long, (b) with GC content ideally between 50 and 60% and 
(c) with minimal hairpin loop formation and self-complementarity were chosen. 
All primer sequences were submitted to the NCBI BLAST site and the ones 
with more than 90% similarity with a nucleotide sequence of the human 
genome other than the target sequence were rejected. The two primers of a 
primer pair had closely matched melting temperatures (difference <5 °C). 
Amplimer length for standard PCR was up to 1,000 base pairs. 
 
2.5.2 DNA Sequence Analysis 
 
2.5.2.1 Sanger Sequencing Data 
 
The Seqman Pro application (Lasergene version 8.02 sequencing analysis 
software suite, DNASTAR Inc., Madison, WI, USA) was used to assemble and 
analyse sequencing data (AB1 files). On occasion, the ABI Sequence Scanner 
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Software v1.0 or the Sequencher 4.10.1 (Gene Codes Corporation, Ann Arbor, 
USA) tools were utilised to inspect the raw signal data. 
 
2.5.2.2 Exome Sequencing Data 
 
Mining data sets generated from high-throughput sequencing platforms poses 
several hurdles for analysis and storage; thus high-performance computational 
infrastructure is essential [288]. A computer cluster optimised for many classes 
of computationally intense applications was used (UCL Genetics Institute 
cluster running OpenBSD 4.5, a unix-like operating system). 
 
Raw sequencing data were shipped in a storage drive from BGI, Shenzhen, 
China. For each patient sample, two compressed (gzip) Solexa/Illumina 
FASTQ files [260] were received. Initially, a high-quality data compressor 
(bzip2 1.0.6) was used. Subsequently, the relatively short (~100 base pair), 
paired-end reads generated by the Illumina HiSeq2000 sequencer were 
aligned against a reference sequence [289]. The novoalign short-read mapper 
(v2.05 and v2.07, Novocraft, Selangor, Malaysia; arguably the most accurate 
aligner to date: http://lh3lh3.users.sourceforge.net/NGSalign.shtml) and the 
novoindex utility (Novocraft) were used. The g1k (NC_012920.1) version of the 
mitochondrial genome and the GRCh37.p5 human coverage assembly were 
combined into a reference sequence. A tab-delimited text file containing 
alignment information (SAM file format [290]) was generated for each pair of 
FASTQ files. SAM files were then imported into the SAMtools software 
package [290], converted into a highly compressed binary form (BAM files 
created), sorted and had duplicate reads removed (using Picard’s 
MarkDuplicates tool with REMOVE_DUPLICATES option). The resulting file 
was indexed (BAI file created) and the output was one _sorted_unique.bam 
file with its respective _sorted_unique.bam.bai file for each sequenced 
sample. 
 
BAM is a key file format separating the alignment step from downstream 
analysis enabling a “generic or modular approach to the analysis of genomic 
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sequencing data” [290]. Importantly, most assembly programs and alignment 
tools directly produce SAM/BAM files and the space-efficient BAM format is 
routinely used for storing and sharing raw high-throughput sequencing data 
[291].  
 
Each BAM file was imported in a number of alignment viewers (including 
Savant [292] and IGV [293]); these tools allow to visually understand the 
alignment and validate variant calls and structural variation. Other downstream 
analysis of BAM files included obtaining index statistics (e.g. count of aligned 
and unaligned reads; Picard’s BamIndexStats tool was used) or mapping 
statistics (e.g. coverage in the targeted/exome regions; Picard’s 
CalculateHsMetrics tool was used) and producing pileup datasets (using 
SAMtools pileup option). In the pileup format, each line represents a genomic 
position, consisting of chromosome name, coordinate, reference base, read 
bases, read qualities and alignment mapping qualities. Notably, information on 
match, mismatch, insertions-deletions and mapping quality are encoded at the 
read base column (http://samtools.sourceforge.net/samtools.shtml). 
Processing the resulting pileup files with SAMtools enabled calling single 
nucleotide variants and short insertions-deletions as well as storing them in 
tab-delimited text files (VCF file format [294]); functional annotation of detected 
genetic variation was performed by processing these VCF files with the 
ANNOVAR tool [295]. Finally, sequential filtering of variants was carried out 
using R scripts or spreadsheet applications. 
 
Most software used (bzip2, novoalign, SAMtools, Picard and ANNOVAR) have 
been designed to work on a stream. Consequently, several commands were 
combined in unix pipes. The reference pipeline code (in bash) was written by 
Dr Vincent Plagnol under whose supervision all the exome sequencing data 
analysis was performed.  
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2.5.3 Expression Analysis Databases 
 
Expression of genes can be tested by RT PCR followed by Sanger 
sequencing, whole transcriptome shotgun sequencing (RNA-Seq), Northern 
blotting, in situ hybridization against mRNA in tissue section, SAGE and 
expression microarrays. Furthermore, immunohistochemistry using labelled 
antibodies is a widely used method to assess protein expression in different 
parts of a biological tissue. 
 
From a list of genes within a chromosomal region identified by linkage, one 
would look for a gene that shows appropriate expression and/or appropriate 
function. Genes paralogous or orthologous to a relevant gene should also be 
tested [134].  
 
To assist selection and prioritisation of genes for mutation screening, an SQL 
database has been created. In general, genes preferentially or specifically 
expressed in the retina or knowingly associated with retinal disease have been 
included. The database contains the Retinal Information Network dataset 
(http://www.sph.uth.tmc.edu/retnet/) and results from experiments using either 
DNA microarrays or SAGE to analyse expression patterns [296-314]. Data 
from experiments using chromatin immunoprecipitation followed by high-
throughput sequencing (ChIP-seq) to identify binding sites for the transcription 
factor CRX across the mouse genome (genome-wide protein-DNA interaction 
or cis-regulatory mapping) [315] have also been included in the devised 
database. 
 
Further to the database, four different datasets were queried: 
(a) dbEST (http://www.ncbi.nlm.nih.gov/dbEST) [316]: a database of over eight 
million deposited expressed sequence tags (generated by RT PCR and cDNA 
sequencing) from human tissue.  
(b) The EyeSAGE database (http://neibank.nei.nih.gov/EyeSAGE/) [297]: a 
database summarising the results from SAGE experiments [317] on donor 
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eyes; frequency data for genes expressed in retina, RPE, macular and 
peripheral retinal tissue are included. 
(c) Genenetwork (http://www.genenetwork.org): a database of mouse 
phenotypes including the levels of expression of several genes in the retina 
(generated by expression microarrays) [318]. Often genes of similar function 
or genes involved in the same biochemical pathway have expression levels 
that are tightly correlated in different mouse strains.  
(d) Positional Medline (http://omicspace.riken.jp/PosMed) [319] a database 
that interrogates pubmed (http://www.ncbi.nlm.nih.gov/pubmed/) for 
occurrences of both search terms and all genes within a specified genomic 
region.  
 
2.5.4 Genome-wide Genotyping Data Analysis 
 
Primary data (CEL files) analysis was performed with the Genotyping Console 
Software (Affymetrix). Either the BRLMM (for the Affymetrix GeneChip Human 
Mapping 50K Array Xba; http://array.mc.vanderbilt.edu/microarray/dna/ 
brlmm.pdf) or the birdseed v2 (for the Affymetrix Genome-Wide Human SNP 
Array 6.0; http://www.broadinstitute.org/mpg/birdsuite/birdseed.html) algorithm 
was used to genotype SNP data; the canary algorithm was used for copy 
number data [320]. 
 
For SNPs, a call confidence score threshold was set (typically ≤0.01) and 
genotyping results were exported to a comma-separated values (CSV) file for 
further analysis. For copy number probes, analysis was performed on the 
Chromosome Analysis Suite (ChAS) software (Affymetrix). 
 
2.5.4.1 Excel visual basic 
 
A macro was written by Dr Andrew R Webster in Visual Basic programming 
language within the Microsoft Excel spreadsheet application (Microsoft, 
Redmond, WA). Detection of genomic regions of shared haplotype 
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(homozygosity) and regions of linkage in family data as well as sex checks 
based on X chromosome SNPs and testing for non-Mendelian transmission 
were enabled. 
 
2.5.4.2 Perl 
 
The aforementioned macro code (section 2.5.4.1) was translated to Perl 
programming language (v5.12; http://www.perl.org/) and further enriched. In 
the Perl version, after a threshold of consecutive SNPs fitting a certain 
criterion (homozygosity or linkage) is set, regions of interest and a results 
summary table are automatically exported into a spreadsheet format (XLS 
file). 
 
Perl is a flexible, high-level, general-purpose, interpreted, dynamic 
programming language that borrows features from C and is extensively used 
in bioinformatics. It has become popular with biologists because it is well-
suited to several bioinformatics tasks [321]: (a) it has a well supported 
biological suite, (b) it has an extensive library of modules to support 
bioinformatics/ genomics work (BioPerl, http://bioperl.org/; 
http://www.cpan.org/) [322] and (c) it can be integrated with other languages 
such as R and C (both of which are common in bioinformatics). 
 
2.5.4.3 Python 
 
In order to be able to analyse the large amount of SNP data generated by the 
Affymetrix Genome-Wide Human SNP 6.0 Arrays, an approach skipping the 
initial processing in a spreadsheet application and indexing the data was 
necessary. Due to the first step being the merging of selected columns from 
the appropriate annotation files (available in http://www.affymetrix.com/) with 
the genotyping data (AA, AB, BB, NoCall), processing in a database 
environment was required. MySQL (www.mysql.com), a relational database 
management system that runs as a server providing multi-user access to a 
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number of databases [323], was used to store and annotate the data. A python 
(www.python.org/) script interacting with a MySQL database and allowing 
identification of regions of homozygosity or linkage was composed (section 
6.2). The program is running on a Ubuntu 10.04 Linux machine with python 
2.6.5, MySQL 5.1 and a python-mysqldb 1.2.2-7ubuntu1 module. 
 
Python (www.python.org/) is a general-purpose, high-level programming 
language whose design philosophy emphasizes code readability [324]. 
Python’s collection of modules intended for bioinformatics (BioPython, 
http://biopython.org/) was founded in 1999, four years after BioPerl. 
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3 RESULTS 
 
3.1 Screening Genes Knowingly Associated with Retinal Disease 
 
3.1.1 Mutation Detection 
 
Once the first links between a list of genes and a list of well recognised clinical 
entities have been drawn, attention must turn to identifying genotypically 
homogeneous groups of patients and carefully obtaining information on their 
phenotype. Over the last two decades a wide variety of mutations in a number 
of different genes have been shown to cause dysfunction and premature death 
of the photoreceptor cells. However, as we are still in the early days of 
practical genetic tests, the “boundaries that are inherent in focused 
prospective studies funded by research organizations” [325] have not been 
broken and our knowledge of the phenotype and clinical course of inherited 
retinal disorders is still limited. 
 
One part of this study aims to review and take advantage of the knowledge 
accumulated so far in order to examine small portions of the retinal disease-
associated gene set (RetNet) in carefully selected groups of patients (e.g. 
NYX, GRM6, TRPM1 in individuals with CSNB). Once a sequence variant had 
been identified and statistically significantly associated with disease, the 
consequences on retinal function and structure were investigated in the light of 
this new information. Clinical observations of genetically similar patients were 
pooled and data on variability (phenotypic range) and natural history of 
disease were generated. 
 
Understanding and, ultimately, predicting the downstream events that occur in 
response to a specific genotype is invaluable for two main reasons. Firstly, 
counselling and prognosis: specific outcomes can be predicted years before 
they occur. Secondly, treatment: better design of clinical therapeutic trials, 
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better judgement of the risk/benefit ratio of treatment and more informed 
interpretation of the therapeutic benefits are enabled. 
 
Over twenty genes previously reported to be associated with recessive retinal 
disease have been sequenced in selected panels of patients; many likely 
disease-causing variants have been detected and the retinal phenotype of 
subjects with biallelic changes has been characterised. These results are 
discussed in this chapter (sections 3.1.2, 3.1.3, 3.1.4, 3.1.5, 3.1.6 and 3.1.7) 
and have contributed to published (MFRP, MERTK, CRB1, C2ORF71, RDH5, 
KCNV2, GRM6, OAT) [326-331] or under preparation (CYP4V2, NR2E3) 
manuscripts. 
 
Likely disease-associated variants identified as part of this study can be found 
in table 3-1. Mainly biallelic changes with convincing pathogenic effect 
(previously reported or segregating with disease and not identified in control 
DNAs) are included. 
 
 
 
Table 3-1. Summary of knowingly associated with retinal disease genes screened and 
pairs of likely disease-associated variants identified. 
Gene Allele 1 Reference Proven or 
Presumed Allele 2 
Reference 
CRB1 
OMIM 604210 
c.2401A>T, 
p.Lys801X 
den Hollander et 
al. [332] 
c.3320T>C, 
p.Leu1107Pro 
Hanein et al. 
[333] 
c.2843G>A, 
p.Cys948Tyr 
den Hollander et 
al. [334] 
c.2688T>A,  
p.Cys896X 
Hanein et al. 
[333] 
c.2843G>A, 
p.Cys948Tyr 
den Hollander et 
al. [334] 
c.2955insAG, 
p.Asn986AlafsX2 
novel 
c.2843G>A, 
p.Cys948Tyr  
den Hollander et 
al. [334] 
c.727_743delCTGGGG
GCCTATTTCT, 
p.Leu243AlsfsX50 
novel 
c.2843G>A, 
p.Cys948Tyr  
den Hollander et 
al. [334] 
c.936T>G,  
p.Asn312Lys 
novel 
c.2506C>A, 
p.Pro836Thr 
den Hollander et 
al. [332] 
c.470G>C,  
p.Cys157Ser 
novel 
c.584G>T, 
p.Cys195Phe 
den Hollander et 
al. [332] 
c.3442C>T, 
p.Cys1148Arg 
novel 
c.584G>T, 
p.Cys195Phe 
den Hollander et 
al. [332] 
not identified 
c.2842+5G>A den Hollander et 
al. [334] 
not identified 
KCNV2 
OMIM 607604 
c.1381G>A, 
p.Gly461Arg 
Thiagalingam et 
al. [335] 
c.377T>A, 
p.Leu126Gln 
Wu et al. [175] 
c.1381G>A, 
p.Gly461Arg 
Thiagalingam et 
al. [335] 
c.966G>C, 
p.Ala322Pro 
novel 
c.451T>C, 
p.Phe151Leu 
novel not identified 
c.1199delT, 
p.Phe400fsX53 
novel c.8_11delAACA, 
p.Lys3fsX93 
novel 
c.568delG, 
p.Gly189fsX21 
novel c.568delG, 
p.Gly189fsX21 
novel 
c.1318C>T, 
p.Asn439Ile 
novel c.1318C>T, 
p.Asn439Ile 
novel 
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NR2E3 
OMIM 604485 
c.119-2A>C Haider et al. [336] c.119-2A>C Haider et al. 
[336] 
c.119-2A>C Haider et al. [336] c.767C>A, 
p.Ala256Glu 
Sharon et al. 
[337] 
c.119-2A>C Haider et al. [336] c.1018G>A, 
p.Glu340Lys  
novel 
c.932G>A; 
p.Arg311Gln 
Haider et al. [336] c.1112C>G, 
p.Leu371Trp 
novel 
c.572-2A>C novel c.572-2A>C novel 
c. 646G>A, 
p.Gly216Ser 
novel c. 646G>A, 
p.Gly216Ser 
novel 
c.166G>A, 
p.Gly56Arg 
Coppieters et al. 
[338] 
Dominant inheritance 
GRM6 
OMIM 604096 
c.2122C>T, 
p.Gln708X 
Dryja et al. [157] c.1054C>T, 
p.Arg352Cys 
novel 
c.2029C>T, 
p.Arg677Cys 
novel c.2029C>T, 
p.Arg677Cys 
novel 
c.2030G>A, 
p.Arg677His 
novel c.2030G>A, 
p.Arg677His 
novel 
c.712C>T, 
p.Arg238X 
O’Connor et al. 
[339] 
c.2029C>T, 
p.Arg677Cys 
novel 
c.2267G>A, 
p.Gly756Asp 
novel c.2267G>A, 
p.Gly756Asp 
novel 
c.575delG, 
p.Val193fsX15 
novel c.575delG, 
p.Val193fsX15 
novel 
c.823G>A, 
p.Gly275Asp 
Zeitz et al. [340] c.2062delC, 
p.Pro689fsX24 
novel 
TRPM1 
OMIM 603576 
c.220C>T, 
p.Arg74Cys 
novel c.3004A>T, 
p.Ile1002Phe 
novel 
RDH5 
OMIM 601617 
c.712G>T, 
p.Gly238Trp 
Yamamoto et al. 
[149] 
c.712G>T, 
p.Gly238Trp 
Yamamoto et al. 
[149] 
c.712G>T, 
p.Gly238Trp 
Yamamoto et al. 
[149] 
c.310+1 G>A novel 
c.346_348insGCA, 
p.Gly116_Ile117insSer 
novel c.346_348insGCA, 
p.Gly116_Ile117insSer 
novel 
c.346G>C, 
p.Gly116Arg 
novel c.710A>C, 
p.Tyr237Ser 
novel 
RLBP1 
OMIM 180090 
c.12+2delT novel c.141+2T>C novel 
c.346+3delG novel not identified 
CYP4V2 
OMIM 608614 
c.998C>A, p.Thr333Lys novel c.998C>A, p.Thr333Lys novel 
c.283G>A, p.Gly95Arg Shan et al. [341] c.637_641delAGTAA, 
p.Ser213X 
novel 
c.792-8_del17insGC Lai et al. [342] c.792-8_del17insGC Lai et al. [342] 
c.792-8_del17insGC Lai et al. [342] not identified 
CNGA3 
OMIM 600053 
c.1279C>T, 
p.Arg427Cys 
Wissinger et al. 
[343] 
c.1279C>T, 
p.Arg427Cys 
Wissinger et al. 
[343] 
change found in homozygous state in an unaffected member of the family 
c.1688G>A, 
p.Arg563His 
Wissinger et al. 
[343] 
c.106_109delCACT, 
p.His36fs 
novel 
CNGB3 
OMIM 605080 
c.1208G>A, 
p.Arg403Gln 
Michaelides et al. 
[344] 
c.1208G>A, 
p.Arg403Gln 
Michaelides et 
al. [344] 
c.1208G>A, 
p.Arg403Gln 
Michaelides et al. 
[344] 
c. 1908G>T, 
p.Arg636Ser 
novel 
LCA5 
OMIM 611408 
c.835C>T, 
p.Gln279X 
den Hollander et 
al. [345] 
c.1756A>T, 
p.Lys586X 
novel 
CEP290 
OMIM 610142 
c.2991+1655A>G, 
p.Cys998X 
den Hollander et 
al. [346] 
c.5254C>T, 
p.Arg1752Trp 
novel 
MFRP 
OMIM 606227 
c.492delC, 
p.Asn167ThrfsX25 
Sundin et al. [347] c.492delC, 
p.Asn167ThrfsX25 
Sundin et al. 
[347] 
c.492delC, 
p.Asn167ThrfsX25 
Sundin et al. [347] c.1622_1625 delTCTG, 
p.Val541AlafsX188 
novel 
CLRN1 
OMIM 606397 
c.144T>G, 
p.Asn48Lys 
Adato et al. [348] c.144T>G, 
p.Asn48Lys 
Adato et al. 
[348] 
RP1L1 
OMIM 608581 
c.133C>T, p.Arg45Trp Akahori et al. [349] 
Dominant inheritance 
GPR143 
OMIM 300808 
c.793 C>T, 
p.Arg245X 
Schnur et al. [350] 
X-linked inheritance 
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3.1.2 A Study of DNA Sequence Variation in the C2ORF71 Gene 
 
In 2009 Baye et al. [351], followed by Nishimura et al. [352] and Collin et al. 
[353], used linkage analysis to identify missense and truncating mutations in 
the C2ORF71 gene in five families affected with autosomal recessive retinal 
dystrophy. Three additional families were subsequently reported [354-355]. 
Most affected individuals in these reports had adult-onset rod cone dystrophy 
[352-354]. Nevertheless, early-onset disease [354], a cone rod pattern of 
dysfunction [353, 355] and considerable intra-familial variability with both 
childhood-onset and adult-onset disease [352] have also been described. 
 
Human C2ORF71 is a two exon gene spanning a 12.5 kb region on 2p23. The 
gene is conserved in vertebrates and, in human, it encodes a 1288-amino-
acid, photoreceptor-specific protein. Subcellular localisation is hypothesised to 
be within the outer segment and/or the connecting cilium of the photoreceptor 
cells [352]. C2ORF71 function remains unknown. The gene does not contain 
any known functional domains but does include motifs suggesting that the 
encoding protein may undergo post-translational lipid modification [352]. From 
the expression patterns in the developing mouse eye, C2ORF71 is presumed 
to play a role in retinal development [353]. 
 
In this section, HRM (section 2.4.15) was combined with PCR and Sanger 
sequencing (sections 2.4.9 and 2.4.16) to perform C2ORF71 variation analysis 
in a cohort of probands with various forms of autosomal recessive retinal 
degeneration and controls. 
 
3.1.2.1 Methods 
 
3.1.2.1.1 Subjects 
 
(also see sections 2.1.5 and 2.1.2) 
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Overall, 286 unrelated affected individuals were evaluated for DNA variants; 
95 of these were affected with LCA or autosomal recessive childhood-onset 
retinal dystrophy. The remaining 191 individuals had a diagnosis of autosomal 
recessive adult-onset rod cone or cone rod dystrophy. DNA from 151 
European and 40 South Asian control individuals with normal vision was also 
screened. Parental DNA was tested to determine the phase of interesting 
variants.  
 
3.1.2.1.2 Genetic analysis 
 
Amplimers were designed to cover the two previously reported exons 
(NM_001029883.1). Two methods of mutation screening were utilised. On the 
basis of the reported polymorphisms in C2ORF71 at the time of the 
experiment design (18 polymorphic sites, NCBI dbSNP130 database, 
accessed November 2009) amplimers were divided in two groups: 
(a) Four out of ten amplimers (group 1), covering two or more polymorphic 
sites each, were amplified by PCR and mutation analysis was performed by 
direct sequencing of all PCR products (sections 2.4.9 and 2.4.16). 
(b) Six out of ten amplimers (group 2), covering one or no polymorphic sites 
each, were analysed using PCR (with highly saturating fluorescent dye), HRM 
analysis and Sanger sequencing (sections 2.4.15 and 2.4.16).  
 
To avoid false positive results, DNA variants within group 2 fragments 
identified in less than three control or patient DNA samples were confirmed by 
independent regular PCR followed by direct sequencing. 
 
3.1.2.1.3 Genetic variation quantification 
 
As a large amount of DNA sequence alterations were being identified, it was 
deemed appropriate to quantify coding sequence variation and allelic 
complexity of C2ORF71 and compare it with other genes. The total expected 
amount of heterozygosity and its number density per nucleotide were used as 
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measures of genetic variation. Expected heterozygosity (hE) is defined as the 
probability of an individual being heterozygous at a site. The probability of 
heterozygosity at a site equals one minus the probability of homozygosity for 
each allele. The individual probabilities from m randomly associated sites can 
be algebraically summed to give a total value of heterozygosity in a sample. Its 
value assuming Hardy-Weinberg equilibrium is: 

(1 pij
2 )
i1
n

j1
m
  
where pij denotes the prevalence of the i
th of n alleles (maximum of two alleles 
per site in this case) at the jth of m sites. The total heterozygosity density per 
nucleotide is equal to the average heterozygosity 

H
^
 as defined by Nei and 
Roychoudhury [356]: 
mhH
m
j
j /
1
^


 = 

(1 pij
2 )
i1
n

j1
m
 /m  
where hj denotes the expected heterozygosity at the j
th of m sites.  
 
On the assumption of the standard neutral model and taking into account the 
many sites tested, the low average MAF of the detected polymorphisms and 
the large number of control subjects, 

H
^
 of a sample of controls estimates the 
expected average heterozygosity in a population and is a good measure of 
genetic variability, comparable to nucleotide diversity ( ) [357-358] and 
Watterson’s estimate ( w) [359]. 
 
3.1.2.2 Results 
 
A total of 40 DNA sequence variants were identified (table 3-2). A number of 
changes that are not reported in dbSNP130 were detected: (a) 17 (eight 
missense, seven synonymous, one three base pair deletion and one two base 
pair insertion-deletion) of them were found in controls; (b) the remaining 11 
(six missense, five synonymous) were found in 20 alleles of 19 affected 
individuals (3.5% of all patient alleles) and not in controls. No truncating 
variants were identified. Two missense changes, p.Pro177Leu and 
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p.Glu227Lys, were identified in a recessive RP patient in trans. Segregation 
analysis revealed her unaffected father to be homozygous for p.Glu227Lys 
(figure 3-1B). Multiple primer pairs were used to exclude allele-specific 
amplification caused by a variant underlying the primer. All C2ORF71 DNA 
variation identified in the cohort of 286 patients and 191 controls screened is 
summarised in table 3-3. 
 
Table 3-2. Overview of variants in C2ORF71 identified in patient and control DNAs 
Type of change 
Controls 
(n=191) 
Patients (n=286) Total 
 
Synonymous 
 
 
 12  
   
  5 
 
17 
Missense 
 
 14   6 20  
Other    3  (1x delCAinsAG 
        1x delCCC  
        1x dupAGC) 
 
  0   3 
Total  29 
 
11 40  
 
The proportion of polymorphic sites in C2ORF71 was found to be 5% 
(64/1288). The mean expected heterozygosity of the coding region in 
unaffected control subjects was 2.728 (value for affected individuals: 2.48). 
Therefore, on average, 2.728 nucleotides will differ in the C2ORF71 sequence 
of two randomly chosen chromosomes of the population. The probability of 
each nucleotide being nonidentical between two randomly chosen control 
subject sequences is approximately the average hetrozygosity 
^
H  and in 
C2ORF71 equals 21.18x10-4 (19.26x10-4 in affected individuals). 
Consequently, if two chromosomes have been chosen at random, a sequence 
variation would have been identified every 472 base pairs. These values are 
higher than those of BEST1 (0.14 sites, 0.8x10-4 sites per nucleotide), 
EFEMP1 (0.003 sites, 0.03x10-4 sites per nucleotide) and ABCA4 genes (1.28 
sites, 1.8x10-4 sites per nucleotide) in unaffected subjects [360] suggesting 
that the C2ORF71 coding sequence is more variable in the control population.  
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Figure 3-1. Normalised melting curve and difference plots and electropherograms generated 
by downstream sequencing of the amplified product. 
[A] Amplimer 1_5 for European control plate 1: two clusters of samples (blue and red groups) 
and one isolated sample (green group) demonstrate melting difference plots significantly 
deviating from the majority of control DNAs screened in the plate (grey group). When 
sequenced, samples from the same group contained the same missense change in 
heterozygous state (c.1739C>T, p.Thr580Met for the red group; c.2063G>A, p.Cys688Tyr for 
the blue group and c.1942G>A, p.Alal648Thr. for the green group).  
[B] Amplimer 1_2 for RP panel plate 2: three samples demonstrate differences in 
fluorescence compared to the majority of the examined samples. Sequencing revealed two 
samples being heterozygous for c.679G>A, p.Glu277Lys (red group) and one sample being 
compound heterozygote for c.530C>G, p.Pro177Leu and c.679G>A, p.Glu277Lys (blue 
group). None of those two changes was identified in the control DNA panels studied. Family 
members of the patient in the blue group were screened with unaffected father being 
homozygous for c.679G>A, p.Glu277Lys 
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Table 3-3. Summary of C2ORF71 sequence variants; predicted impact on C2ORF71 protein and 
frequency in patients and controls. 
DNA Variants SIFT
 
PolyPhen and PolyPhen-2 Frequency in 
(chromosomes) Nucleotide Protein dbSNP130 Prediction Toleran
ce Index 
(0-1) 
Prediction§ PSIC 
Score 
Difference  
(0-4) 
Hum 
Div 
Score 
(0-1) Ver1 Ver2 Controls Patients 
c.37A>T p.Ser13Cys  rs10084168 intolerant 0.01 POS 1.548 0.774 0/364  1/572 
c.60G>A p.(=) rs35929540 not applicable 82/364  101/572 
c.99G>A p.(=)  not applicable 1/364 2/572 
c.158 C>T p.Ala53Val  tolerated 0.26 Benign 1.129 0.022 0/364 1/572 
c.258G>A p.(=) rs62132765 not applicable 77/364  111/572 
c.530C>T p.Pro177Leu  intolerant 0.00 POD 2.550 0.999 0/382 1/572 
c.531G>A p.(=)  not applicable 0/382 1/572 
c.679G>A   p.Glu227Lys  intolerant 0.01 Benign POD 1.409 0.949 0/382 3/572 
c.1262A>G p.Lys421Arg rs17007544 tolerated 0.47 Benign POS 1.047 0.665 3/190 0/572 
c.1387G>T p.Val463Phe  tolerated 0.05 Benign POS 1.284 0.375 1/190 1/572 
c.1452C>T p.(=) rs13385188 not applicable 81/190  153/572 
c.1739C>T p.Thr580Met rs10166913 intolerant 0.01 POS 1.665 0.798 5/190  0/572 
c.1844T>A p.Val615Asp  tolerated 0.40 POS POD 1.970 0.925 0/190 1/572 
c.1942G>A p.Ala648Thr rs75276619 tolerated 0.59 Benign 0.211 0.022 1/190  11/572 
c.2063G>A p.Cys688Tyr  tolerated 0.52 POD 2.938 0.996 3/190 0/572 
c.2112T>C p.(=) rs10200693    not applicable 123/380  168/572 
c.2234G>A p.Arg745Lys  tolerated 0.92 Benign POS 1.132 0.788 1/380 0/572 
c.2374C>G p.Leu792Val rs17744093 tolerated 0.30 Benign POS 1.017 0.426 66/380  103/572 
c.2406A>G p.(=)  not applicable 1/380 1/572 
c.2498C>T p.Pro833Leu  intolerant 0.01 POD 2.550 0.994 0/380 1/572 
c.2499G>A p.(=) rs34253433 not applicable 70/380  106/572 
c.2502T>C p.(=)  not applicable 0/382 1/572 
c.2600C>T p.Pro867Leu  tolerated 0.72 Benign 0.213 0.20 1/380 2/572 
c.2864G>A p.Arg955Gln  tolerated 0.81 Benign 0.192 0.192 1/190 0/572 
c.2875G>A p.Ala959Thr  tolerated 0.23 Benign 0.995 0.109 2/190 1/572 
c.2889C>T p.(=)  not applicable 2/190 3/572 
c.3037C>G p.Pro1013Ala  tolerated 0.23 POD 2.100 0.908 1/372 0/572 
c.3058_3059
delCAinsAG 
p.Gln1020Arg  tolerated 0.52 Benign  0.900  2/372 3/572 
c.3264_3266
delCCC 
p.Pro1089del  not applicable 1/372 6/572 
c.3291G>A p.(=)  not applicable 1/372 3/572 
c.3395A>C p.Glu1132Ala rs78874550 tolerated 0.32 Benign  1.350  1/174 1/572 
c.3447G>A p.(=)  not applicable 1/174 5/572 
c.3522C>T p.(=)  not applicable 1/174 2/572 
c.3609G>A p.(=)  not applicable 0/174 1/572 
c.3626A>G p.Asp1209Gly  tolerated 0.43 POS  1.575  0/174 1/572 
c.3673_3675dup3 rs72183347, rs72122505                        not applicable 43/300 84/572 
c.3739G>A p.Gly1247Ser  tolerated 1.00 Benign  0.225  3/300 4/572 
c.3780C>T p.(=) not applicable 0/300 1/572 
c.3789G>A p.(=)  not applicable 1/300 4/572 
c.3840G>A p.Ala1280Ala  not applicable 0/300 2/572 
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3.1.2.3 Comment 
 
To improve molecular testing of retinal genes in panels of affected individuals 
and controls the advances of HRM technology were exploited. To date, over 
60 genes have been analysed by this method including ABCA4 [361-362]. In 
this study, HRM analysis using the LightScanner System was utilised to study 
the parts of the C2ORF71 sequence containing one or no reported 
polymorphisms (dbSNP130). Standard PCR and Sanger sequencing were 
performed in the remaining amplimers as the presence of three or more 
polymorphic sites could potentially hinder the analysis and interpretation of 
melting curves. 
 
HRM had previously been markedly efficient in detecting heterozygous 
variants and is widely used as a method to detect carriers in BRCA1 and 
BRCA2 genes [363-364]. For heterozygous sequence alterations, sensitivity 
and specificity approach 100% for all categories of substitution as well as 
insertions and deletions small enough to be amplified by PCR (reviewed by 
Taylor [365]). Such variants are detectable at any location in the PCR 
amplimer, including those within a few base pairs of the primers [366]. 
Homozygous changes are harder to distinguish from wild-type sequence and 
16% of SNPs demonstrate minimal or no differences between the melting 
temperatures of the two homozygous states [361]. Compared with the wild-
type sequence, most homozygous changes produce a melting temperature 
shift with symmetric melting transitions [367-368] whereas heterozygous 
samples are identified by differences in melting curve shape (distortion) with a 
more gradual, complex transition [246, 369-370]. Only one sequence alteration 
(c.1452C>T) was detected in homozygous phase in the C2ORF71 amplimers 
analysed with HRM. The low carrier frequency of the remaining 16 
heterozygous changes could explain the absence of homozygotes (x2 test). 
Despite the fact that the average coefficient of inbreeding in the studied 
cohorts is likely to be low, it may still be possible that a homozygous change 
could not be detected with the method used. 
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Common variants may be recognised by characteristic melting patterns [371] 
although this is debated [365]. In this study, common polymorphisms were 
identified by melting curve identity and rare sequence variants by sequencing. 
On average, 12% (11 samples) of each 96-well plate was sequenced; 
numbers widely varied between amplimers and runs. Unnecessary 
downstream sequencing was generated by HRM false positive results. 
Importantly, on one occasion, a false positive result could not be resolved by 
sequencing directly after HRM analysis (figure 3-2). Independent regular PCR 
followed by Sanger sequencing revealed that both patients, initially tagged as 
heterozygotes for a p.Pro1083Leu mutation, were wild-type. It can be 
speculated that this substitution occurred due to a "hot spot" for polymerization 
errors in the sequence of the target DNA [372]. This observation resulted in 
modification of study design: all variants 
identified in three or less patient or 
control samples were independently 
amplified and sequenced. 
 
During the study it became evident that 
the total number of C2ORF71 sequence 
variants discovered in controls or 
reported in dbSNP130 (48 in total) was 
disproportionately greater compared to 
other retinal genes even without 
accounting for gene size. However, 
analysing the proportion of polymorphic 
nucleotides does not assess how 
variable the coding sequence of the 
gene is in a population. This is more 
obvious in C2ORF71 as most sequence 
alterations were found to have small 
minor allele frequencies. Average 
heterozygosity (
^
H ) was used to 
 
Figure 3-2. Melting curve difference plots 
for amplimer 1_8 in LCA panel are 
presented. Among the different groups, 
two samples with similar melting 
behaviour can be observed (blue group). 
Electropherograms of amplimer 1_8 in 
those two individuals affected with LCA 
were generated. Rows 1 and 2 are the 
result of sequencing the product of 
amplification using HRM protocol while 
rows 3 and 4 show the same samples 
amplified through normal PCR. A 
c.3248C>T, p.Pro1083Leu variant was 
suspected initially but could not be 
confirmed in either patient. 
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summarise variation as a function of both the number of polymorphic sites and 
their frequencies in the population. 
^
H calculates the probability of nonidentity 
of two randomly chosen chromosomal sites [356]. C2ORF71 demonstrated 
greater genetic variability compared to BEST1, EFEMP1 and ABCA4 [360]. 
 
Comparison of the C2ORF71 peptide sequence with its orthologs revealed 
minimal conservation. Notably, multiple “islands” of conserved sequence are 
observed between amino acids 173 and 359. Four out of seven previously 
reported mutations (p.Gln186X [353], p.Ile201Phe [351-352], 
p.Asn316MetfsX5 [353] , p.Trp253X [352]) fall within this 173-359 interval. No 
polymorphisms in this region were detected in the control DNA panels studied 
and only an unaffected parent was found homozygous for a p.Glu227Lys 
change. Other regions, completely conserved between species, included the 
first 3 amino acids of the protein and amino acids 830 to 834. The significance 
of complete conservation of glycine at position two and cysteine at position 
three (G2/C3), a motif subject to lipid modification, also found in RP2, has 
been investigated by Nishimura et al. [352]. In the region between amino acids 
830 and 834, three variants were identified: a known polymorphism, 
c.2499G>A, p.(=) (rs34253433); a missense change, c.2498C>T, 
p.Pro833Leu, in one LCA patient; and a silent change, c.2502T>C, p.(=), in 
another LCA patient. All three were only identified in the heterozygous state; 
no second change was identified in either of the two affected individuals.  
 
C2ORF71 does not harbour any known functional domains and results from 
protein analysis tools (section 2.5) were negative. The region between amino 
acids 176 and 331 is predicted as a potential globular domain by GlobProt 
[373] but this might be falsely positive because of the conservation observed 
in this region. A region of compositional bias is described in UniProt 
(http://www.uniprot.org/uniprot/A6NGG8) with proline being over-represented 
within the subsection between amino acids 1013 and 1095. There is little 
functional knowledge on COOH-terminal PRDs. Importantly, PRDs are 
implicated in a number of aberrant protein interactions and certain protein-
interaction domains prefer ligand sequences that are proline-rich [374]. 
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Recently, a PRD in a microtubule-associated protein, mainly existing in 
neurons, has been shown to mediate interactions with actin [375]. The 
photoreceptor connecting cilium contains clusters of actin [376] and previous 
work suggests interaction of C2ORF71 with the connecting cilium [352]. A 
number of genes like TULP1 [377] and MYO7A [378] interacting with actin are 
also associated with nonsyndromic or syndromic RP. 
 
HRM and Sanger Sequencing were utilised to detect mutations in C2ORF71 
and the technical challenges of screening a polymorphic gene with numerous 
rare variants were encountered. The high degree of genetic variability was 
quantified and the implications of the polymorphic site distribution were 
interrogated. There was no convincing evidence that biallelic mutations in 
C2ORF71 were responsible for the retinal degeneration in any of the 286 
families tested. C2ORF71 variants must therefore be a rare cause of RP. 
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3.1.3 Nonsense Mutation in SAG Causes Oguchi Disease 
 
The SAG gene encodes S-antigen, a visual/β arrestin abundant in rod 
photoreceptor cells. S-antigen binds to light-activated rhodopsin preventing 
further interaction with transducin during the recovery phase of 
phototransduction [379-381]. Mutations in SAG are primarily associated with 
Oguchi disease, a rare autosomal recessive form of CSNB characterised by 
yellow-gold discolouration of the fundus that disappears in the dark-adapted 
state and reappears shortly after the onset of light (Mizuo phenomenon) [382-
383]. Typically patients with mutations in SAG have no obvious signs of 
photoreceptor degeneration [384]. However, significant inter- and intra-familial 
phenotypic variability have been described and a number of cases with 
biallelic SAG mutations developing RP have been reported [385-388]. 
 
The clinical and electrophysiological findings in a case of Oguchi disease 
harbouring a homozygous nonsense mutation in SAG (c.874C>T, p.Arg292X) 
are presented. SAG screening (NM_000541.4) was performed by Dr Alice E 
Davidson using standard PCR and Sanger sequencing (sections 2.4.9 and 
2.4.16). The proband was a 7-year-old girl of South Asian origin referred for 
evaluation of congenital nyctalopia. Visual acuity was 0.12 logMAR in each 
eye. Fundus examination revealed widespread golden discolouration and 
peripheral RPE mottling (figure 3-3A). Fundus autofluorescence imaging was 
normal (figure 3-3B). SD OCT is presented in figure 3-3C. In the foveola, three 
hyperreflective bands representing the IS/OS junction of the photoreceptors, 
the cone outer segment tips and the RPE/Bruch’s membrane complex are 
visible. Outside the fovea, the hyporeflective band corresponding to the outer 
segments is not apparent. These findings were consistent on three different 
tests over a one year interval. SD OCT of an age-matched control is also 
presented in figure 3-3D. 
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Figure 3-3 
[A] Colour fundus photography of both eyes showing typical golden fundus reflex and pigment 
mottling in the far periphery. Discolouration is less profound in the macular area. 
[B] Fundus autofluorescence imaging of the right eye demonstrating no abnormality. 
[C] Axial cross sectional image of the proband’s right macula obtained using SD OCT. In the 
parafovea, SD OCT failed to detect the hyporeflective band (outer segments; OS) that is 
observed between the hyperreflective layers associated with the IS/OS junction (IS/OS) and 
the RPE/Bruch's membrane complex (RPE/BM). 
[D] SD OCT of the right eye of a 9-year-old control individual.  
Scans in C and D are to scale and acquired using the same SD OCT protocol. A panel with 
enlarged images of boxed regions (1, patient; 2, control) shows outer retina in detail. 
 
ISCEV standard full field ERGs were consistent with severe generalised rod 
photoreceptor dysfunction. Prolonged dark adaptation resulted in partial ERG 
recovery, in keeping with abnormally slow rod dark adaptation. There was 
marked desensitization following a single bright flash (figure 3-4). Generalised 
cone function was normal. PERG revealed no evidence of macular 
dysfunction. 
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Figure 3-4. Full field ERGs from the right (RE) and left (LE) eyes of the patient and normal 
examples (N) for comparison. After 25 minutes dark adaptation, left eye rod ERGs were 
undetectable and bright flash ERGs had a waveform that resembled the early component of 
the red flash ERG, consistent with a dark-adapted cone system origin. After overnight dark 
adaptation of the right eye, ERGs showed partial recovery but a second bright flash (3.0 
cd·s·m
-2
; inter-stimulus interval 60 seconds) resulted in marked ERG attenuation. Light-
adapted ERGs revealed no evidence of generalised cone system dysfunction. The pERG (left 
eye only) revealed no evidence of macular dysfunction. After photopic testing, ERGs were 
repeated following an additional 20 minutes dark-adaptation of both eyes (last two columns). 
 
To test for the Mizuo-Nakamura phenomenon, the patient’s right eye was 
dark-adapted overnight and images were obtained with a nonmydriatic camera 
in a totally darkened room. This type of camera was selected as it uses an 
infrared illumination source instead of the common white light to view the 
fundus prior to flash photography. Fundus appearance was initially normal in 
the dark-adapted eye but after 10 to 15 flashes, the golden sheen appeared 
(figure 3-5). 
 
Oguchi disease has been previously shown to be caused by mutations in 
either SAG or GRK1, a gene encoding rhodopsin kinase [389-390]. Mutated 
GRK1 alleles are considered the commonest cause of Oguchi in South Asians 
and, to date, only one Indian family has been reported to harbour SAG 
mutation [391]. 
 
SD OCT findings similar to the proband have been previously described in two 
nongenetically confirmed Oguchi cases [392-393]; this outer retinal 
appearence has been attributed to microstructural changes [392-393] and 
could indicate increased reflectivity in the light-adapted state. Additional outer 
RESULTS – Nonsense mutation in SAG causes Oguchi Disease 
 
101 
 
retinal attenuation demonstrated in two cases (aged 31 and 43 [388, 392]), 
was not evident in the presented case.  
 
 
Figure 3-5. Colour fundus photography of the posterior pole of the right eye using a 
nonmydriatic camera (TRC-NW65, Topcon, Tokyo, Japan; images obtained by Mr Kulwant 
Sehmi). After overnight (12 hour) dark adaptation, a series of images were obtained over a 20 
minute interval. Disappearance of the golden reflex can be seen in the first image taken (top 
left). The golden colour gradually reappears after 10 to15 flashes. Bottom right image is after 
20 minutes and 32 flashes.  
 
A retinal sheen similar to Oguchi disease can be associated with RS1 
mutations. Furthermore, partial or complete ERG recovery following prolonged 
dark adaption can occur in RDH5- or RLBP1-related disease (section 3.1.4) 
[329, 394-396] and rapid ERG attenuation to successive flashes can result 
from RGS9/R9AP mutation [397-398] but the combination of normal cone 
function, delayed rod ERG dark adaptation and marked rod desensitisation to 
a bright flash is distinctive for Oguchi disease. 
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3.1.4 Phenotypic Variability in RDH5 Retinopathy 
 
The 11-cis retinol dehydrogenases are stereo-specific enzymes capable of 
oxidising 11-cis retinol to 11-cis retinaldehyde, the universal vertebrate 
chromophore of visual pigments [399-402]. Retinol dehydrogenase 5 (RDH5) 
is a protein found in abundance in the smooth endoplasmic reticulum of the 
RPE [403]. Its enzymatic activity accounts for most of the 11-cis retinol 
dehydrogenase activity in the retina [149, 404-407]. Human RDH5 is a highly 
conserved among species, 318-amino-acid, protein [408]. 
 
Mutations in the RDH5 gene are usually associated with fundus albipunctatus 
[149], an autosomal recessive disorder characterised by night blindness, 
delayed dark adaptation and distinct fundus abnormalities [384, 409]. 
Individuals with fundus albipunctatus have numerous white-yellow subretinal 
spots scattered in the mid-periphery and parafovea; spot shape and number 
tend to vary with age [410-412]. Importantly, both dark adaptometry and rod-
specific ERGs have been reported to normalise following sufficiently prolonged 
dark adaptation [384, 413-414]. 
 
Since the first identification of clinically significant changes of the RDH5 
sequence in 1999, there have been reports of missense, in-frame and 
frameshift mutations [411-412, 415-433]. Most affected individuals had 
nonprogressive night blindness, normal visual acuities and severely abnormal 
rod ERGs. Additional cone ERG abnormalities and/or macular dysfunction 
have been reported, as has disease progression [412, 417-419, 423, 425-426, 
429-430]. Notably, biallelic null RDH5 alleles have been associated with 
stationary night blindness and white spots [432]. 
 
This section addresses phenotypic variability in patients with RDH5 mutations. 
Comprehensive ERG recordings in the dark-adapted state were performed in 
order to gain insight into the retinal function of these patients. Four of the 
cases have been described in a preliminary report [434]; RDH5 mutation 
screening in these four patients was performed by Dr Zheng Li. Analysis of 
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electrophysiological data was supervised or performed by Dr Anthony G 
Robson and Professor Graham E Holder. Extended testing in the dark-
adapted state in one subject was performed by Dr Vikki A McBain. 
 
3.1.4.1 Methods 
 
3.1.4.1.1 Subjects 
 
Nine affected individuals from eight families with electrophysiological or 
fundoscopic suggestion of RDH5 retinopathy were ascertained. All had 
congenital night blindness. Blood samples were collected for DNA extraction 
and subsequent mutation screening of RDH5 (sections 2.4.3, 2.4.9 and 
2.4.16). The proband of one family declined to donate DNA for analysis and 
screening was performed on maternal DNA. 
 
3.1.4.1.2 Retinal imaging and electrophysiology 
 
Fundus autofluorescence imaging was performed in six and SD OCT in three 
affected inidividuals. Electrophysiological assessment routinely included the 
recording of dark-adapted ERGs to a red flash enabling the assessment of 
dark-adapted cone function. Photopic ON-OFF ERGs were performed in eight 
cases using an orange stimulus (560 cd·m-2, duration 200 ms) superimposed 
on a constant green background (150 cd·m-2). Short wavelength flash ERGs 
were also performed; a blue stimulus (445 nm, duration 5 ms, 80 cd·m-2) 
superimposed on a constant orange background (620 nm, 560 cd·m-2) was 
utilised. Full field ERG recordings were either repeated following two hours of 
dark adaptation (subjects RD2 and RD8b) or performed after overnight 
patching of one eye (seven cases). In order to address the nature of the 
electronegative waveform and the recovery of the b-wave during prolonged 
dark adaptation, extended testing was performed in one patient (subject RD5). 
His right eye was patched overnight to achieve extended dark adaptation and 
RESULTS – Phenotypic variability in RDH5 retinopathy 
 
104 
 
his left eye was exposed to a 100 cd·m-2 bleach for ten minutes prior to ERG 
recording. Sequential scotopic responses (11 cd·s·m-2) were acquired every 2 
to 5 minutes for 90 minutes until the response from the left eye resembled that 
from the dark-adapted right eye. A series of progressively increasing intensity 
backgrounds (0.1, 0.3, 1.6 and 6.3 cd·m-2) were then applied (10 minutes for 
the first intensity, 6 minutes for subsequent intensities) while sequential bright 
flash responses were recorded as during the period of dark adaptation. 
 
Dark adaptometry at two test locations (3° and 9°) was performed in two 
patients (subjects RD4 and RD5). The Humphrey field analyser (Carl Zeiss 
Meditec, Inc., Jena, Germany) used was controlled by a computerised 
program (PS/2 model 50; International Business Machines, Armonk, NY, 
USA). 
 
3.1.4.1.3 Genetic analysis 
 
Primers were designed to cover the coding region and intron-exon boundaries 
of exons 2 to 5 of RDH5 (NM_002905.3). For RLBP1 (NM_000326.4), primers 
were used as previously described [150]. 
 
3.1.4.2 Results 
 
3.1.4.2.1 Clinical Findings 
 
Clinical findings are summarised in table 3-4. Visual acuity was 0.2 logMAR or 
better in all but one eye of one patient. All affected individuals described night 
blindness from birth and delay in dark adaptation after exposure to bright light. 
The individual with poor acuity in one eye complained of progressive visual 
loss and patchy central vision (subject RD7). 
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Table 3-4. Summary of clinical findings in individuals with RDH5-related disease 
Subj
ect 
Sex Age at 
exam 
Visual 
Acuity 
Ishihara 
colour 
vision test 
Visual Fields Fundus 
appearance 
Fundus 
autofluorescence 
imaging 
SD OCT Comments 
OD OS 
RD1 Male 18 6/6 6/5 Test plate 
only 
Full to confrontation Multiple deep 
whitish dots; 
subtle RPE 
changes in the 
foveal region 
High density spots within 
the arcades that spatially 
associate with some of the 
white dots seen on 
fundoscopy 
not performed  
RD2 Female 19 6/5 6/5 17/17 Full to confrontation Multiple deep 
whitish dots 
not performed not performed  
RD3 Female 26 6/6 6/6 3/17 Full to confrontation; 
Normal binocular 
static perimetry 
Multiple deep 
whitish flecks 
and dots; subtle 
RPE changes in 
the foveal region 
High density spots within 
the arcades that minimally 
spatially associate with the 
white dots seen on 
fundoscopy 
not performed  
RD4 Male 36 6/6 6/6 17/17 Monocular static 
perimetry: mild 
superior and temporal 
loss of sensitivity in 
each eye 
Multiple deep 
whitish dots; 
subtle RPE 
changes in the 
foveal region 
Demarcated area of 
increased 
autofluorescence inferiorly 
Hyperreflective 
lesions in the 
outer retina 
Dark adaptometry 
performed: final thresholds 
severely elevated after 45 
minutes dark adaptation. 
Normal after overnight dark 
adaptation of the other eye. 
RD5 Male 37 6/6 6/6 17/17 Normal binocular 
static perimetry. 
Monocular static 
perimetry: loss of 
sensitivity in the upper 
field in each eye 
Multiple deep 
whitish dots; 
subtle RPE 
changes in the 
foveal region 
not performed not performed Dark adaptometry 
performed: No evidence of 
rod cone interaction after one 
hour of dark adaptation. Rod 
and cone final thresholds 
severely elevated 
RD6 Female 41 6/6 6/9 3/17 Full to confrontation Multiple deep 
whitish dots; 
subtle RPE 
changes in the 
foveal region 
Ring of high density 
around the fovea 
not performed  
RD7 Male 55 
 
6/6 3/60 Test plate 
only 
Monocular static 
perimetry: central loss 
of sensitivity in each 
eye 
 
Within normal 
limits 
Irregular autofluorescence 
around the fovea 
Irregular IS/OS 
junction; debris; 
wrinkling of the 
outer retina 
Refraction: 
-1.50/-3.00x15   OD 
-5.50/-1.00x175 OS 
RD8a Female  7 6/9 6/9 not tested not performed Multiple deep 
whitish flecks 
not performed Hyperreflective 
lesions in the 
outer retina 
First cousins once 
removed 
 RD8b M 48 6/6 6/5 not tested Full to confrontation Multiple deep 
whitish dots 
Irregular autofluorescence 
around the fovea 
not performed 
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Fundus photographs and fundus autofluorescence images are shown in figure 
3-6. Diffuse subretinal white or pale yellow spots, usually extending into the 
midperipheral regions, were present in the fundi of all but subject RD7 (figure 
3-6F). Pigment irregularity is present in the foveal regions of five individuals 
(5/9). The oldest study subject (subject RD7, 55 years old) had a normal 
fundus appearance. 
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Figure 3-6. Fundus photographs and fundus autofluorescence images of subjects RD1, RD3, 
RD4, RD5, RD6, RD7, RD8a and RD8b (A to H respectively). 
 
Fundus autofluorescence imaging (n=6) showed a variety of distinct features. 
High-density foci were noted to associate spatially with some of the white dots 
in the fundus in one individual (subject RD1, aged 18, figure 3-6A). Similar 
hyper-autofluorescent lesions associating with white dots in the fundus were 
also observed in a 26-year-old subject (subject RD3), although most 
fundoscopic lesions did not autofluoresce (figure 3-6B). A crescent of 
increased autofluorescence, similar to that reported in RP [435], was seen 
inferiorly to the temporal vessels of a 36-year-old affected individual (subject 
RD4, figure 3-6C). Concentric parafoveal rings of high density were present in 
a 41-year-old subject (subject RD6, figure 3-6E). Fundus autofluorescence 
image quality in the studied cohort of individuals with RDH5 retinopathy was 
compromised and many frames had to be aligned and averaged. Furthermore, 
signal detection sensitivity had to be near the maximum sensitivity of the 
system. Digital enhancement artefacts like autofluorescence from the optic 
disc and large vessels can be observed (figure 3-6). Similar challenges are 
faced when imaging patients with RPE65 mutations suggesting abnormal 
lipofuscin accumulation and low fundus autofluorescence to 488 nm [436]. 
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SD OCT in three affected individuals (subjects RD4, RD7 and RD8a aged 36, 
55 and 7 respectively) also revealed a variety of features. Discrete highly 
reflective lesions extending below the OLM and corresponding in location with 
the white dots in the fundus were observed in subjects RD4 and RD8a (figure 
3-7). In the older patient (subject RD7) disruption and focal loss of the IS/OS 
junction, debris-like material external to the OLM and remarkable preservation 
of the OLM were observed (figure 3-7B).  
 
 
Figure 3-7. SD OCT findings. Spatial association between dots on fundus photography and 
deep hyperreflective lesions on SD OCT (A). SD OCT of the left eye of subjects RD8a (B), 
RD4 (C) and right and left eye of subject RD7 (D). 
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3.1.4.2.2 Electrophysiological findings 
 
Representative examples of full field ERGs are shown in figure 3-8 and 
electrophysiological data are summarised in figure 3-9. 
 
Figure 3-8. 
Full field ERGs 
from the right 
(RE) and left (LE) 
eyes of subjects 
RD1 (A), RD7 
(B), RD4 (C) and 
normal traces 
(N). Dark-
adapted ERGs 
are shown for 
white flash 
strengths of 0.01 
and 11.0 cd·s·m
-2
, 
recorded after 
standard dark 
adaptation (left 
eyes of subjects 
RD1 and RD7, 
right eye of 
subject RD4) or 
after overnight 
dark adaptation 
(right eyes of 
subjects RD1 and 
RD7, left eye of 
subject RD4). 
Both eyes of 
subject RD1 
underwent 
subsequent 
standard dark 
adaptation and 
additional 
recordings were 
obtained (A, 
columns 6 and 
7). Standard 
light-adapted full 
field ERGs are 
shown for a flash 
intensity of 3.0 
cd·s·m
-2 
(30 Hz 
and 2 Hz).
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Figure 3-9. Scotopic ERG parameters after standard (20 minutes) and after prolonged dark 
adaptation shown for the dark-adapted 0.01 cd·s·m
-2
 rod ERG (A) and dark-adapted 11.0 
cd·s·m
-2
 (DA 11.0) bright flash ERG a and b-waves (B and C) and the b:a ratio (D). Prolonged 
dark adaptation was for 2 hours (subjects RD2 and RD9; same eye) or overnight (same eye in 
case 5; other eye in all others). Standard photopic (light-adapted; LA) 30 Hz flicker ERG and 
pERG parameters are summarised (E and F). Broken lines show lower limit of normal 
amplitude or upper limit of normal timing. 
 
(a) Standard (20 minutes) dark adaptation 
The dim flash rod-specific ERG (DA 0.01) was undetectable in three subjects 
and showed moderate-severe reduction in others; maximum amplitude was 
47% of normal (subject RD1, figure 3-8A). Red flash ERGs under dark 
adaptation showed a clear cone component in six of seven cases; the rod 
component was markedly subnormal or undetectable. The bright flash ERG a-
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wave (DA 11.0) showed mild-moderate reduction in seven cases; the b-wave 
was subnormal in all nine with an electronegative waveform (b:a ratio <1) in 
six affected individuals (figures 3-8A, 3-8B and 3-9). 
 
(b) Extended dark adaptation 
All scotopic responses normalised in two patients after two hours of dark 
adaptation (subjects RD2 and RD8b; figure 3-9A). Seven affected individuals 
underwent overnight dark adaptation. Overall, dim flash rod ERGs normalised 
in seven out of nine cases while in two cases amplitudes increased by 48% 
(subject RD6) and 90% (subject RD4; figure 3-8C) but failed to attain normal 
amplitude. The bright flash ERG a- and b-waves normalised in six patients 
with normalisation of the b:a ratio (figure 3-9B, C). Subject RD4 showed 
minimal improvement and was the only patient to retain an electronegative 
ERG after prolonged dark adaptation (figure 3-8D).  
 
(c) Light-adapted ERGs 
Photopic 30 Hz flicker ERGs were delayed by 3 to 10 ms in six affected 
individuals; three showed additional amplitude abnormality (figure 3-9E). Long 
duration ON-OFF ERGs, performed in all eight adults, contained delayed ON 
b-waves in the four cases with the greatest flicker ERG delay; the ON b-waves 
were subnormal in two of those individuals. OFF d-waves were of normal 
timing in seven cases but were subnormal in the patient with the most severe 
flicker ERG delay (subject RD6). Short wavelength flash ERGs were of 
borderline timing in two of eight individuals (subject RD4 and RD5) and were 
subnormal in subjects RD4 and RD6. 
  
PERG P50 was normal in two patients; markedly or severely subnormal in 
three patients; and borderline in three patients of the eight in which pERG was 
performed. PERG reduction was proportional to the flicker ERG amplitude 
(figure 3-9) in all but subject RD7, who presented with central scotoma, 
undetectable pERGs and normal photopic full field ERGs. 
 
(d) Extended testing in dark-adapted state  
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Subject RD5 underwent extended ERG testing. Responses to a bright flash 
from the right eye, which was dark-adapted overnight, were normal and 
remained so throughout the 90 minutes of testing under scotopic conditions 
(figure 3-10). Responses from the left eye were subnormal, with a reduced b:a 
ratio until approximately 70 minutes of dark adaptation. The a- and b-wave 
amplitudes gradually increased between 45 and 70 minutes of testing. After 70 
minutes the waveform resembled that from the right eye. The a-wave peak 
time did not significantly differ throughout the 90-minute period of dark 
adaptation. The peak time of the b-wave was significantly earlier than that from 
the right eye during the initial 45 minutes of testing, consistent with a 
predominantly cone system origin; the b-wave peak time then increased in 
keeping with a greater rod system contribution and normalised after 
approximately 70 minutes. 
 
Figure 3-10.  
[A] Sequential dark-adapted response traces (11.0 cd·s·m
-2
) recorded from an overnight 
dark-adapted eye (RE) and a fully light-adapted eye (LE) during 90 minutes of dark 
adaptation. Note the changing waveform of the traces from the left, previously light-adapted 
eye with increasing dark adaptation as the waveform changes from that arising in dark-
adapted cones to that arising from the rod system.  
[B] Sequential responses (11.0 cd·s·m
-2
) acquired during a 30 minute period with an 
increasing intensity adapting background (0.1 to 6.3 cd·m
-2
).  Both eyes were dark-adapted 
prior to testing (right eye overnight; left eye 1.5 hours). The waveform of the bright flash 
response changed in both eyes with increasing light adaptation, returning to that seen 
following standard dark adaptation as the rod contribution becomes effectively bleached out 
due to impaired regeneration of rhodopsin.  
 
The application of a dim background light (0.1 cd·m-2) significantly reduced the 
b-wave amplitude in both eyes (figure 3-9B). There was approximately 70% 
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reduction in amplitude of the b-wave compared with minimal reduction in the a-
wave (~15%). Further increase in background light intensity (0.3 cd·m-2) 
produced greater b-wave and a significant a-wave amplitude reduction. With a 
background intensity of 1.6 cd·m-2, both amplitudes decreased further, with the 
b-wave becoming smaller than a-wave. The final increment in background light 
intensity (6.3 cd·m-2) continued to induce a reduction in the a- and b-wave 
amplitudes while retaining a reduced b:a ratio (figure 3-9B). 
 
3.1.4.2.3 Genetic analysis results 
 
Either homozygous or compound heterozygous likely disease-associated 
RDH5 variants were detected in eight affected individuals from seven families. 
One patient declined to donate blood but analysis of her mother’s DNA 
disclosed heterozygosity for a previously unreported variant. RLBP1 sequence 
was also examined in all study subjects and only previously reported 
polymorphisms were detected. It is therefore assumed that mutant RDH5 
alleles are disease-causing in all nine patients. Overall, eleven disease-
associated variants were identified with two (p.Arg157Gln and p.Gly238Trp) 
having been previously reported and predicted to severely affect RDH5 in vivo 
enzymatic activity and expression [437]. Nine novel RDH5 mutations were 
found; these included five missense (p.Ile33Thr, p.Arg19Gly, p.Gly116Arg, 
p.Gly139Val, p.Tyr237Ser), one in-frame three base pair insertion 
(p.Gly116_Ile117insSer) and one mutation affecting pre-mRNA splicing 
(c.310+1G>A), all altering the catalytic ectodomain in the lumenal 
compartment of the endoplasmatic reticulum (amino acids 19-288) [403]. One 
frameshift mutation (p.Arg275fsX60), changing the sequence of the COOH-
terminal transmembrane domain (amino acids 289-310), and one nonstop 
mutation in the translation termination site (p.X319ArgextX32) extending the 
short cytosolic tail (amino acids 311-319) were also identified [359]. None of 
these changes were present in DNA from 55 European and 40 South Asian 
control subjects tested. Nevertheless, testing larger numbers and including 
samples from control individuals of Middle Eastern origin will provide further 
insight. These results are summarised in table 3-5. 
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 Table 3-5. RDH5 mutation analysis results and predicted impact of identified likely disease-associated variants on protein function 
Subject Origin Mutation Status Reference SIFT PolyPhen-2 
Prediction 
Tolerance 
index (0-1) 
Prediction
 HumVar 
Score (0-1) 
RD1 
Middle 
Eastern 
c.417G>T, p.Gly139Val^ this study intolerant 0.00 POD 0.999 
c.956T>C, p.X319ArgextX32^ this study not applicable 
mother of 
subject RD2 
European 
c.55A>G, p.Arg19Gly^ this study intolerant 0.03 POS 0.468 
wild-type  
RD3 
Middle 
Eastern 
c.824-825delGA, p.Arg275fsX60* this study not applicable 
RD4 South Asian c.470G>A, p.Arg157Gln* Hajali et al.[431]
 
intolerant 0.00 POD 0.997 
RD5 European 
c.98T>C, p.Ile33Thr^ this study intolerant 0.00 POD 0.989 
c.712G>T, p.Gly238Trp^ 
Yamamoto et 
al.[149]
 intolerant 0.00 POD 0.993 
RD6 South Asian 
c.346_348insGCA, 
p.Gly116_Ile117insSer* 
this study not applicable 
RD7 European 
c.346G>C ,p.Gly116Arg^ this study tolerated 0.52 POS 0.656 
c.710A>C, p.Tyr237Ser^ this study intolerant 0.00 POD 0.999 
RD8a South Asian c.712G>T; p.Gly238Trp* 
Yamamoto et 
al.[149]
 intolerant 0.00 POD 0.993 
RD8b South Asian 
c.310+1G>A^ this study not applicable 
c.712G>T; p.Gly238Trp^ 
Yamamoto et 
al.[149] 
intolerant 0.00 POD 0.993 
*homozygous state; ^heterozygous state 
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3.1.4.3 Comment 
 
Classically, mutations in RDH5 are associated with fundus albipunctatus, 
where there is night blindness from birth and white dots in the fundus. All 
affected individuals in the present series were night blind, but fundus 
appearance was variable. Patient RD7 had a normal fundus and was initially 
diagnosed on the basis of the electrophysiological findings (see below). 
Abnormalities in other patients ranged from minimal white dots (subject RD5) 
to numerous larger coalescent spots (subject RD8a). Although no clear pattern 
of longitudinal change emerged, speculative conclusions can be drawn when 
these data are placed in the context of those in the literature [411-412, 416, 
428, 431]. The white spots in the posterior pole have a discrete appearance, 
are small in size and appear to decrease in number with age. Spots are larger 
at a young age, in both the mid and far periphery and tend to be confluent and 
form reticular networks. With increasing age, the spots may become smaller, 
discrete and less apparent, especially in the far periphery. Disappearance of 
white dots has been previously described in individuals with RDH5 retinopathy 
in association with increasing age or following uveitis [412, 438]. Importantly, a 
55-year-old patient in the present series (subject RD7) with life-long night 
blindness and normal fundus (figure 3-6F) had previously been noted to have 
a normal fundus at 43 years of age; routine ERG testing after standard dark 
adaptation revealed severe and selective rod dysfunction (figure 3-8B) that 
prompted prolonged dark adaptation and additional ERG testing. A normal 
fundus therefore does not exclude RDH5-related retinal dysfunction and 
appropriate screening is enabled by the electrophysiological findings.  
 
Loss of retinal sensitivity was demonstrated psychophysically in three patients. 
One proband (subject RD7) presented with patchy central vision and reading 
problems and perimetry revealed paracentral scotomata. Similar findings have 
previously been reported [412, 423, 425, 433]. 
 
Fundus autofluorescence imaging was performed in six patients; only the two 
younger adults demonstrated hyperautofluorescent spots. As mutations in the 
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murine ortholog Rdh5 do not result in increased N-retinylidene-N-retinyl 
ethanolamine (A2E) formation compared to double knockout mice of Rdh8 and 
Rdh12 [439], an increase in autofluorescence would not be predicted. 
Accumulation of 11-cis and 13-cis retinyl esters seen in the RDH5-related 
disease animal model does not result in autofluorescent substances [406-407]. 
The only mildly abnormal autofluorescence in the older patients suggests that 
there is no progressive abnormal accumulation of fluorophores. A low 
autofluorescent signal was noticed in all six patients, an observation 
compatible with a recent report of lack of autofluorescence in four individuals 
with RDH5 retinopathy [440]. Further studies measuring absolute levels of 
fundus autofluorescence should assist in the determination of the significance 
of these observations. 
 
SD OCT imaging of a 47-year-old woman with RDH5-related disease has 
previously been reported to demonstrate dome-shaped lesions and focal loss 
of IS/OS junction [415]. Discrete hyperreflective elements in the outer retina, 
spatially associated with the white dots, were recently shown in the SD OCTs 
of four mutation-positive subjects aged 8, 19, 32 and 35 [440]. Similar lesions 
and preserved IS/OS junction line were observed in the SD OCTs of two 
patients in this study (subjects RD4 and RD8a). In an older patient (subject 
RD7), apparent focal loss of outer segments and hyperreflective material 
external to the OLM were observed (figure 3-7). Future studies with long-term 
follow-up will elucidate any possible longitudinal changes in retinal structure. 
 
To date, 68 individuals from 51 families have been reported with likely 
disease-causing variants in RDH5 [329]. Despite the fact that in most studies, 
patients with a diagnosis of fundus albipunctatus were screened, the 
electrophysiological phenotype is variable. Generalised cone and macular 
dysfunction have been described in RDH5 retinopathy although nongenetic 
factors may have influenced the electrophysiological phenotype [417, 419, 
426]. Photopic ERG responses were abnormal in six individuals from the 
largely Caucasian present series (67% compared with a previously reported 
Japanese series of 38%) [429]. Macular function, as assessed by the pERG 
P50 component, was definitely abnormal in three of eight cases.  
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All patients showed a moderate to severe loss of the rod-specific ERG b-wave 
following a standard period of dark adaptation. Most showed normalisation of 
the rod ERG following extended dark adaptation, but recovery was incomplete 
in two patients (subjects RD4 and RD6). Partial recovery in the rod system 
sensitivity has been demonstrated in retinitis punctata albescens (Bothnia 
dystrophy; mutations in RLBP1) but only in some individuals after periods of 
dark adaptation ranging from 10 to 24 hours [394]. Mutations in RLBP1, which 
encodes a soluble 11-cis retinoid carrier found in RPE and Müller cells [441] 
were excluded in all patients in the present series. 
 
A reduced b:a ratio or electronegative ERG is usually associated with 
dysfunction that is post-phototransduction or inner retinal [442] and, 
superficially, is perhaps a surprising observation in the context of a disorder 
primarily affecting rod photoreceptor function. Use of a red flash under dark 
adaptation in normal subjects elicits an early response arising in the cone 
system and a later response arising in the the rod system. The intensity of the 
red flash stimulus is such that in a normal subject the amplitude of the rod 
component to the red flash is equivalent to that of the rod-specific response to 
a dim white flash (DA 0.01). In patients with RDH5 mutations, there is usually 
a clear cone component but no detectable rod component (figure 3-8B); thus 
the ERGs under dark adaptation are probably dominated by dark-adapted 
cone activity rather than rods. Normal cone-mediated ERGs under photopic 
conditions exhibit a characteristic intensity-response known as the “photopic 
hill”, such that increasing stimulus intensity initially results in an increase in 
both photopic a-wave and photopic b-wave but following further increase in 
stimulus intensity the b-wave starts to reduce in amplitude relative to a 
continuing increase in a-wave amplitude, giving an electronegative waveform 
[443]. This has been shown to result from the reduction of the ON component 
amplitude and the delay in the positive peak of the OFF component at higher 
stimulus intensities [444]. It has previously been shown in patients with vitamin 
A deficiency, who lack rhodopsin and typically have a functionally cone-
isolated retina, that this phenomenon is a property of dark-adapted as well as 
light-adapted cones [445]; this suggests that the term “photopic” hill is perhaps 
inappropriate. The electronegative ERG to a bright flash associated with RDH5 
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mutations is thus consistent with a dark-adapted cone-mediated origin, 
exposed in the absence of normal rod photoreceptor function and should not 
be taken to reflect inner retinal rod system dysfunction. Comprehensive 
recordings in the dark-adapted state performed in one patient support this 
hypothesis (figure 3-10) and the use of a red flash under dark adaptation is 
generally recommended to assist accurate ERG interpretation. 
 
Prior to this study, 25 likely disease-causing variants in RDH5 have been 
reported [329]; 11 of these were found only in pedigrees of Japanese ancestry. 
Among the remaining 14 mutations, 12 occur in non-Japanese pedigrees and 
two in both Japanese and non-Japanese. The families in the present study 
were either of European, Middle Eastern or South Asian origin (table 3-5). 
Eleven disease-associated variants were identified, nine of which were novel; 
the remaining two have been previously reported in Caucasian families [149, 
428]. In general, no significant correlation between genotype and severity of 
electrophysiological or clinical phenotype could be found; this was in 
agreement with the conclusions of previous studies [427, 429]. 
 
The presence of 11-cis retinal, the lack of retinal degeneration and the normal 
dark adaptation kinetics observed in Rdh5 knockout mice, suggest that RDH5 
is not the only enzyme responsible for oxidation of 11-cis retinol [407]. The 
presence of another enzyme, Rdh11 that can oxidise 11-cis retinol has been 
described in mice but its role in human is debated [446]. Nevertheless, the 
presence of other 11-cis retinol dehydrogenases could explain the relatively 
mild clinical disease seen in RDH5-retinopathy compared to RLBP1-related 
disease, which features more severe and progressive retinal degeneration. 
Furthermore, there may be alternative pathways responsible for regenerating 
11-cis retinal and, for cones, this may occur in outer segments rather than in 
the RPE [405]. Since RDH5 is situated in the RPE [447], this alternative cone 
pathway could account for the relative sparing of cone function in patients with 
biallelic RDH5 mutations. 
 
To conclude, the clinical and electrophysiological phenotype of RDH5-related 
retinal dysfunction is variable. This may relate to genetic variability and 
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consequent availability of chromophore but progression of disease may also 
be a contributory factor. Electrophysiology is fundamental to making the 
diagnosis, but the ERGs should be performed and interpreted in consideration 
of the underlying pathophysiological mechanisms. 
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3.1.5 Optical Coherence Tomography in KCNV2 Retinopathy 
 
Voltage-gated potassium channels, Kvs, are transmembrane proteins that 
control excitability of electrically active cells and play a fundamental role in all 
organs and tissues. The human genome contains 40 Kvs, involved in diverse 
physiological processes [448]. Each channel is formed by four α-subunits, 
each containing six transmembrane regions, clustering around a central pore. 
KCNV2 encodes Kv8.2, a 545-amino-acid Kv subunit highly expressed in the 
inner segments of rod and cone photoreceptors of the human retina and 
known to form heteromeric channels with Kv2.1 subunits [175, 449]. 
 
Recessive mutations in KCNV2 have been shown to cause a specific retinal 
dystrophy, “cone dystrophy with supernormal rod ERG”, which is the first 
disorder of the visual system to be associated with a potassium channel defect 
in man [175]. This condition was initially described in 1983 as a progressive 
degeneration of the cone photoreceptors associated with unique rod system 
abnormalities [450]. Patients typically present in the first two decades of life 
with reduced visual acuity, disturbance of colour vision and photophobia. 
Nyctalopia may also be a feature of the disorder. Affected individuals are 
usually myopic, have a normal peripheral retinal appearance and a range of 
macular abnormalities on fundoscopy and fundus autofluorescence imaging 
[451]. Early diagnosis and targeted mutation screening is enabled by 
pathognomonic electrophysiological findings (section 1.3.2) [176, 451]. 
  
This section details structural changes associated with KCNV2 mutations. SD 
OCT findings in 12 patients with KCNV2 retinopathy are described and four 
novel disease-associated variants are reported.  
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3.1.5.1 Methods 
 
3.1.5.1.1 Subjects 
Twelve subjects (eight simplex cases and two sibling pairs) with clinical and/or 
electrophysiological examination suggestive of KCNV2-related disease were 
ascertained. Blood samples were collected for DNA extraction and subsequent 
mutation screening of KCNV2 (sections 2.4.3, 2.4.9 and 2.4.16). The proband 
of one family (subject KC2) declined to donate blood and screening was 
performed on parental DNA. 
 
3.1.5.1.2 Retinal imaging and electrophysiology 
 
Clinical assessment included fundus autofluorescence imaging and SD OCT. 
The Spectralis HRA+OCT with viewing module version 5.1.2.0 (Heidelberg 
Engineering; 3.9 μm axial resolution) was used to acquire tomographs. The 
protocol included a horizontal, centred on the fovea, linear scan and a volume 
scan (19 B-scans, 20° x 15°) for each eye. When subjects were unable to 
comply the number of frames per B-scan was adjusted. 
 
SD OCT data were analysed qualitatively; comparisons were made between 
affected individuals and the degree of interocular symmetry was investigated. 
Central point and retinal thickness in the ETDRS central subfield were 
assessed. The HEYEX software interface (version 1.6.2.0; Heidelberg 
Engineering) was used for all measurements. Identification and evaluation of 
the true dimensions of the outer nuclear layer would be a better indicator of 
photoreceptor loss compared to global thickness but the technique used to 
acquire images was not optimal for accurate segmentation and appropriate 
normative data are lacking [223].  
 
All subjects underwent electrophysiological assessment that included full field 
and pERG testing that incorporated the minimum ISCEV standards. The 
protocol also included the recording of dark-adapted ERGs to an intensity 
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series of flashes ranging from 0.001 cd·s·m-2 to 11.5 cd·s·m-2 in eight 
increments. 
 
3.1.5.1.3 Genetic analysis 
 
The KCNV2 coding region (NM_133497.2) and intron-exon boundaries were 
amplified and sequenced according to previously described methods [175]. 
The novel c.1318C>T, p.Thr439Ile variant was tested in 50 ethnically matched 
control DNAs tested, while the c.964G>C, Ala322Pro variant was tested in 95 
control DNAs (ECACC, HRC-2). 
 
3.1.5.2 Results 
 
3.1.5.2.1 Clinical and electrophysiological findings 
 
Clinical findings are summarised in table 3-6. Affected individuals were 
between 13 and 48 years old and presented with reduced central vision and/or 
photophobia that had commenced in the first or second decade of life. Visual 
acuity ranged from 0.20 to 1.30 logMAR (mean 0.71). None of the individuals 
participating in this study reported history of epilepsy or seizures. Subjects 
KC2, KC5 and KC8 as well as the sibling pair of KC6 and KC7 were born to 
consanguineous parents. 
 
PERGs were undetectable in all 11 individuals tested, indicating severe 
macular dysfunction. Full field ERGs showed the characteristic combination of 
findings previously described as pathognomonic for “cone dystrophy with 
supernormal rod ERG”, in all 12 cases (figure 3-11) [451]. 
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Table 3-6. Summary of clinical findings in individuals with KCNV2-related disease 
Case Age at 
examination 
Visual Acuity*  Refraction Ishihara 
colour 
vision test 
Macular 
appearance on 
fundoscopy 
 Fundus autofluorescence 
imaging 
Foveal appearance on SD 
OCT OD OS 
KC1 13 0.90 1.10 
+5.00/-3.50x165 OD 
+4.50/-3.50x10   OS 
test plate only 
Granular macular 
appearance 
Abnormal foveal autofluorescence; 
small parafoveal ring of increased 
autofluorescence 
Focal disruption of reflective 
band at IS/OS junction 
KC2 13 0.90 0.75 
+1.50/+1.00x90 OD 
+1.50/+1.25x90 OS 
test plate only Normal Parafoveal area of mildly 
increased autofluorescence 
Complete loss of 
photoreceptor layers  in the 
fovea 
KC3 16 0.45 0.35 myopic prescription test plate only 
Subtle RPE mottling in 
the fovea 
Parafoveal area of increased 
autofluorescence 
Focal disruption of reflective 
band at IS/OS junction 
KC4 18 0.25 0.25 emmetropic test plate only 
Granular macular 
appearance 
Abnormal foveal autofluorescence; 
small parafoveal ring of increased 
autofluorescence 
Focal disruption of reflective 
band at IS/OS junction 
KC5 18 0.20 0.30 
-8.50/-0.50x130 OD 
-7.00/-0.75x5     OS 
test plate only Granular macular 
appearance 
Parafoveal area of mildly 
increased autofluorescence 
Focal disruption of reflective 
band at IS/OS junction 
KC6 18 0.80 0.80 emmetropic test plate only 
Macular atrophy and 
flecks 
Abnormal foveal autofluorescence; 
high density foci around the fovea 
Optical gap in the fovea  with 
absent IS/OS junction line 
KC7 20 0.80 0.80 emmetropic 3/17 
Subtle RPE mottling in 
the fovea 
Parafoveal area of increased 
autofluorescence 
Small optical gap with 
disruption of reflective band at 
IS/OS junction 
KC8 34 0.80 0.80 
-12.00/-1.50x180 OD 
-12.50/-1.50x180 OS 
test plate only RPE mottling in the 
fovea 
Parafoveal area of increased 
autofluorescence 
Focal disruption of reflective 
band at IS/OS junction 
KC9 43 0.60 0.78 emmetropic test plate only Normal 
Parafoveal area of increased 
autofluorescence 
Focal disruption of reflective 
band at IS/OS junction 
KC10 44 1.00 1.30 
-2.75/-1.75x50   OD 
-5.50 OS 
unable to see 
test plate 
Macular atrophy Central loss of autofluorescence 
Complete photoreceptor layers 
loss; RPE layer loss 
KC11 44  0.50 0.80 
-9.00/-2.00x180 OD 
-6.50/-2.00x5     OS 
test plate only Subtle RPE mottling in 
the fovea 
Central area of increased 
autofluorescence with surrounding 
area of reduced signal 
Loss of photoreceptor layers  
in the fovea  
KC12 48 1.00 1.00 
-3.00/-2.00x160 OD 
     ∞/-3.00x30    OS 
2/17 Macular atrophy Central atrophy surrounded by ring 
of increased AF 
Complete photoreceptor layers  
loss, RPE layer loss 
* LogMAR or logMAR equivalent. 
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Figure 3-11. 
Representative full field and pERG traces. Subject KC8 (upper row) carries biallelic nonsense mutations. Subject KC12 (middle row) is homozygous for a 
mutation affecting the pore. The lower row shows representative normal traces. Both patients had characteristic findings. The dim flash ERGs are 
undetectable and the ISCEV standard dark-adapted 0.01 shows a profoundly delayed and subnormal b-wave. With increasing stimulus intensity there is 
then a rapid increase in b-wave amplitude and shortening of peak time despite relatively small increase in stimulus intensity. The brighter flash (dark-
adapted 11.5) ERGs show a normally developing a-wave with a broadened trough and a sharply rising high amplitude b-wave. Cone flicker (light-adapted 
30 Hz flicker) and single flash (light-adapted 3.0) ERGs are delayed and reduced. pERGs are undetectable. 
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Fundus autofluorescence imaging revealed abnormal macular 
autofluorescence in all affected individuals. The pattern of abnormality was 
variable and ranged from a small parafoveal ring of increased signal (e.g. 
subject KC1) to a central area of absent autofluorescence corresponding to 
RPE atrophy (e.g. subject KC12) (figure 3-12). 
 
SD OCT demonstrated structural changes in all 23 eyes tested (one eye was 
not included in the analysis due to unstable fixation). The findings were 
concordant between eyes in all study subjects. Discontinuous reflectivity of the 
hyperreflective band corresponding to the photoreceptor IS/OS junction was 
the predominant feature in eleven eyes (subjects KC1, KC3, KC4, KC5, KC8 
and KC9). In four eyes (subjects KC6 and KC7), disruption was more profound 
and an optical gap was seen (elsewhere described as hyporeflective zone) 
[452]. The thin reflective line corresponding to the OLM was relatively 
preserved in both groups. Extensive loss of IS/OS junction reflectivity with 
significant foveal depth reduction and a preserved RPE/Bruch’s membrane 
complex was seen in four eyes (subjects KC2 and KC11). RPE/Bruch’s 
membrane band thinning was observed in addition to the photoreceptor loss in 
four eyes (subjects KC10 and KC12). Mean CPT was 141.26 μm (n=23) and 
mean ETDRS CSF was 204.84 μm (n=19). Both CPT and CSF were 
significantly reduced compared to normative data (CPT: 227.3 ± 23.2 μm, 
CSF: 270.2 ± 22.5 μm); although part of this difference may be due to age, sex 
and axial length variability [453]. Peripheral outer retinal architecture was 
relatively well preserved on the basis of the 20° x 15° OCT volume scans 
(n=19 eyes). 
 
In terms of age, two groups can be highlighted in the present cohort. OCTs in 
the first group (subjects KC3 to KC7, aged 16 to 20) revealed relative 
preservation of the OLM and focal loss of photoreceptor outer segments. A 
more severe phenotype was observed in the second group (subjects KC9 to 
KC12, aged 43 to 48), where there was more marked photoreceptor and/or 
RPE loss in three out of four affected individuals (figure 3-12).  
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Figure 3-12. Fundus photography, autofluorescence and SD OCT of 12 individuals with “cone dystrophy with supernormal rod ERG” and mutations 
in KCNV2. The number relating to each triplet of images corresponds to case number (KC1 to KC12). Patients are ordered by age. SD OCT image 
quality in case KC5 was compromised by unstable fixation. 
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3.1.5.2.2 Genetic analysis results 
 
Either homozygous or compound heterozygous disease-associated variants 
were detected in all affected individuals within nine families (table 3-7). Only 
one single heterozygous variant could be detected in one family (subject KC1). 
Four previously unreported mutations were identified, including two missense 
variants: one (p.Ala322Pro) altering a residue that is located in the second 
transmembrane helix and is not particularly conserved and one (p.Thr439Ile) 
occurring at a site located in close proximity to the pore region (amino acids 
446-463) that is fully conserved across vertebrates and highly conserved in 
other Kvs, [454]. None of these changes was found to be present in the control 
chromosomes tested.  
 
Table 3-7. KCNV2 mutation analysis results  
Subject Mutation Status 
Protein Domain/ 
Position 
References 
Mutation Study subject 
KC1  
c.451T>C, p.Phe151Leu^ Cytoplasmic (NAB) Robson et al.[176] case partially detailed in 
Robson et al.[176]          not identified not applicable 
affected 
mother 
of 
KC2 
c.427G>T, Glu143X* Cytoplasmic (NAB) Wu et al.[175] 
previously unreported 
case; family members 
partially detailed in Wu et 
al.[175] and Robson et 
al.[176] 
KC3 & 
KC4  
c.964G>C, p.Ala322Pro^ Transmembrane (S2) novel previously unreported 
cases c.1381G>A, p.Gly461Arg^ Pore (P loop) Thiagalingam et 
al. [335] 
KC5 c.1318C>T, p.Thr439Ile^ Extracellular novel 
previously unreported 
case 
KC6 & 
KC7 
c.568delG, p.Gly189fsX21^ Cytoplasmic novel 
cases partially detailed in 
Robson et al.[176] 
KC8 c.916G>T, p.Glu306X^ Transmembrane (S2) Wu et al.[175] 
case partially detailed in 
Wu et al.[175] and 
Robson et al.[176] 
KC9 
c.1381G>A, p.Gly461Arg^ Pore (P loop) 
Thiagalingam et 
al. [335] case partially detailed in 
Robson et al.[176] c.1637T>C.p.X546TyrextX61^ Cytoplasmic 
(COOH-terminus) 
Thiagalingam et 
al. [335] 
KC10 
c.430C>T, p.Gln145X^ Cytoplasmic (NAB) Wu et al.[175] 
case partially detailed in 
Wu et al.[175] and 
Robson et al.[176] 
c.776C>T, p.Ala259Val^ Extracellular (EC1) Wu et al.[175] 
KC11 
c.1199delT,p.Phe400fsX53^ Cytoplasmic novel case partially detailed in 
Robson et al.[176] c.8_11delAACA, p.Lys3fsX93^ Cytoplasmic     
(NH2-termimus) 
Wissinger et al. 
[455] 
KC12 c.1381G>A, p.Gly461Arg* Pore (P loop) 
Thiagalingam et 
al. [335] 
case partially detailed in 
Robson et al.[176]  
Subjects KC3 and KC4 and subjects KC6 and KC7 are pairs of siblings. NAB represents the cytoplasmic domain 
NH2-terminal A and B box. *homozygous state; ^heterozygous state 
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Two novel frameshift mutations were also identified; both are one base pair 
deletions and occur within exon 1 (table 3-7). In the case of c.568delG, 
p.Gly189fsX21, mRNA would be predicted to succumb to nonsense-mediated 
decay; if however they were translated, the encoded proteins would be 
severely truncated and predicted to be nonfunctional since they would lack all 
transmembrane helices and the pore region. The c.1199delT, p.Phe400fsX53 
mutation shifts the protein frame before the fifth transmembrane domain and 
the pore. 
 
3.1.5.3 Comment 
 
Mutations in Kv channel genes cause many diverse phenotypes both in animal 
models and man. These include long QT Syndrome and neonatal seizures 
[456-458]; notably, heterozygosity for missense KCNV2 variants (p.Arg7Lys 
and p.Met285Arg) has been recently associated with epilepsy [459].  
 
SD OCT enables high resolution, cross sectional visualization of retinal 
structure and allows assessment of the structural integrity of the photoreceptor 
layer, an important parameter for the success of gene therapy or 
pharmacological modulation strategies (section 1.3.3.3) [205, 460]. Thinning 
and nonspecific changes in the foveal outer retinal layers were present in all 
affected individuals. An unusual optical gap similar to that described in 
individuals with rod monochromacy [452] caused by mutations in PDE6C [461] 
or CNGA3 [462], occult macular dystrophy [463] and less commonly in 
Stargardt disease [464], was observed in the SD OCTs of a sibling pair 
(subjects KC6 and KC7).  
 
In this cross sectional study more severe morphologic changes in SD OCT 
with increasing age cannot be excluded suggesting that there might be 
progressive loss of foveal photoreceptors; this is consistent with observations 
from other reports [176, 465]. However, it is noted that the two youngest 
individuals in the studied cohort (subjects KC1 and KC2) presented with a 
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relatively severe OCT phenotype and large longitudinal studies are needed to 
more accurately determine the natural history of the disorder. 
 
Fundoscopic and gross OCT abnormalities appear to be confined to the 
central retina. This is despite the fact that KCNV2 is expressed in both rod and 
cone photoreceptors and the ERG changes indicate widespread retinal 
dysfunction. The severity of peripheral retinal dysfunction does not correlate 
with age and serial recordings, described in a few cases, have shown mild or 
no deterioration [176, 465]. Colour vision testing has shown relative 
preservation of S-cone function [451, 466]. These findings together with the 
OCT changes suggest that foveal cones are particularly susceptible to the 
deleterious effects of mutant KCNV2 or that KCNV2 is more highly expressed 
in foveal cones. Future studies with cellular-resolution retinal imaging will more 
accurately map cone abnormalities in the foveal and parafoveal area and 
provide further insight [467]. 
 
Kv8.2 (KCNV2) subunits are not functional in isolation and do not form 
homomeric potassium channels. Instead, they coassemble with Kv2.1 to 
constitute functional heteromers [449, 454]. Kv2.1 (KCNB1) subunits are 
expressed in neurons and neuroendocrine cells and can form both homomeric 
and heteromeric channels [468]. Mutations in KCNV2 can lead to either 
completely absent or dysfunctional Kv8.2/Kv2.1 channels. When KCNV2 
mRNA is not translated, Kv2.1 homomeric channels are formed [449, 469]. 
This is predicted to be the case in individuals with biallelic mutations that 
trigger nonsense mediated mRNA decay. Conversely, mutations affecting the 
pore forming loop like p.Gly461Arg are expected to result in present but 
nonfunctional Kv8.2/Kv2.1 heteromers [449, 469]. Subjects KC2, KC6, KC7 
and KC8 carry alleles in the first category while subject KC12 is homozygous 
for a mutation in the pore. No significant difference in severity of clinical, 
electrophysiological, or OCT phenotype emerges when comparing these 
groups between them or with other study subjects. 
 
KCNV2 retinopathy is a recessive early-onset retinal dystrophy which has a 
characteristic electrophysiological phenotype. Foveal structural abnormalities 
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are demonstrated in SD OCT even in the early stages of disease. 
Undetectable pERG recordings are a consistent feature and suggest that there 
is widespread macular dysfunction affecting even morphologically intact 
photoreceptors. Future therapeutic approaches such as gene replacement or 
pharmacological therapy may restore function to these cells or slow the 
degenerative process.  
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3.1.6 Phenotypic Study of CSNB Caused by GRM6 Mutations 
 
The term CSNB denotes a clinically and genetically heterogeneous group of 
hereditary retinal disorders associated with lifelong nyctalopia. Types of this 
condition differ in fundus appearance, mode of inheritance and 
electrophysiological characteristics [384, 470]. CSNB is usually associated 
with an electronegative ERG in response to a bright white flash in the dark-
adapted eye (section 1.3.2) [471-472]. This selective reduction in the b-wave 
reflects dysfunction occurring post-phototransduction [442].  
 
CSNB with electronegative ERG has been further subdivided into complete 
and incomplete forms according to whether there is a rod-specific ERG 
response to a dim light from the dark adapted eye [473]. Mutations in NYX are 
associated with X-linked complete CSNB [474] whereas mutations in GRM6 
[157] and TRPM1 [475-477] are associated with autosomal recessive 
complete CSNB. 
 
GRM6 encodes the 877-amino-acid, retina-specific, metabotropic glutamate 
receptor 6 (mGluR6) situated on the dendrites of rod and cone ON bipolar 
cells [478]. Photoreceptors respond to changes in photon catch by changing 
the release rate of glutamate, a neurotransmitter acting differently on the two 
fundamental bipolar cell classes: OFF bipolar cells, which have sign-
conserving ionotropic receptors and ON bipolar cells, which have sign-
inverting metabotropic receptors (mGluR6) [141, 479]. The majority of cones 
connect with at least two bipolar cells, one of which is ON and the other OFF 
while rods interact mainly with ON bipolar cells [480-481]. Biallelic GRM6 
mutations result in defective signal transmission from cones and rods to ON 
bipolar cells and lead to a complete CSNB phenotype [157]. Twelve mutations 
in eight families with GRM6-related retinal dysfunction had been reported prior 
to this study [157, 339, 482-484]. 
 
In this section, novel mutational data and phenotypic detail in nine patients 
with GRM6 mutations are reported. 
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3.1.6.1 Methods 
 
3.1.6.1.1 Subjects 
 
The cohort consisted of nine patients from seven families with a history 
suggestive of autosomal recessive inheritance and clinical and 
electrophysiological findings suggestive of complete CSNB. Blood samples 
were collected for DNA extraction and subsequent mutation screening of 
GRM6 (sections 2.4.3, 2.4.9 and 2.4.16). 
 
3.1.6.1.2 Retinal imaging and electrophysiology  
 
Fundus autofluorescence imaging was performed in two affected individuals. 
All study subjects had electrophysiological assessment. Four younger patients 
were tested using surface (n=3) or gold-foil (n=1) recording electrodes and a 
shortened protocol that included light-adapted 30 Hz flicker and dark-adapted 
ERG testing. Five patients had full field ERGs performed using protocols that 
exceeded the ISCEV standard [169, 171] and included ON-OFF ERG and 
short wavelength flash (“S-cone”) ERG testing (detailed in section 3.1.4.1.2). 
PERGs were performed in five cases without marked nystagmus. 
 
3.1.6.1.3 Genetic analysis 
 
The GRM6 coding region (NM_000843.3) and intron-exon boundaries were 
screened. In a sib-pair (subjects GR1 and GR2), prior to GRM6 sequence 
analysis, genotyping was performed by Dr Zheng Li (GeneChip Human 
Mapping 50K Array Xba; sections 2.1.3 and 2.4.18.2.1). Novel missense 
variants were tested with 50 control DNAs from normally sighted individuals of 
South Asian origin and 45 DNAs from UK blood donors (ECACC, HRC-2). 
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3.1.6.1.4 Statistical analysis 
 
Individuals with GRM6 retinopathy described here and elsewhere (n=19) were 
split into three groups: those with 0, 1 or 2 alleles harbouring nonsense or 
frameshift mutation in GRM6. A greater effect of nonsense/frameshift than 
missense mutations on protein expression and function was assumed. 
Kruskal-Wallis nonparametric analysis of variance for three groups was used 
to assess correlation between overall mutation impact on patient mGluR6 and 
the presence or absence of high myopia. Spherical equivalent averaged 
between the two eyes of -6.00 dioptres or more myopic was considered high 
myopia. 
 
3.1.6.2 Results 
 
3.1.6.2.1 Clinical findings 
 
The age of affected individuals ranged from 7 to 75 years (mean 24, median 
10 years); all but one (subject GR3) presented in the first decade of life. The 
most common presenting symptoms were reduced visual acuity despite 
myopic correction and nystagmus. Only two individuals presented with night 
blindness: subject GR3 in her 20s and subject GR4 at nine years of age. 
Overall, five of nine complained of nyctalopia. Two had strabismus: one had 
mild exophoria (subject GR4) and one had manifest esotropia requiring 
surgery (subject GR8). Five of nine subjects had nystagmus of various 
amplitudes with one patient (subject GR9) adopting a head posture to utilise a 
null position. Two sib-pairs with no other family history of retinal disease were 
included in the studied cohort (subjects GR1, GR2 and GR5, GR6); the 
remaining five patients were simplex cases. Four of nine had consanguineous 
parents (subjects GR4, GR5, GR6 and GR8). 
 
The median visual acuity was 0.2 logMAR (ranging from 0.0 to 3.0). Myopic 
astigmatism was the most common refractive error and a median spherical 
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equivalent refraction of -5.375 dioptres was observed. Colour vision was 
normal in all four affected individuals tested. Fundus examination was within 
normal limits in 15 eyes and revealed signs of severe myopic maculopathy in 
three eyes (left eye of subject GR1, both eyes of subject GR2). Fundus 
autofluorescence imaging was normal in both patients tested. The clinical 
findings in these and other individuals so far reported with GRM6-related 
retinal dysfunction are summarised in table 3-8. 
 
3.1.6.2.2 Electrophysiological findings 
 
In all study subjects that underwent ISCEV standard testing (n=5), the rod-
specific ERG was undetectable. The dark-adapted bright flash ERG a-wave 
was subnormal in the oldest patient and was normal in others; waveforms 
were markedly electronegative in all and b:a ratios ranged from 0.3 to 0.45 
(figure 3-13). Light-adapted 30 Hz flicker ERGs had an abnormal waveform in 
three of five patients with a broadened trough but no definite delay and normal 
amplitude. Additional delay was observed in the four eyes of the two oldest 
subjects, a brother and sister with myopic degeneration. The light-adapted 
single flash cone ERG was of abnormal waveform in all five individuals with a 
broadened a-wave and a sharply rising b-wave lacking photopic oscillatory 
potentials; b:a ratios ranged from 1.5 to 3.5. The ON-OFF ERGs showed 
severe ON b-wave reduction and sparing of both the a-wave and the OFF 
response. Short wavelength flash ERGs were subnormal in four of four cases, 
in keeping with ON pathway dysfunction. The waveforms in the four younger 
patients that had been tested with a shortened protocol were qualitatively 
similar to those described above. PERG P50 was variable, being normal in 
subject GR5, subnormal in subjects GR3 and GR4; and undetectable in 
subjects GR1 and GR6. 
RESULTS – Phenotypic study of CSNB due to GRM6 mutations 
 
135 
 
 
Table 3-8. Clinical characteristics and molecular pathology of subjects with GRM6 retinopathy reported here and elsewhere 
Reference Sex 
Age at 
exam 
Refractive error (dioptres)                VA* 
Nystagmus Molecular diagnosis 
OD OS OD OS 
T
h
is
 s
tu
d
y
 
subject GR1 Male 75 -16.50/-1.00x110 -17.00 (balance) 0.36 3.00 Yes p.[Arg352Cys (+) Gln708X] 
subject GR2 Female 58 -12.00/-2.00x  7 -11.00/-2.00x150 1.78* 0.80* Yes p.[Arg352Cys(+) Gln708X] 
subject GR3 Female 30 -1.00/-1.25x105 -0.50/-2.50x 50 0.18* 0.18* No p.[Arg677Cys (+) Arg677Cys] 
subject GR4 Female 11 -0.50/-1.00x 80 -0.50/-1.50x105 0.20 0.00 Yes p.[Gly756Asp (+) Gly756Asp] 
subject GR5 Female 10 -7.00/-3.50x 10 -7.00/-1.75x175 0.20* 0.18* No p.[Val193fsX15 (+) Val193fsX15] 
subject GR6 Female 7 -4.50/-2.75x 20 -6.00/-2.00x180 0.08 0.14 No p.[Val193fsX15 (+) Val193fsX15] 
subject GR7 Female 9 -3.50/-3.50x180 -3.50/-4.00x180 0.58 0.28 Yes p.[Arg238X (+) Arg677Cys] 
subject GR8 Male 8 -4.25/-1.50x175 -2.50/-1.00x180 0.54 0.2 No p.[Arg677His (+) Arg677His] 
subject GR9 Female 7 +0.25/-0.75x 25 +0.25/-1.50x160 0.22 0.2 Yes p.[Gly275Asp (+) Pro689fsX24] 
Dryja et al. [157] 
Male 37 -0.25^ (averaged between two eyes)
 
0.0 0.0 No p.[Arg621X] + [Arg621X] 
Male 31 -4.62^ (averaged between two eyes)
 
0.3 0.3 Yes p.[Gly150Ser] + [Gln708X] 
Female 14 -5.38^ (averaged between two eyes)
 
0.1 0.18 No p.[Glu781Lys (+) Glu781Lys] 
Zeitz et al. [482]
 
Male 46 +3.50^
  
+1.50^ 0.3 0.1 Yes p.[Pro46Leu] + [Val243fs] 
Male 36 -3.00^ -3.00^
 
0.4 0.4 Yes p.[Cys522Tyr] + [Cys522Tyr] 
Female 13 -9.00^ -10.00^ 1.0 0.2 No p.[Gly58Arg] + [Leu26fs] 
Female 10 -10.00^ -8.00^ 0.1 0.1 Yes p.[Gly58Arg] + [Leu26fs] 
Female 8 -6.50^ -6.00^ 0.5 0.5 No p.[Gly58Arg] + [Leu26fs] 
O’Connor et al. 
[339] Female 7 -2.50/-3.50x 85 -2.50/-4.00x100 0.3 0.3 Yes p.[Arg238X (+) Tyr409X] 
Leifert et al. 
[484]; Zeitz et 
al.[483]
 
Female 63 -6.00/-3.00x 80 -9.00/-2.00x 90 0.3* 0.4* No p.[Ile405Thr (+) Ile405Thr] 
Subjects GR1 and GR2 and subjects GR5 and GR6 are pairs of siblings. Subjects GR1 and GR2 have British origin while subjects GR3 to GR9 
originate from South Asia. 
* Snellen acuity converted to logMAR equivalent 
^ spherical equivalent 
Previously unreported changes are in bold font. 
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3.1.6.2.3  Genetic analysis results 
 
Analysis of array data from subjects GR1 and GR2 (section 2.5.4.2) showed 
that among the 25% of the genome predicted to be shared between siblings 
there was a chromosomal segment around GRM6 but not one around TRPM1. 
Overall, nine mutations in GRM6 were detected in the seven families studied. 
Those include five missense variants, two nonsense mutations and two one 
base pair deletions. Tables 3-8 and 3-9 summarise the results and review the 
 
Figure 3-13. Full field ERGs and pERGs from individuals with GRM6-related complete 
CSNB. Normal traces are shown for comparison. Dark-adapted responses are shown for 
flash strengths of 0.01 and 11.0 cd·s·m
-2
 (DA 0.01; DA 11.0). Photopic ERGs are shown for 
flash strength 3.0 cd·s·m
-2
 (LA 3.0; 30 Hz and 2 Hz) and for ON-OFF and S-cone system 
stimulation. All responses show a high degree of inter-ocular symmetry and are for one eye 
only. A 10 ms prestimulus delay was used in subject GR4. Missing traces in subjects GR2 
and GR8 were unrecordable due to nystagmus or eye movement artefact. 
RESULTS – Phenotypic study of CSNB due to GRM6 mutations 
 
137 
 
variants identified in the GRM6 coding region that are likely to be pathogenic. 
No statistically significant correlation between severity of mutated alleles per 
individual and high myopia could be found.  
 
Four novel missense disease-associated variants were identified: the 
p.Arg352Cys change occurs at a residue located in the extracellular, ligand-
binding, part of the receptor without directly affecting the glutamate binding 
pocket [483]; two novel changes occur at the same site (p.Arg677Cys, 
p.Arg677His), a highly conserved across species and other group III mGluRs 
residue that is located in the intracellular part of the protein; the p.Gly756Asp 
mutation alters an amino acid located in the fifth transmembrane helix. None 
of these missense changes is predicted to interfere directly with the 
dimerisation of mGluR6 [483]. Two novel one base pair deletions that cause 
premature termination codons were also identified (p.Val193fsX15, 
Pro689fsX24). 
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Table 3-9. Coding sequence changes in GRM6 that are likely to be pathogenic and in silico analysis of their effect 
Nucleotide substitution Amino acid exchange 
Number of 
alleles in 
affected 
SIFT PolyPhen-2 
Reference 
Prediction 
Tolerance 
index (0-1) 
Prediction
 HumVar 
Score (0-1) 
c.57_75dup19 p.Leu26fs 3 not applicable Zeitz et al. [482]
 
67_82delCAGGCGGGCCTGGCGCinsT p.Gln23_Arg28del5insCys 1 not applicable Xu et al. [485]
 
c.137C>T p.Pro46Leu 1 intolerant 0.00 POD 1.00 Zeitz et al. [482] 
c.172G>C p.Gly58Arg 3 intolerant 0.03 POD 0.91 Zeitz et al. [482] 
c.448G>A p.Gly150Ser 1 intolerant 0.00 POD 1.00 Dryja et al. [157]
 
c.575delG p.Val193fsX15 4 not applicable this study 
c.712C>T p.Arg238X 2 not applicable O’Connor et al. [339], this study 
c.720_721insG p.Val243fs 1 not applicable Zeitz et al. [482]
 
c.823G>A p.Gly275Asp 2 tolerated 0.07 POD 0.94 Zeitz et al. [340],this study 
c.1054C>T p.Arg352Cys 2 tolerated 0.07 POS 0.55 this study 
c.1214T>C p.Ile405Thr 2 tolerated 0.29 POS 0.78 Zeitz et al. [483]
 
c.1227C>A p.Tyr409X 1 not applicable O’Connor et al. [339]
 
c.1537G>A p.Val513Met 4 tolerated 0.33 Benign 0.01 Xu et al .[485] 
c.1565G>A p.Cys522Tyr 2 intolerant 0.00 POD 1.00 Zeitz et al. [482] 
c.1861C>T p.Arg621X 2 not applicable Dryja et al. [157] 
c.2029C>T p.Arg677Cys 3 tolerated 0.21 POD 1.00 this study 
c.2030G>A p.Arg677His 2 tolerated 0.22 POD 1.00 this study 
c.2062delC p.Pro689fsX24 1 not applicable this study 
c.2090A>T p.Gln697Leu 1 intolerant 0.00 POD 0.96 Zeitz et al. [340] 
c.2267G>A p.Gly756Asp 2 tolerated 0.21 POS 0.45 this study 
c.2122C>T p.Gln708X 3 not applicable Dryja et al. [157], this study 
c.2341G>A p.Glu781Lys 2 intolerant 0.01 POD 1.00 Dryja et al. [157] 
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3.1.6.3 Comment 
 
Complete CSNB is usually but not always associated with high myopia [473]. 
Spherical equivalent in six of nine patients in the studied cohort was less 
myopic than -6.00 dioptres (12 out of 19 in all published cases including this 
study). Mutations in NYX and GRM6 have been reported to contribute to high 
myopia without additional features of CSNB [485-486] but further studies are 
needed to confirm this association. 
 
All affected individuals had a full field ERG phenotype consistent with 
complete CSNB. There was ON pathway involvement in rod and cone 
systems and evidence of S-cone system involvement. Two siblings with 
myopic degeneration showed 30 Hz flicker ERG delay but, as with other 
causes of complete CSNB, delay was not a prominent feature. A 75-year-old 
study subject had a subnormal ERG a-wave (DA 11.0), consistent with 
additional rod photoreceptor involvement. Dark-adapted ERG a-wave 
reduction was not present in any other patient, although this has been 
previously documented in two teenage patients without severe myopia [157].  
 
Electrophysiology and family history can assist diagnosing different forms of 
CSNB and direct molecular genetic testing. Complete forms of CSNB with 
electronegative ERG can be inherited in an autosomal recessive (GRM6, 
TRPM1) or X-linked (NYX) fashion. Mutations in NYX are considered the most 
common cause, even when an X-linked inheritance pattern cannot be 
convincingly established through family history [340]. Mutations in GRM6 or 
TRPM1 should be suspected when a pedigree is not suggestive of X-linked 
inheritance. TRPM1 is considered the most frequently mutated gene in 
autosomal recessive complete CSNB [476-477]. If the mode of inheritance is 
unclear, the only difference in electrophysiological phenotype among complete 
CSNB patients has been described using a dark-adapted 15 Hz flicker ERG 
[487]; patients with TRPM1 mutations showed responses similar to those with 
NYX mutations, but different from those with GRM6 mutations [476, 482].  
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To conclude, presentation of GRM6-related retinal dysfunction can be variable 
and electrophysiology is fundamental to the diagnosis. Identifying disease-
causing variants in GRM6 confirms autosomal recessive inheritance and 
facilitates accurate counselling. 
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3.1.7 Structure, Function and Molecular Pathology in Gyrate Atrophy 
 
Gyrate atrophy of the choroid and retina is an autosomal recessive condition 
associated with significantly increased plasma ornithine levels [488]. Patients 
typically report night blindness and/or loss of peripheral vision in the second 
decade of life; myopia and early cataracts are also features of the disorder. On 
fundoscopy, sharply demarcated, circular areas of chorioretinal atrophy 
distributed around the peripheral fundus are observed that, later in the disease 
process, coalesce and spread posteriorly. The macula and consequently, 
central vision is often preserved into the fourth or fifth decade of life [489-490]. 
Over 200 individuals with gyrate atrophy have been reported since it was first 
described in the late 19th century, with a significant proportion of them being 
Finnish [491]. 
 
The underlying biochemical defect of gyrate atrophy is in OAT, a vitamin B6 
dependant mitochondrial matrix enzyme. This enzyme catalyzes the 
conversion of L-ornithine, a nonproteinaceous amino acid, to proline and 
glutamic acid. OAT plays a role in cellular detoxification by disposing ornithine 
derived from dietary arginine thus removing uncoupled ammonia [492-495]. 
Chronic reduction of plasma ornithine levels with an arginine-restricted diet 
has been reported to slow disease progression in some instances [496]. 
 
The gene that encodes the 439-amino-acid human OAT precursor is 
expressed in most tissues, including liver, brain, neurosensory retina and RPE 
[497]. To date, over 50 mutations have been reported in OAT (HGMD) with 
their deleterious consequences largely confined to the eye. As the RPE is 
considered the primary site of dysfunction in gyrate atrophy, clinical trials of 
gene replacement therapy targeting the RPE or cellular therapeutic 
approaches involving induced pluripotent stem cell-derived RPE may be 
relevant to gyrate atrophy patients [498-501].  
 
Histopathologic study of postmortem tissue and in vivo cross sectional imaging 
with time domain OCT have been previously used to provide insight into 
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structural changes in gyrate atrophy [502-506]. Retinal histopathology has 
been reported in human as well as in animal models of gyrate atrophy [498, 
502, 507]. In a 98-year-old patient, later identified to be homozygous for a 
p.Glu318Lys mutation [508], focal areas of photoreceptor atrophy with an 
underlying hyperplastic RPE were observed in the posterior pole. Near the 
transition from relatively preserved to atrophic retina, the RPE was either 
absent or dysmorphic. More peripherally to this transition zone both RPE and 
photoreceptor cells were absent. At a short distance into the area of atrophic 
RPE, photoreceptor cell nuclei abutted directly onto Bruch’s membrane; the 
underlying choriocapillaris were preserved. Complete absence of outer retina, 
RPE, choriocapillaris and most medium and large choroidal vessels was 
observed in the atrophic region [502]. Regarding in vivo investigation, although 
resolution is relatively low in time domain OCT detection, features such as 
oedema and macular hole have been described [504-506].  
 
In this section SD OCT (an alternative to time domain OCT with significant 
sensitivity and speed advantages; section 1.3.3.3) and fundus 
autofluorescence imaging findings in gyrate atrophy are detailed. Fundus-
controlled perimetry (also known as “microperimetry”, a method for accurate 
functional assessment of the central retina with high spatial resolution and 
continuous fixation monitoring [509]), features and novel mutational data are 
also reported.  
 
3.1.7.1 Methods 
 
3.1.7.1.1 Subjects 
 
Seven unrelated patients with a diagnosis of gyrate atrophy were ascertained 
over a 10-year period of time; all had a retinal dystrophy and fundoscopic 
features compatible with those previously described in gyrate atrophy together 
with a significantly raised plasma ornithine level. Subjects GA1 to GA7 are 
numbered according to age (youngest to oldest).  
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3.1.7.1.2  Retinal imaging and perimetry testing 
 
Fundus autofluorescence imaging, SD OCT and fundus-controlled static 
perimetry were performed (imaging was performed by Dr Eva Lenassi and PS, 
perimetry testing was performed by Dr Eva Lenassi). The Spectralis 
HRA+OCT with viewing module version 5.1.2.0 (Heidelberg Engineering) was 
used to acquire fundus autofluorescence images (over a 30° × 30° and/or a 
55° × 55° field; six patients tested) and tomographs (all seven patients tested). 
The SD OCT protocol included a horizontal, linear scan (100 B-scans 
averaged to improve the signal-to-noise ratio) centred on the fovea and a 
volume scan (minimum of 19 B-scan slices, 20° x 20° or 20° x 15°) for each 
eye. Retinal thickness in the central and inner macula ETDRS subfields were 
assessed; the HEYEX software interface (version 1.6.2.0; Heidelberg 
Engineering) was used for all measurements. Static perimetry (MP1 
Microperimeter, Nidek Technologies, Padova, Italy) was performed in six 
patients. The semi-automatic examination with number of stimuli ranging from 
49 to 82, threshold sensitivities from 0 to 20 dB, test spot size Goldmann I, 
projection time 1000 ms and 4-2 staircase test strategy was used. A smaller 
than usual stimulus size was chosen as it has been previously suggested that 
with such stimuli, it is possible to observe little islands with residual function 
[510]. 
 
3.1.7.1.3 Genetic analysis 
 
Blood samples were collected and the OAT gene (NM_000274.3) was 
screened in all affected individuals (screening was performed by Dr Alice E 
Davidson; sections 2.4.3, 2.4.9 and 2.4.16). When possible, parental DNA 
samples were screened to establish phase of variants (subjects GA4 and 
GA6). 
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3.1.7.2 Results 
 
3.1.7.2.1 Clinical findings 
 
Table 3-10 presents data on the seven affected individuals studied (age range 
10 to 52). The mean visual acuity was 0.26 logMAR (range 0.10 to 0.50). 
Presentation was in the first decades of life: four patients were noted to have 
abnormal retinal appearance in routine refraction following difficulty reading 
the blackboard in early school years (subjects GA1, GA2, GA4, GA6); one 
presented with night vision problems around the age of 12 (subject GA5); one 
recalls night blindness from a young age and problems with peripheral vision 
from early teenage years, but medical advice was only sought at age 26 
(subject GA7); one presented with poor central vision (1.00 logMAR in each 
eye) with electrophysiology suggesting that this is caused by functional visual 
loss. Six of seven affected individuals were night blind and seven of seven had 
elevated plasma ornithine concentration. Subject GA5 and GA7 had bilateral 
cataract extractions with intraocular lens implants at age 29 and 41 
respectively; subject GA6 had the right eye operated at age 22 and the left at 
age 26. Subject GA7 had late-onset sensorineural hearing loss and a paternal 
family history of hearing impairment; hearing problems were also reported for 
subject GA1. All individuals had a negative family history of retinal disease; 
subjects GA1 and GA2 were born to consanguineous parents. Fundoscopy 
revealed typical changes of gyrate atrophy in all seven patients. Importantly, 
retinal pigment migration was minimal or absent and retinal vessel diameter 
was relatively preserved. Sharply demarcated areas of increased or preserved 
signal were observed in autofluorescence images of all six cases tested. 
Colour fundus photography and fundus autofluorescence imaging are 
presented in figure 3-14. 
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Table 3-10. Clinical characteristics and molecular pathology of subjects with gyrate atrophy 
S
u
b
je
c
t 
Sex 
Age at 
exam 
Refractive error (dioptres) VA (logMAR) 
Colour 
vision 
Presenting complaint  
(age at diagnosis) 
Nyctalopia 
(age first 
noticed) 
Ornithine 
levels at 
diagnosis 
(μmol/l) 
Molecular diagnosis, 
mutations in OAT OD OS OD OS 
GA1 Female 10 .-6.75/-4.00x180*  .-6.50/-4.00x180* 0.34 0.30 HRR full increasing myopia (9) yes (8) 1390  p.[Gly91Glu];[Gly91Glu] 
GA2 Female 14 -6.00/-2.50x25 -5.50/-2.50x155 0.10 0.16 HRR full increasing myopia (11) no 1152 p.[Gly51Asp];[Gly51Asp] 
GA3 Female 17 .-2.00 .-1.75/-0.50x170 0.22 0.20 ISH 17/17 poor central vision (17) yes (17) 775  p.[Glu318Lys];[?] 
GA4 Male 30 Myopic astigmatism 0.18 0.20 ISH 17/17 increasing myopia (6
#
) yes (14) 908 p.[Pro199Gln];[Pro417Leu] 
GA5 Female 34 .-13.50/-1.50x75^ .-11.00/-1.50x120^ 0.50 0.20 
ISH test 
plate only 
night blindness (13) yes (12) ~900 p.[Pro199Gln(;)Pro417Leu] 
GA6 Female 38 Myopic astigmatism^ 0.10 0.40 ISH 6/17 increasing myopia (9) yes (27) ~1000 p.[Gly121Asp];[Tyr299X] 
GA7 Female 52 .-9.50/-2.00x177^ .-7.75/-3.00x7^ 0.50 0.20 ISH 5/17 night blindness (26) yes (always) ~700 p.[Tyr55His(;)Arg250X] 
*cycloplegic refraction 
^prior cataract surgery 
#diagnosed with retinal dystrophy; gyrate atrophy was diagnosed at age 30 
Normal plasma ornithine levels: 20 to 114 μmol/l. Novel changes are in bold font 
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Figure 3-14. Colour fundus 
photography and fundus 
autofluorescence imaging of 
individuals with gyrate atrophy 
and OAT mutations. The 
number relating to each pair of 
images corresponds to the 
case number (subjects GA1 to 
GA7) and patients are 
numbered according to age 
(youngest to oldest; age range 
10 to 52). Bone spicule 
pigmentation is minimal, retinal 
vessels are relatively 
preserved and circular areas of 
chorioretinal atrophy are 
evident in fundus photography. 
Sharply demarcated areas of 
increased or normal signal are 
observed in fundus 
autofluorescence images. 
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SD OCT demonstrated structural changes concordant between eyes in all 
affected individuals. For subjects GA1 and GA3, SD OCT revealed multiple 
intraretinal cystic spaces bilaterally and no other significant abnormality (figure 
3-15). Hyporeflective cysts varying in size were also detected in the remaining 
five cases. In these patients (subjects GA2, GA4, GA5, GA6 and GA7), the 
hyperreflective band corresponding to the photoreceptor IS/OS junction was 
preserved in the regions where autofluorescence signal was normal or 
increased. Outside these regions, typically at the edges of foveal scans and at 
the more peripheral scans of the volume series, extensive loss of IS/OS 
junction reflectivity and significant thinning were observed. The thinning was 
not confined to the scattering layers in the outer retina, but also extended to 
the inner retinal layers, the hyperreflective band corresponding to the 
RPE/Bruch’s complex and the structures often seen posterior to it. Structures 
corresponding to the external choroidal margins, large choroidal vessels and 
inner scleral surface were visible on the scans of all affected individuals. A 
loss of focal hyperreflectivity in the inner choroid was frequently observed and 
structures resembling large choroidal vessels appeared to be in close 
proximity to the hyperreflective band interpreted as Bruch’s membrane. 
Vitreomacular traction and/or epiretinal membrane causing irregularity of the 
retinal surface were observed in the four oldest subjects. An interesting shared 
feature in the SD OCT of all seven individuals was the presence of 
hyperreflective deposit in the ganglion cell layer, particularly over the regions 
of preserved, or at a short distance into the regions of absent, 
autofluorescence. When the amount of hyperreflective material was increased 
deposits coalesced and were depicted as vertical hyperreflective lines (for 
example figure 3-15, subjects GA3 and GA4; figure 3-16B, subject GA4). 
Another interesting finding was the presence of round or ovoid hyporeflective 
spaces with hyperreflective borders on SD OCT scans from the four older 
patients (subjects GA4, GA5, GA6 and GA7). These were typically found in 
the transition from relatively preserved to atrophic retina (figure 3-17, subject 
GA4) and previously were termed “outer retinal tubulation” [511]. Finally, when 
thickness profiles were evaluated, relative thickening was observed in the 
more central ETDRS subfields of younger subjects (figure 3-16A, subjects 
GA1, GA2 and GA3). 
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Figure 3-15. Foveal linear 
SD OCT scans of seven 
individuals with gyrate 
atrophy (subjects GA1 to 
GA7, ordered by age). 
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Figure 3-16. SD OCT findings in 
gyrate atrophy. 
[A] Thickness profiles of foveal 
region of subjects GA1 (aged 10), 
GA2 (aged 14), GA3 (aged 17) and 
GA4 (aged 30). A healthy 28-year-
old control (N) is also shown. 
Thickening of the central subfields is 
evident in the three younger 
subjects and thinning of 
midperipheral subfields is 
demonstrated in the older patient.  
[B] 55° field fundus 
autofluorescence, infrared imaging 
and SD OCT scans from subjects 
GA4 (aged 30) and GA7 (aged 52). 
The borders from preserved to 
absent autofluorescence correspond 
to transition zones in SD OCT 
(arrows). In subject GA4, the 
structures corresponding to 
choroidal layers are very thin and 
the scleral surface is clearly visible. 
Hyperreflective deposit arranged in 
a linear pattern is observed in the 
band corresponding to the ganglion 
cell layer (asterisk). In subject GA7, 
a linear scan from a peripheral area 
of preserved autofluorescence is 
presented. Preservation of the 
hyperreflective layer corresponding 
to the RPE is observed. 
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# 
Figure 3-17. Functional assessment of the central retina in six individuals with gyrate atrophy. 
[A] Static perimetry testing results overlaid with fundus autofluorescence images and SD OCT 
scans from subjects GA3 (aged 17) and GA4 (aged 30) are presented. Mild reduction of 
foveal sensitivity is observed in the younger patient were fundus autofluorescence in normal 
and SD OCT only shows some cystic spaces. In the older patient, sensitivity is reduced over 
areas of relatively preserved fundus autofluorescence and with an intact IS/OS junction line. 
However, outside these regions there is no response even to the brightest stimulus. The 
asterisk marks a round hyporeflective space with hyperreflective borders (“retinal tubulation”). 
This could reflect photoreceptors forming rosettes in the absence of RPE. 
[B] Static perimetry results from subjects GA1 (aged 10), GA5 (aged 34), GA6 (aged 38) and 
GA7 (aged 52). Datasets have been overlaid with infrared (subject GA1) or fundus 
autofluorescence (subjects GA5, GA6 and GA7) images. Similarly to subject GA3, subject 
GA1 presents with mildly reduced retinal sensitivity despite structurally intact retina. 
Conversely, in the older subjects, retina is functional only over areas of preserved 
autofluorescence, thus highlighting the clinical value of fundus autofluorescence imaging in 
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gyrate atrophy. 
[C] Static perimetry testing results overlaid with fundus autofluorescence images and SD OCT 
scans from subjects GA4 (aged 30) and GA7 (aged 52) are presented. Surprisingly, retinal 
function appears preserved over areas of absent autofluorescence signal (on fundus 
autofluorescence) and very thin outer and total retina (on SD OCT). The scleral surface is 
clearly visible and the presence of islands of preserved photoreceptors cannot be excluded 
(arrowhead). 
Threshold values of retinal sensitivity derived from fundus-controlled perimetry are presented 
according to the pseudocolour scale at the lower right hand corner; numbers indicate the 
scale in dB (0 to 20 dB). Normal sensitivity is indicated by green colour, and decreased 
sensitivity is indicated by red colour. Hollow red squares correspond to areas where the 
brightest perimetry stimulus was not detected by the subject (absolute scotoma). 
 
Static perimetry testing results were overlaid with fundus autofluorescence 
images and SD OCT and are presented in figure 3-17. Stable fixation was 
observed in all eyes tested. In patients with structurally preserved posterior 
pole, although appropriate normative data are lacking, a mild reduction in 
macular sensitivity is likely (figure 3-17A and B, subjects GA1 and GA3). In the 
more severely affected individuals (subjects GA4 to GA7), reduced sensitivity 
was evident over regions of increased or preserved autofluorescence signal 
(on fundus autofluorescence imaging) and relatively intact IS/OS line (on SD 
OCT). In six out of eight eyes, outside these areas, patients did not respond 
even to the brightest stimuli (figure 3-17A and B, subjects GA4, GA5, GA6, 
GA7). Interestingly, in the remaining two eyes, consistent responses were 
documented over areas with significant outer retinal (absent IS/OS line on SD 
OCT) and RPE (no signal on fundus autofluorescence imaging) loss (figure 3-
17C, subjects GA4 and GA7). 
 
3.1.7.2.2 Genetic analysis results 
 
Overall, nine likely disease-causing DNA variants in OAT were detected in 13 
alleles of seven patients; these included seven missense and two nonsense 
changes (table 3-11). The bioinformatics programs SIFT and PolyPhen-2 both 
supported the likely pathogenicity of each of the identified missense mutations, 
including p.Gly51Asp, p.Gly91Glu and p.Gly121Asp which are novel to this 
study. Furthermore, all novel mutations identified (p.Gly51Asp, p.Gly91Glu, 
p.Gly121Asp and p.Arg250X) were found to be absent from the 1000 
genomes project dataset (628 individuals from the 20100804 sequence and 
alignment release). 
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Table 3-11. Missense coding sequence changes in OAT that are likely to be pathogenic and in silico analysis of their effect 
Nucleotide 
substitution 
Amino acid 
exchange 
SIFT PolyPhen-2 
Reference 
Prediction 
Tolerance 
index (0-1) 
Prediction
 HumVar 
Score (0-1) 
c.152G>A p.Gly51Asp intolerant 0.00 POS 0.867 this study 
c.163 T>C p.Tyr55His intolerant 0.00 POD 0.980 Kaufman et al.[512]
 
c.272 G>A p.Gly91Glu intolerant 0.00 POD 1.000 this study 
c.362 G>A p.Gly121Asp intolerant 0.01 POD 0.995 this study 
c.596 C>A p.Pro199Gln intolerant 0.00 POD 0.994 Kaufman et al.[512]
 
c.952 G>A p.Glu318Lys intolerant 0.02 POS 0.626 Mashima et al.[508]
 
c.1250 C>T p.Pro417Leu intolerant 0.00 POD 0.997 Brody et al.[513]
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3.1.7.3 Comment 
 
All seven study subjects had myopic refraction, fundus changes typical of 
gyrate atrophy and greatly elevated plasma ornithine. Six of seven subjects 
complained of poor night vision and/or increasing myopia as their first 
symptom. In a previous report, more than 70% of patients presented with 
myopia [491]. Fundoscopy through dilated pupils in highly myopic children with 
or without night blindness is key for the early diagnosis of gyrate atrophy. 
However, it is noted that presentation can be unusual as in subject GA3, a low 
myope that presented with poor central vision, probably unrelated to the 
primary retinopathy. 
 
Visual acuity loss in individuals with gyrate atrophy can be the result of 
disease progression causing central photoreceptor cell death, but also 
cataract or macular oedema. By the second decade, cataract is considered a 
uniform finding in gyrate atrophy patients [514]. Cataracts are typically 
posterior sutural, may have unique histological characteristics and require 
surgical intervention by the third or fourth decade of life [490, 514]. In the 
present series, the three older patients (subjects GA5, GA6 and GA7) had 
already undergone bilateral cataract surgery. Cystoid macular oedema can be 
another ocular manifestation of gyrate atrophy with at least four cases 
reported to date; fluorescein angiography and time domain OCT have been 
used to confirm this macular complication [504-505]. Hyporeflective cystic 
spaces, predominantly at the inner retina were identified with SD OCT in all 
affected individuals suggesting that oedema is also a uniform finding. RPE 
dysfunction/loss leading to disruption of the outer blood-retinal barrier and 
diffusion of fluid toward intraretinal spaces is likely to be the main mechanism 
of oedema formation in gyrate atrophy. The fact that it is observed even in 
younger subjects with structurally intact, although thickened (figure 3-15), 
retina may suggest RPE dysfunction as an early abnormality leading to 
photoreceptor cell exposure to toxic agents from choroidal circulation. In older 
subjects, in addition to the inner retinal hyporeflective cystic spaces, SD OCT 
detected epiretinal membrane and vitreomacular traction. 
RESULTS – Structure, function and molecular pathology in gyrate atrophy 
 
154 
 
Hyperreflective deposits on SD OCT were observed in the ganglion cell layer 
of all individuals in the present series (figure 3-15, subjects GA3 and GA4; 
figure 3-16B, subject GA4). This material was more obvious but not confined 
to the areas near the transition from relatively preserved to atrophic retina. 
Colourless, elongated glittering crystals, better seen in the fluorescein 
angiogram and located over or proximal to the preserved areas have been 
previously described in gyrate atrophy patients [489, 515]. Immunofluorescent 
localization of glial fibrillary acidic protein in the Oat-/- mouse retina, revealed 
labelling of the astrocytes in the innermost retina [498]. This finding suggests 
gliotic response to ongoing cell death [516] and one possibility is that the 
hyperreflective deposits on SD OCT reflect retinal gliosis. Inner retinal globular 
hyperreflective aggregates, with some similarities to the ones described in this 
study, have been previously reported in eyes with acute zonal occult outer 
retinopathy [517]. 
 
Another interesting finding in the tomographs of older gyrate atrophy patients 
was the presence of outer retinal tubulation (figure 3-17, subject GA4). Similar 
structures were observed in choroideremia and have been previously 
described in Bietti crystalline dystrophy, pseudoxanthoma elasticum and age-
related macular degeneration [511]. It has been proposed that these rosettes 
are formed by degenerating photoreceptor cells becoming arranged in a 
circular or ovoid fashion [511]. This could partially explain the relative 
preservation of visual function over these structures (figure 3-17, subject 
GA4). As RPE is an early site of dysfunction in all conditions mentioned 
above, it can be speculated that the first step in the process may be RPE loss. 
In support to this is evidence from transplantation studies in murine eyes, 
which suggest that symbiosis of photoreceptors with microglia in rosettes 
promotes photoreceptor cell survival in the absence of RPE [518]. 
 
This study showed that in individuals with gyrate atrophy, perimetry stimuli are 
recognised over areas of preserved or increased signal in fundus 
autofluorescence imaging. Surprisingly, in two eyes of two patients (figure 3-
17B), preserved retinal function was also observed over areas of absent 
autofluorescence signal, corresponding to RPE atrophy. When the relevant 
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perimetry data points were overlaid with SD OCT, a very thin retina with 
complete loss of IS/OS line was observed (figure 3-17C). It can be speculated 
that reflection, or scatter, of the stimulus from the sclera, onto preserved and 
functioning anterior retina, might account for the absence of an absolute 
scotoma, which would be expected from an area of complete loss of RPE and 
outer retina. Of the two eyes concerned, the results were reproducible and not 
evidently the result of poor compliance. When the subjects were asked to 
report the direction of the stimuli, again this was reproducibly reported, but did 
not always map to the area stimulated. Each eye had areas of intact anterior 
retina and the most likely explanation is that scatter towards the functioning 
areas allowed the subject to “see” these stimuli. Alternative explanations 
include small areas of preserved retina missed by OCT and fundus 
autofluorescence imaging and inner-retinal phototransduction. This finding 
suggests the need for caution in the interpretation of perimetry data when 
investigating dystrophies such as gyrate atrophy and is particularly relevant to 
its use in characterising the deficit in choroideremia in preparation for relevant 
therapeutic trials. 
 
Six of seven individuals in the present series were identified to harbour either 
proven (subjects GA1, GA2, GA4 and GA6) or presumed (subjects GA5 and 
GA7) biallelic mutations in OAT. Subjects GA4 and GA5, who are not 
knowingly related, share the same genotype. The observed phenotypic 
differences between the two patients most likely can be attributed to other 
currently unidentified genetic factors and/or environmental modifying factors. 
Subject GA3 was found to harbour only a single previously reported [508] 
heterozygous OAT mutation, p.Glu318Lys. Interestingly, patient GA3 is of 
British ancestry and all previously reported individuals carrying this mutation 
are also of British or Irish descent [508]. 
 
The Glu318 residue is important for pyridoxal phosphate (PLP; the active form 
of vitamin B6) cofactor binding to OAT [494] and it has been suggested 
previously that a p.Glu318Lys substitution disrupts it [502, 508]. This missense 
change is one of only a handful of OAT mutations demonstrated to be 
responsive to PLP supplementation [508, 519-521]. Importantly, gyrate 
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atrophy patients reported with PLP responsive genotypes have been noted to 
have a less severe and progressive clinical presentation [508]; a finding in 
keeping with the clinical presentation of subject GA3 in this study. 
 
To conclude, structural changes in gyrate atrophy are reported in detail: 
macular oedema is a common finding, the fovea is relatively thick in early 
stages of disease, deposits that could suggest retinal gliosis are observed and 
retinal tubulation is present in advanced disease. Functional testing highlights 
the importance of fundus autofluorescence imaging as a monitoring tool for 
gyrate atrophy and suggests that retinal sensitivity can be reduced even over 
structurally intact retina and in early stages of disease progression. 
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3.2 Identifying Novel Retinal Disease-associated Genes and Loci 
 
Identifying novel retinal disease-associated genes is important for both 
scientists and clinicians. For scientists interested in understanding the 
development, function and structure of the visual system, each discovery 
elucidates a gene-protein component and biochemical pathway; thus 
important insights into the complex biochemistry and cellular physiology of the 
human eye are provided. For clinicians, knowledge of the molecular pathology 
of an affected individual allows improved counselling and management as well 
as access to relevant clinical therapeutic trials [522]. A method termed 
homozygosity mapping [105], both in isolation (section 3.2.3) and combined 
with exome sequencing (sections 3.2.4 and 3.2.5), was used to identify three 
novel retinal disease-associated genes. 
 
3.2.1 Homozygosity Mapping 
 
As previously mentioned (section 1.1.1.3), the simplest form of genetic 
mapping is linkage analysis [28, 64, 523]. Families with recessive retinal 
disease are small, often containing only one individual; this makes traditional 
linkage analysis challenging. In addition, the striking genetic heterogeneity of 
retinal disease (arguably the most genetically heterogeneous class of 
disorders in man [159]) makes pooling families to increase power unreliable. A 
genetic mapping strategy proposed by Lander and Botstein in 1987 [105], 
exploiting the increased power of consanguineous pedigrees, was utilised to 
tackle these issues. 
 
Table 3-12 summarises some of the families in which homozygosity mapping 
was performed as part of this study; this work was part of a collaborative 
project with Drs Alice E Davidson and Zheng Li. 
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Table 3-12. Summary of families analyzed using SNP arrays on the assumption that affected 
individuals will be autozygous for a chromosomal region surrounding the mutated gene 
(homozygosity mapping) 
family 
id 
members of family 
genotyped 
level of 
parental 
consanguin
ity 
condition 
Affymetrix
SNP array 
used 
(experiment 
conducted  by) 
result 
{presumed disease-associated allelic variants 
in affected individuals or possible disease-
related gene} 
hz1786 two affected siblings first cousins RP SNP 6.0 
(outsourced) 
analysis ongoing; exome 
sequencing performed 
hz3774 
three affected and 
one unaffected 
siblings; unaffected 
parents 
first cousins 
benign fleck 
retina 
50K 
(Zheng Li) 
exome sequencing performed; 
{PLA2G5: 
p.[Gly45Cys];[Gly45Cys]} 
hz3796 two affected siblings first cousins RP 50K 
(Zheng Li) 
analysis ongoing; largest region 
around RP28 locus {FAM161A?} 
hz4078 one affected first cousins 
cone rod 
dystrophy 
SNP 6.0 
(outsourced) 
analysis ongoing; exome 
sequencing performed 
hz4466 two affected siblings first cousins 
Usher syndrome 
type 1 
50K 
(Zheng Li) 
{USH1C: c.[446_448delAGG]; 
[446_448delAGG]} 
hz4665 one affected 
multiple 
consanguine
ous unions 
RP SNP 6.0 
(outsourced) 
analysis ongoing; CERKL 
screening negative 
hz14463 two affected siblings third cousins 
syndromic 
retinal disease 
50K 
(PS) 
analysis ongoing; small regions on 
20p and 16q  
hz15567 
two affected and two 
unaffected siblings; 
unaffected parents 
first cousins 
syndromic 
retinal disease 
50K 
(Zheng Li); 
SNP 6.0 
(outsourced) 
analysis ongoing 
hz15617 one affected 
second 
cousins 
RP SNP 6.0 
(outsourced) 
analysis ongoing; large region on 
6q {EYS?} 
hz15793 one affected first cousins CSNB 50K 
(PS) 
analysis ongoing; GRM6, TRPM1, 
NYX excluded 
hz15894 two affected siblings first cousins 
cone rod 
dystrophy 
50K 
(Zheng Li) 
analysis ongoing; largest region 
around RP58 locus {ZNF513?} 
hz16071 
three affected 
siblings 
first cousins retinal dystrophy 50K 
(Zheng Li) 
{MFRP: p.[His384Profs8X]; 
[His384Profs8X]} 
hz16128 two affected siblings first cousins 
rod 
monochromasy 
SNP 6.0 
(outsourced) 
{CNGA3: 
p.[Arg439Trp];[Arg439Trp]} 
hz16138 two affected siblings first cousins 
cone rod 
dystrophy 
50K 
(PS) 
analysis ongoing; large regions on 
2p, 11q, 1p; CNGA3 screening 
negative 
hz16219 one affected first cousins 
cone rod 
dystrophy 
SNP 6.0 
(outsourced) 
analysis ongoing 
hz16329 
two affected and 
one unaffected 
siblings; unaffected 
parents 
first cousins RP 50K 
(Zheng Li) 
analysis ongoing; EYS screening 
negative 
hz16359 one affected 
second 
cousins 
benign fleck 
retina 
SNP 6.0 
(outsourced) 
{PLA2G5: p.[Trp62X];[Trp62X]} 
hz16597 two affected siblings first cousins RP 50K 
(Zheng Li) 
analysis ongoing; largest region in 
chromosome 3 {IMPG2?} 
hz16857 one affected first cousins RP SNP 6.0 
(outsourced) 
analysis ongoing 
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hz17761 one affected 
uncle-niece 
union 
RP SNP 6.0 
(outsourced) 
large regions on 16q, 6p, 4q; 
CYP4V2 screening negative 
hz17775 two affected siblings first cousins LCA SNP 6.0 
(outsourced) 
exome sequencing performed; 
{KCNJ13: 
p.[Arg166X];[Arg166X]} 
hz17811 one affected 
distantly 
related 
rod 
monochromasy 
SNP 6.0 
(outsourced) 
{CNGA3: 
p.[Asp260Asn];[Asp260Asn]} 
hz17857 
affected proband 
and two of her 
mother’s sisters 
(both also affected) 
multiple 
consanguine
ous unions 
rod 
monochromasy 
50K 
(PS) 
analysis ongoing; {proband:  
CNGA3: 
p.[Arg427Cys];[Arg427Cys] and 
CNGB3: p.[Arg403Gln];[?]; 
proband’s unaffected sister: 
CNGA3: 
p.[Arg427Cys];[Arg427Cys]; 
proband’s affected maternal aunts: 
CNGB3: 
p.[Arg403Gln];[Arg403Gln]} 
hz17880 one affected first cousins RP SNP 6.0 
(outsourced) 
analysis ongoing; NPHP3, RGR, 
CDHR1 and CRB1 screening 
negative 
hz17901 one affected first cousins RP SNP 6.0 
(outsourced) 
analysis ongoing; NPHP3, RBP3, 
RD3, CRB1, LRAT and GUCY2D 
screening negative;  
{USH2A or C2ORF71?}  
hz17962 one affected 
distantly 
related 
FEVR SNP 6.0 
(outsourced) 
exome sequencing performed; 
{LRP5: 
p.[Gly479Arg];[Asp1366Gly]} 
hz17987 one affected 
aunt-
nephew 
union 
RP SNP 6.0 
(outsourced) 
{CERKL: p.[Arg364X];[Arg364X]} 
hz18014 
one affected and her 
unaffected husband 
first cousins CSNB 50K 
(Zheng Li) 
{TRPM1: 
c.[2021+2T>C];[2021+2T>C]} 
hz18043 one affected 
distantly 
related 
cone rod 
dystrophy 
50K 
(PS) 
analysis ongoing; FAM19A3 
excluded 
hz18061 one affected 
second 
cousins 
late-onset 
macular 
dystrophy 
SNP 6.0 
(outsourced) 
{ABCC6: 
p.[Arg1141X];[Arg1141X]} 
hz18120 one affected 
distantly 
related 
RP SNP 6.0 
(outsourced) 
analysis ongoing 
hz18173 one affected first cousins 
rod 
monochromasy 
SNP 6.0 
(outsourced) 
{CNGA3: c.[1773_1776delCCCC] 
;[1773_1776delCCCC]} 
hz18180 
four affected siblings 
and their affected 
mother 
first cousins RP 
50K 
(PS) 
SNP 6.0 
(outsourced) 
analysis ongoing; only one large 
region on 6q {EYS partially 
screened and found negative} 
hz18193 one affected first cousins 
rod 
monochromasy 
50K 
(PS) 
large region on 8q {CNGB3} 
hz18196 one affected 
distantly 
related 
cone dystrophy SNP 6.0 
(outsourced) 
large region on 1p {GNAT2} 
hz18393 one affected 
second 
cousins 
RP SNP 6.0 
(outsourced) 
{TULP1: 
c.[190+1G>A];[190+1G>A]} 
hz18419 one affected first cousins RP SNP 6.0 
(outsourced) 
analysis ongoing 
hz18502 one affected first cousins 
late-onset 
macular 
dystrophy 
50K 
(PS) 
exome sequencing performed; 
among variants identified was 
CNGB3: 
p.[Arg403Gln];[Arg403Gln] 
hz18504 one affected first cousins cone dystrophy 50K 
(PS) 
analysis ongoing; largest region on 
12q; ABCA4, ADAM9, GNAT2, 
CNGB3, CNGA3 and CLUL1 
excluded; {CEP290?} 
hz18529 one affected first cousins cone dystrophy 50K 
(PS) 
{PDE6C: 
p.[Arg102Trp];[Arg102Trp]} 
hz18573 one affected first cousins 
Stargardt 
disease 
SNP 6.0 
(outsourced) 
largest region on 1p {ABCA4} 
hz18588 one affected third cousins retinal dystrophy SNP 6.0 
(outsourced) 
multiple regions; among others 
11q {MFRP} 
hz18598 one affected first cousins 
rod 
monochromasy 
SNP 6.0 
(outsourced) 
analysis ongoing; exome 
sequencing performed 
hz18603 two affected siblings first cousins ocular albinism 
50K 
(PS); 
SNP 6.0 
(outsourced) 
multiple regions; OA1 screening 
negative but allele shared between 
the two affected (both male) 
hz18610 one affected first cousins RP SNP 6.0 
(outsourced) 
exome sequencing performed; 
{RP1L1: c.[601delG];[601delG]} 
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hz18614 
two affected siblings 
and their affected 
father 
first cousins RP SNP 6.0 
(outsourced) 
analysis ongoing 
hz18655 
two affected siblings 
and their affected 
first cousin 
first cousins  RP SNP 6.0 
(outsourced) 
analysis ongoing; exome 
sequencing performed; 
{proband has RP1: 
p.[Glu487_Glu488delinsGluX]; 
[Glu487_Glu488delinsGluX]; 
proband’s brother has RP1: 
p.[Glu487_Glu488delinsGluX];[?]; 
proband’s cousin has RP1: 
p.[Glu487_Glu488delinsGluX]; 
[Glu487_Glu488delinsGluX] 
hz18682 one affected first cousins 
fleck retina 
syndrome 
SNP 6.0 
(outsourced) 
RLBP1 in large region, RDH5 
excluded and screening negative; 
{RLBP1: p.[Val11Ala];[Val11Ala]}  
hz18730 one affected first cousins 
rod 
monochromasy 
SNP 6.0 
(outsourced) 
{PDE6C: p.[Gly835X];[Gly835X]} 
hz18875 one affected first cousins RP SNP 6.0 
(outsourced) 
analysis ongoing; TULP1 
screening negative 
hz18994 one affected first cousins 
occult 
maculopathy 
SNP 6.0 
(outsourced) 
analysis ongoing; largest region on 
6q 
hz19023 one affected 
uncle-niece 
union 
cone dystrophy SNP 6.0 
(outsourced) 
analysis ongoing; {GNAT2?} 
hz19197 one affected first cousins RP SNP 6.0 
(outsourced) 
analysis ongoing; {CRB1?} 
hz19277 one affected first cousins 
RP and primary 
ciliary dyskinesia 
SNP 6.0 
(outsourced) 
analysis ongoing; RPGR exon 6 
excluded; {USH2A?} 
hzbrntn 
three affected 
siblings 
first cousins 
syndromic 
retinal disease 
and cataract 
50K 
(Zheng Li); 
SNP 6.0 
(outsourced) 
analysis ongoing; exome 
sequencing performed; among 
variants identified was TRNT1: 
p.[Arg99Trp];[Arg99Trp] 
 
3.2.2 Exome Sequencing 
 
Exome sequencing was performed in DNA samples from 12 unrelated affected 
individuals previously studied using SNP genotyping arrays (section 2.1.4). 
The Agilent SureSelect 38 Mb exome capture and the Illumina HiSeq2000 
sequencer were used (section 2.4.17). Families were selected on the basis of: 
(a) Regions of linkage (homozygosity or shared among affected individuals) 
not containing genes previously associated with a phenotype similar to the 
proband. In some occasions retinal disease-related genes or obvious 
candidates were excluded using Sanger sequencing. 
(b) A panel of individuals with a similar phenotype being available for 
screening putative novel genes. 
(c) Availability of high molecular weight DNA of sufficient quantity. 
 
This work was part of a collaborative project with Drs Vincent Plagnol and 
Alice E Davidson and some of the results are summarised in table 3-13. 
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Table 3-13. Summary of families analysed using a combination of SNP arrays and whole exome 
sequencing  
family id 
affected family 
members with 
available DNA 
samples 
level of 
parental 
consanguinity 
condition 
number of 
variants 
identified in 
affected 
proband 
result 
hz1786 two siblings first cousins RP 17,949 analysis ongoing 
hz3774 three siblings first cousins 
benign fleck 
retina 
15,611 
 
PLA2G5: p.[Gly45Cys]; 
[Gly45Cys] 
hz4078 one first cousins 
cone rod 
dystrophy 
17,835 analysis ongoing 
hz17775 two siblings first cousins LCA 16,649 
KCNJ13: p.[Arg166X]; 
[Arg166X] 
hz19762 one distantly related FEVR 17,860 
LRP5: p.[Gly479Arg]; 
[Asp1366Gly] 
hz18502 one first cousins 
late-onset 
macular 
dystrophy 
17,853 
analysis ongoing; one 
possibility is CNGB3: 
p.[Arg403Gln]; 
[Arg403Gln] 
hz18598 one first cousins 
rod 
monochromasy 
18,075 analysis ongoing 
hz18610 one first cousins RP 17,397 
RP1L1: c.[601delG]; 
[601delG] 
hz18655 
two siblings, 
their affected 
first cousin 
first cousins RP 17,061 
analysis ongoing 
(see also table 3-13) 
hzbrntn three siblings first cousins 
syndromic 
retinal disease 
and cataract 
18,142 
analysis ongoing; one 
possibility is TRNT1: 
p.[Arg99Trp]; [Arg99Trp] 
nhz4040 two siblings 
not 
consanguineous 
rod 
monochromacy 
18,374 analysis ongoing 
nhz13874 three siblings 
not 
consanguineous 
rod 
monochromacy 
15,986 analysis ongoing 
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3.2.3 Recessive Mutations in TRPM1 Cause Complete CSNB 
 
As discussed in section 3.1.6, on the basis of electrophysiology, two common 
subgroups of CSNB have been described [473]: complete CSNB and 
incomplete CSNB. Prior to this study, recessive mutations in NYX 
(chromosome X [474]) and GRM6 (chromosome 5 [157]), have been 
associated with complete CSNB (for incomplete CSNB-associated genes refer 
to table 1-3, section 1.3). The TRPM1 gene is located on chromosome 15 and 
encodes a transient receptor potential cation channel. In 2008, reduced 
TRPM1 expression was described in the retinae of horses with a complete 
CSNB electrophysiological phenotype [524]. This finding together with 
evidence from other studies [525-526], suggested a possible role for TRPM1 
in the glutamate-mediated ON bipolar cell response. 
 
A consanguineous family of South Asian origin is the basis of this section 
(family 1 in figure 3-18). The proband (V:1, family 1 in figure 3-18), a 2-year-
old girl, was diagnosed with CSNB at eleven months of age. She was noticed 
to have nystagmus and convergent squint at the age of five months. There are 
multiple consanguineous marriages within the family and her mother and a 
maternal uncle also have nonprogressive night blindness. Cycloplegic 
refraction of the proband at 13 months was -14.00/-1.00x170 in the right and -
13.00/-1.00x20 in the left eye. Fundoscopy revealed myopic fundi but was 
otherwise unremarkable. The proband’s father and paternal grandmother had 
a normal ocular examination. Her mother, aged 28, presented with 
nonprogressive nyctalopia from an early age as well as convergent squint. 
She is a high myope (-23 dioptres spherical equivalent in each eye) and best 
corrected visual acuities were 0.26 logMAR for the right and 0.32 logMAR for 
the left eye. Fundus examination revealed myopic fundi (figure 3-19A). 
Electrophysiological findings were typical of complete CSNB, suggesting ON 
pathway dysfunction. It was not possible to examine the proband’s sister (V-2, 
family 1 in figure 3-18) who developed nystagmus within the first year of life. 
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Figure 3-18. Pedigrees from evaluated families. 
Electropherograms of DNA sequence surrounding likely disease-causing variants are shown 
beneath each pedigree. 
 
DNA samples from the proband’s unaffected father and affected mother (IV:2 
and IV:3, family 1 in figure 3-18) were genotyped using the Affymetrix 
GeneChip Human Mapping 50K Array Xba (section 2.4.18.2.1; experiment 
conducted by Dr Zheng Li). The pedigree was consistent with the propagation 
of a single mutant allele from a recent ancestor such that the unaffected father 
was heterozygous and the affected mother autozygous for this allele. The 
largest region obeying this rule consisted of 15.9 Mb and was located on 15q 
(figure 3-20, section 2.5.4.1). One obvious candidate within this locus was the 
predominantly expressed in eye and skin gene TRPM1. Primers were 
designed for amplification of the 27 previously reported exons (NM_002420.4; 
experiment designed and conducted by Dr Zheng Li). A homozygous variant 
was identified in the affected mother (c.2021+2T>C); the father was 
heterozygous for this sequence alteration. This change would be predicted to 
abrogate the canonical donor sequence and affect efficient pre-mRNA splicing 
of intron 16 of the gene; RNA was not available to test this assertion. 
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Additional patients with a phenotype consistent with complete CSNB were 
screened for mutations in GRM6 (section 3.1.6) and, if male, NYX. The cohort 
was purposefully biased towards female patients in order to be enriched for 
autosomal genes. Nine families that had negative GRM6 screening and a 
pedigree not consistent with X-linked segregation were screened for TRPM1 
(screening by Dr Zheng Li and PS). Likely disease-causing alleles were 
detected in two families (figure 3-18, table 3-14) of white European descent. 
Variants identified are summarised in table 3-14.  
 
A 36-year-old female (II:2, family 2 in figure 3-18) with clinical and 
electrophysiological diagnosis of complete CSNB, was found to harbour two 
disease-associated variants in TRPM1: c.416delG, p.Gly139ValfsX10 and 
c.3105T>A, p.Tyr1035X. Analysis of a maternal DNA sample revealed that 
these variants were biallelic. Importantly, both cause a premature termination 
codon. The patient had onset of nystagmus in the first year of life and was 
diagnosed with CSNB at age 16. Visual acuities were 1.00 logMAR in the right 
and 0.84 logMAR in the left eye. She was myopic (-15.50/-1.50x50 and 
−14.50/−1.00×90 in the right and left eye respectively) and had normal colour 
vision and full visual fields on kinetic perimetry (figure 3-19B). On examination, 
right convergent squint and pendular nystagmus were noted; myopic changes 
were evident on fundoscopy. Fundus autofluorescence imaging was normal 
(figure 3-19B) and electrophysiology was typical of complete CSNB. In order 
to determine whether heterozygosity for TRPM1 mutation had a subclinical 
effect, the patient’s unaffected mother (I:2, family 2 in figure 3-18) underwent 
electrophysiological testing; no abnormality was detected.  
 
Two rare missense variants (c.220C>T, p.Arg74Cys and c.3004A>T, 
p.Ile1002Phe) were identified in a 24-year-old female affected with stationary 
night blindness (II:1, family 3 in figure 3-18). The patient reported nystagmus 
and a left divergent squint from birth. Difficulties seeing at night and poorer 
vision in her left eye from an early age were also noted. On examination at 
age 20, visual acuity was 0.28 logMAR in the right and 1.00 logMAR in the left 
eye. She was myopic (-4.25 dioptres in each eye), had a left divergent squint 
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and nystagmus. Fundoscopy revealed bilateral tilted optic discs but was 
otherwise unremarkable. Electrophysiology was typical of complete CSNB. 
 
 
 
Figure 3-19. Clinical characteristics of TRPM1 positive individuals. 
[A] Colour fundus photographs of patient IV:3 in family 1. 
[B] Colour fundus photographs, fundus autofluorescence and Goldmann kinetic perimetry of 
patient II:2 in family 2. Goldmann perimetry isopters for targets III4a, II4a and I4a are shown. 
See figure 3-18 for numbering of study subjects 
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Table 3-14. Summary of TRPM1 coding and splice site variants in patients and controls 
Variant* Affected individuals (9 patients) 
Frequency in controls and 
EVS 
Nucleotide Protein 
homozygous or 
heterozygous 
family id (see 
figure 3-18) 
European 
control 
chromosomes 
EVS 
[rs id] 
c.2021+2T>C not known homozygous family 1 0/382 not applicable 
c.412delG p.Gly139fs heterozygous family 2 0/382 0/3462 
c.3105T>A p.Tyr1035X heterozygous family 2 0/382 0/3460 
c.220C>T p.Arg74Cys heterozygous family 3 0/382 0/3462 
c.3004A>T p.Ile1002Phe heterozygous family 3 0/382 0/3460 
 
c.167A>G p.Tyr56Cys heterozygous 
each change 
detected in a 
simplex 
complete CSNB 
case harbouring 
no second rare 
variant 
0/382 0/3462 
c.2162G>A p.Arg721Gln heterozygous 0/382 0/3462 
c.2648A>G p.Glu883Gly heterozygous 0/382 0/3462 
c.2872A>C p.Met978Thr heterozygous 
found in cis in a 
single simplex 
female patient; 
no third rare 
variant detected 
0/382 0/3460 
c.4312A>G p.Arg1438Gly heterozygous 0/382 0/3460 
 
c.2 T>C p.Met1Thr 
 
76/382 
583/3452 
[rs4779816] 
c.95 G>A p.Ser32Asn 74/382 
757/3462 
[rs2241493] 
c.1239G>A p.(=) 148/382 
1450/3460 
[rs1035705] 
c.1813G>A p.Val605Met 15/382 
112/3460 
[rs17815774] 
c.2307T>C p.(=) 111/382 
934/3454 
[rs12913672] 
c.2340T>C p.(=) 68/382 
817/3456 
[rs2288242] 
c.4182G>A p.Val1395Ile 22/382 
140/3454 
[rs3784588] 
*variant numbering is based on NM_002420.4 
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The initially reported sequence (NM_002420.4 [527]) suggested a translation 
initiation codon within exon 2. Intriguingly, this methionine has been reported 
to contain a SNP (rs4779816; 2T>C, p.Met1Thr). This variant was tested in 
191 control DNAs (ECACC, HRC-1 and 2; section 2.1.2) and a MAF of 0.198 
was observed. This suggests that another position in the transcript is used for 
initiation of protein translation. To investigate the full-length transcripts in 
human retina and skin RNA, 5' and 3' RACE experiments were performed 
(designed and optimised by Dr Zheng Li, conducted by Dr Zheng Li and PS 
under Dr Li’s supervision; figure 3-21, section 2.4.12). Firstly, a 5' extension of 
the initially reported TRPM1 exon 1 was detected (figure 3-20). This sequence 
 
 
Figure 3-20. Homozygosity mapping and analysis of structure of the TRPM1 gene. 
[A] Largest region of homozygosity for family 1. This region is located on 15q, consists of 15.9 
Mb, includes 280 contiguous SNPs and is flanked by rs2090622 and rs10518928. A total of 
106 distinct Unigene clusters were found in this chromosomal interval. Only the partial region 
is shown. 
[B] Results of RACE experiments for TRPM1 transcripts in human retina and skin. One 
transcript with a 201 base pair 5′ extension of the previously reported exon 1 was found in 
both skin and retinal tissue. An alternative 5′ exon of 275 base pairs, denoted here as exon 
1a, was detected in retina approximately 84,000 base pairs upstream of the previously 
reported exon 2. Interestingly, splicing was directly to exon 2, omitting exon 1. Approximate 
physical distances are shown. 
[C] The initiation codon of TRPM1 in the previously reported sequence (NM_002420.4) is 
shown (rs4779816). Other likely translation intitiation sites in the different transcripts are also 
presented. 
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did not extend the reading frame of the gene and contained three termination 
codons. Therefore, this 5' extension is unlikely to generate an alternative 
initiation codon in frame with the downstream sequence. Secondly, an 
unknown sequence was found at the 5' transcript end in a proportion of retinal 
clones. Sequence analysis revealed a 275 base pair long fragment that was 
contiguous with the sequence of exon 2 and contained an extension of the 
open reading frame (figure 3-20). This exonic sequence was found to be 
located approximately 84,000 base pairs upstream of exon 2. Exon 1 was 
absent from these clones. Alignment of TRPM1 orthologs from diverse 
vertebrate genomes demonstrated that this novel 5' exon (henceforth referred 
to as exon 1a) was highly conserved [475]. 
 
In order to confirm the presence of this alternatively spliced transcript, RT PCR 
experiments were undertaken (conducted by Dr Zheng Li and PS, summarised 
in figure 3-21; section 2.4.2). PCR products containing exon 1a were detected 
in the retina but not in the skin. It is therefore likely that, at least in the retina, 
the protein is longer at the amino end than as yet appreciated. 
 
The 3' RACE experiment revealed 3' region sequences identical to the 
previously reported sequence in both retina and skin (NM_002420.4 [527]). 
The novel alternative transcripts identified were screened for mutations in all 
probands; a common coding SNP was found c.16C>T, p.Arg6Trp 
(ss161641214) but no further variants were detected.  
 
The finding of likely disease-causing mutations in TRPM1 in individuals with 
electroretinographic evidence of ON bipolar cell dysfunction (qualitatively 
identical to that seen in GRM6 retinopathy [157]) confirms the important role of 
this cation channel in human ON bipolar cell physiology. Transient receptor 
potential channels are a group of ion channels located mostly on the plasma 
membrane of numerous cell types. To date, 28 mammalian transient receptor 
potential channels have been identified; these demonstrate diverse functions 
and can be divided into six groups: TRPC, TRPV, TRPM, TRPP, TRPML and 
TRPA [528-531]. TRPM1 is the founding member of the TRPM subfamily. It 
was identified as an RNA sequence in a mouse melanoma cell line and was 
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subsequently noticed to be expressed in melanomas with lower metastatic 
potential; thus the protein was termed melastatin [532]. Notably, melanoma-
associated retinopathy, a retinal phenocopy for TRPM1 retinopathy, has been 
recently associated with autoantibodies against TRPM1 [533-534]. 
 
 
 
 
Figure 3-21.  Experiments examining TRPM1 RNA and 5' RACE. 
[A] The integrity of RNA samples from human retina and skin were assessed (section 2.4.1). 
The traces show similar peaks and ratios for 28S and 18S RNA molecules (vertical axis, 
fluorescence intensity; horizontal axis, migration time), suggesting low degradation and 
comparable quality from both tissues. The right panel shows the data as a computer 
generated gel image. 
[B] Agarose gel image of DNA fragments generated from 5' RACE experiments using the 
above assessed RNA (section 2.4.12). With the use of a primer complimentary to a 5' 
adapter oligonucleotide and a TRPM1-specific primer complimentary to exon 3, two main 
bands were produced. The lower band (~200 base pairs) was consistent with the previously 
reported sequence (NM_002420.4). A higher band (~475 base pairs) corresponding to a 
mixture of the previously unreported (a) 5' exon 1a and (b) 5' extension of exon 1 was also 
detected (see text for details). The higher band was predominant in the retina and the lower 
in skin. 
[C] RT PCR experiments were performed on skin and retina RNA (section 2.4.2). A number 
of primers pairs (schematic) were used to determine the presence of various transcripts in 
the two tissues. Exon 1a consistently failed to amplify from skin cDNA.  
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Intriguingly, in the cohort available for this study, there remained a handful of 
families with a complete CSNB phenotype without mutations in NYX, GRM6 or 
TRPM1, suggesting that there may be additional disease-associated genes. 
The future identification of such genes will provide further insights into the ON 
bipolar cell signalling pathway components that link the activation of 
metabotropic glutamate channels with the permeability state of TRPM1 
membrane channels. 
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3.2.4 Recessive Mutations in KCNJ13 Cause LCA 
 
RP is a heterogeneous group of genetic disorders that feature progressive loss 
of photoreceptor cells as a primary or secondary event [159]. Consequent 
visual impairment usually manifests initially as night blindness and visual field 
constriction. However, great variability in age of onset, progression, fundus 
appearance and final visual outcome is observed. LCA represents the most 
severe end of the phenotypic spectrum, causing severe visual impairment from 
the first year of life [159, 535]. Genetic heterogeneity of RP and LCA is striking 
(see table 1-3, section 1.3); inheritance is predominantly monogenic 
(autosomal and X-linked), but polygenic and mitochondrial inheritance patterns 
as well as cases with de novo mutations have also been reported (RetNet and 
OMIM). The most prevalent and genetically heterogeneous RP subtype is the 
autosomal recessive form, with more than 30 genes implicated, accounting for 
less than 60% of autosomal recessive RP cases [160]. LCA is typically 
inherited in an autosomal recessive manner and has been linked to over 15 
genes, together explaining approximately 70% of families [160]. Half of the 
LCA genes exhibit clinical heterogeneity with recessive mutations giving rise to 
both LCA and early-onset RP (see table 1-3, section 1.3). Identifying 
previously unrecognised causative genes for these conditions is a major 
challenge, particularly as remaining genes are likely to be less prevalent and 
less obvious candidates than those already known. 
 
A consanguineous family, of Middle-Eastern origin was recruited. Two affected 
family members aged 34 (A-2) and 32 (A-3) (V:3 and V:4, family A in figure 3-
22) were initially assessed. Both affected siblings were noticed to have 
nystagmus and were diagnosed with retinal dystrophy shortly after birth. Poor 
night vision and difficulty reading print from an early age was reported for both 
patients A-2 and A-3; gradual progression of visual problems affecting central 
and peripheral vision was also noted. Both had bilateral cataract surgery in 
their 20s. No other family history of retinal disease was reported. Visual 
acuities were: 2.0 logMAR in each eye of subject A-2; 1.78 logMAR for the 
right and 1.48 for the left eye of subject A-3. Fundoscopy revealed significant 
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pigment at the level of the RPE and in a configuration unlike that of typical RP 
(figure 3-23A). 
 
Figure 3-22. Identification of KCNJ13 mutations in individuals from two families with LCA. 
[A] Pedigree of family A, exome sequencing data from subject A-3 and Sanger sequencing results in 
affected brother A-2 and unaffected sister A-1. Pedigree reveals a recent common ancestor. Exome 
sequencing was performed in DNA from subject A-3. An R script assessing and plotting homozygous 
or heterozygous state of detected SNPs was composed. In chromosome 2, long regions of 
homozygosity were detected; SNPs within them are represented as red lines. Within the largest 
region of homozygosity, a nonsense mutation was identified in KCNJ13 (c.496C>T, p.Arg166X). 
Gene structure of KCNJ13 is presented (reverse strand) comprising of 3 exons. Coverage depth 
distribution of the mapped reads along the three exons is shown. Sequencing reads showing the 
homozygous nonsense mutation are presented (80 reads total: 11 forward and 69 reverse,100% 
adenine). Electropherograms of DNA sequence surrounding the p.Arg166X mutation are shown for 
affected brother A-2 and unaffected sister A-1. 
[B] Pedigree of family B, electropherograms of DNA sequence surrounding the c.722T>C, 
p.Leu241Pro mutation in subjects B-3 and B-2, multiple alignment of ten KCNJ13 orthologs around 
the mutated amino acid, and schematic representation of Kir7.1.[536]. The schematic representation 
of Kir7.1 highlights the structural domains and the location of mutated residue identified.  
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Figure 3-23.  
[A] Colour photographs of right fundi of subject A-2 (aged 34) and subject A-3 (aged 32) in 
family A as well as left fundus of subject B-3 in family B (aged 33); normal left fundus of 39-
year-old unaffected c.496C>T, p.Arg166X carrier (A-1, family A) is also shown.  
[B] Infrared image and linear SD OCT of right (1, 2) and left (3, 4) retina of subject B-3 in 
family B. Right retina of his 64-year-old unaffected mother (B-1) is also shown for comparison 
(5). On some occasions, image quality was compromised by unstable fixation caused by 
nystagmus or posterior capsule opacification. 
 
Initially, DNA from subject A-2 was analyzed using an APEX microarray chip 
containing previously reported disease-causing variants in six LCA genes 
(LCA Chip, Asper Biotech; section 2.4.18.1); no disease-associated alleles 
were detected. As the phenotype exhibited some features previously 
associated with mutations in RDH12 (heavy pigmentation and macular 
atrophy) and CRB1 (nummular pigmented lesions), the coding region and 
intron-exon boundaries of these genes were sequenced and found to be 
normal. Subsequently, homozygosity mapping was performed. Genotypes of 
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both subjects A-2 and A-3 were generated using Affymetrix Genome-Wide 
Human SNP 6.0 Arrays (section 2.4.18.2.2). The birdsuite set of algorithms 
was used to detect and report SNP genotypes (birdseed v2, threshold 0.0025), 
common copy number polymorphisms and novel or rare copy number variants 
in the processed samples (section 2.5.4) [320]. A python script interacting with 
a MySQL database was used to detect shared regions of homozygosity and 
rank them by genetic distance (section 2.5.4.3). Four chromosomal segments 
over 10 cM were identified, the largest being a 45 cM region located on 2q 
(table 3-15). 
 
As mutations were not detected in candidate genes observed within shared 
regions of homozygosity (SAG, PDE6D, WDR17) and no pathogenic copy 
number variants were identified, exome sequencing was undertaken. Solution-
phase hybrid capture with biotinylated RNA baits was used to target 38 Mb of 
genomic sequence from subject A-3 (Agilent SureSelect Human All Exon Kit; 
section 2.4.17). The enriched library was amplified and then sequenced on a 
single lane of an Illumina HiSeq2000, generating 12.2 Gb of mappable 
sequence as 100 base pair paired-end reads. Novoalign version 2.05 was 
used to align these reads to the hg19 reference sequence (section 2.5.2.2). 
The average sequencing depth on the 38 Mb target region was 61 with 85% of 
the bases covered with a depth of at least 10x. A total of 16,649 exonic calls 
with respect to the reference sequence were detected (table 3-16). The exome 
data were used to identify regions of homozygosity and the results were 
consistent with the findings from SNP genotyping. Owing to the prior belief that 
the causal variant is rare, calls that were found in the 1000 genomes pilot 
dataset were filtered. The remaining variants were filtered further on the basis 
of the linkage data and the regions of homozygosity shared by both affected 
individuals (table 3-16). A single loss-of-function homozygous rare variant was 
identified, p.Arg166X in KCNJ13. 
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Table 3-15. Regions of homozygosity that are shared by both affected siblings A-2 and A-3 
Chromosome From To 
Genetic Distance 
(Marshfield linkage map) 
Genes screened by 
direct sequencing 
chr2 207,725,616 [rs10192834] 236,528,938 [rs10199178] 45 cM SAG, PDE6D 
chr2 5,518,359 [rs6727034] 19,331,655 [rs13420305] 27.5 cM   
chr3 194,826,729 [rs6785310] 197,793,905 [rs12639242] 9 cM   
chr4 172,881,246 [rs332971] 178,027,773 [rs2580061] 5.5 cM WDR17 
chr9 140,693,181 [rs4876947] 140,991,359 [rs3812541] 4 cM   
chr5 170,215,394 [rs3792811] 172,822,805 [rs6556073] 3.5 cM   
Genotypes of both subjects A-2 and A-3 were generated (section 2.4.18.2.2). A python script interacting with a MySQL database was written to 
detect shared regions of homozygosity and rank them by genetic distance (section 2.5.4.3). Regions of homozygosity were considered significant if 
>3 cM. 
Table 3-16. Number of variants (departures from hg19) identified in exome sequencing data of subject A-3 and filtering on the basis of genotyping data 
  Total 
Nonsynonymous 
heterozygous 
variants not in 
1000 genomes  
Nonsynonymous 
homozygous 
variants not in 
1000 genomes  
Nonsense/splice 
site/frameshifting 
insertion-deletion 
heterozygous 
variants not in 1000 
genomes 
Nonsense/splice 
site/frameshifting 
insertion-deletion 
homozygous variants 
not in 1000 genomes 
Full exome 16649 329 42 80 37 
Within segments where both parental 
haplotypes are shared with affected sibling 
2914 69 12 26 10 
Within regions of homozygosity 577 2 6 0 4 
Within regions of homozygosity shared with 
affected sibling 
161 2 2* 0 1 
A threshold of 5 cM was used for segments where both parental haplotypes are shared in the two affected siblings. Regions of homozygosity were 
considered significant if larger than 3 cM. The 20100804 sequence and alignment release of the 1000 genomes project was used (628 individuals).                                                                                       
*These two variants [p.Glu180Val in ARMC9 (rs1626451) and p.Arg302His in GEN1] cannot be fully excluded but, on the basis of biology, the loss-of-
function KCNJ13 change is much more likely disease causing. 
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KCNJ13 is a three exon gene encoding Kir7.1, a 360-amino-acid low-
conductance inward rectifying potassium channel (Kir) that functions as a 
homotetramer [537-539]. Like other Kir subunits, Kir7.1 contains two 
transmembrane regions (M1 and M2), one pore-forming loop (H5) and 
cytosolic NH2- and COOH-termini [540]. The protein is localised at the plasma 
membrane of a variety of ion-transporting epithelia; high gene expression has 
been found in intestines, thyroid, choroidal plexus, prostate, kidney and retina 
(Unigene, [538-539, 541]). Within the retina, Kir7.1 is primarily localised to the 
apical membranes of RPE [541-543]. The mutant allele, if the transcript is not 
subjected to nonsense-mediated decay, would produce a peptide lacking 
almost the entire COOH-terminal intracellular segment of 204 amino acids. 
Such a protein product is unlikely to form functional homotetramers, as this 
portion is known to be critical for Kir channel subunit assembly [540]. 
Additionally, the COOH-terminus is required for correct targeting of Kir7.1 to 
the apical membrane of epithelial cells [544] and its absence in this mutant 
would likely lead to mislocalization. 
 
Previously, a missense mutation in KCNJ13 (p.Arg162Trp) has been 
associated with a distinct ocular condition, autosomal dominant snowflake 
vitreoretinal degeneration in a large pedigree comprised of 14 affected family 
members [543]. The disorder’s name is derived from the presence of small 
inner retinal crystalline-like deposits that are often observed in the fundi of 
affected individuals [545]. Other ocular features include corneal guttae, early-
onset cataract, fibrillar vitreous degeneration, optic nerve head dysmorphism, 
normal macular appearance and granular changes near the equatorial fundus 
[546]. Increased predisposition to retinal detachment has also been reported 
[547]. Visual acuity is normal and retinal function testing reveals only mild 
abnormalities [547]. Although the term snowflake vitreoretinal degeneration 
has been used in another eight families, currently, these do not appear to be 
the same condition by clinical or genetic evaluation [545-546, 548-552].  
 
To assess whether mutations in KCNJ13 are a common cause of autosomal 
recessive retinal dystrophy, bidirectional Sanger sequencing of the entire 
coding region and intron-exon boundaries of the gene in 333 additional 
RESULTS – Recessive mutations in KCNJ13 cause LCA 
 
177 
 
unrelated patients was performed. Among those affected individuals, 132 were 
affected with recessive LCA or childhood-onset retinal dystrophy; this panel 
was enriched for mutations in novel genes, as the patients’ DNA had been 
screened and excluded for previously reported LCA-causing variants through a 
microarray chip (LCA Chip, Asper Biotech; sections 2.1.5 and 2.4.18.1). The 
remaining 201 individuals were diagnosed with autosomal recessive adult-
onset rod cone or cone rod dystrophy and had unknown molecular diagnosis 
(section 2.1.5). A homozygous missense variant (p.Leu241Pro) was identified 
in an individual of white European descent with a remarkably similar 
phenotype to that observed in family A. This sequence change has not been 
previously reported (EVS, dbSNP135 and 1000 genomes) and was absent 
from 382 ethnically matched control chromosomes. The mutated amino acid is 
highly conserved across a broad range of species [536]; among other human 
Kir family members, it is either conserved or replaced by another nonpolar 
hydrophobic residue (Ile, Met or Val; figure 3-24). 
 
In order to further evaluate the physiological significance of the p.Leu241Pro 
change, homology modelling was performed. Leu241 is located in the cytosolic 
COOH-terminus of Kir7.1 and is the first of six amino acids to form a β-sheet 
(βI) [553]. The mutant Pro241 residue does not take part in this β-sheet 
formation, alters the orientation of the β-sheet and distorts a proximal similar 
 
 
Figure 3-24.  Amino acid sequence alignment of 15 Kir channel subunits around the mutated 
Kir7.1 residue Leu241. Subunits have been classified into four functional group in 
accordance with Hibino et al. [540]. The alignment was performed with ClustalW2 using 
appropriate Ensembl transcripts [536]. 
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structure, thus inducing a considerable conformational change (figure 3-25). 
 
The proband, a 33-year-old male (B-3; III:2, family B in figure 3-22), was 
noticed to have strabismus, nystagmus and poor vision before the age of one. 
At two years of age, the diagnosis of retinal degeneration was made. Only mild 
 
Figure 3-25. Predicted protein structure of the human Kir7.1 subunit 
[A] Overlay of wild-type (wt; green) and mutant (yellow) Kir7.1 monomer models. Similar to 
other Kir family members, the Kir7.1 monomer is comprised of an α helical membrane domain 
and an intracellular domain primarily composed of β-sheets (asterisk highlights the position of 
the p.Leu241Pro). 
[B] Detail of the region around the 241
st
 amino acid. Distortion of the protein secondary 
structure is evident in the mutant when compared to the wild-type monomer.  
[C] The side chains of the Leu241 (wild-type; blue) and Pro241 (mutant; red) residues are 
highlighted; the cyclic R group structure of proline bends the amino acid chain. 
[D] Detail of C. 
The structural model was generated by using the SWISS-MODEL protein homology modeling 
server; the crystal structure of KirBac1.1 (Protein Data Bank code 1q7b) was used as a 
template. Similar findings were observed when the structure of cKir2.2 (Protein Data Bank 
code 3jycA) was used as a template. PyMOL was used to view the three-dimensional 
molecular structures (table 2-5, section 2.5). 
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progression was reported with night vision having most noticeably 
deteriorated. He is a moderate myope, had strabismus surgery at age 2 and 
an ERG at the age 10 years showed no consistent rod- or cone-driven 
responses. Bilateral cataract surgery was undertaken in his early 20s. There 
was no family history of retinal disease and his parents originate from the 
same isolated geographic area making the existence of a recent common 
ancestor highly likely. Visual acuities were 1.45 logMAR in each eye. There 
was bilateral nystagmus and confrontational visual field testing showed severe 
field loss but relative preservation of the inferior field. Fundus examination 
revealed areas of nummular pigment at the level of the RPE, especially over 
the posterior pole (figure 3-23A). In vivo cross sectional imaging using SD 
OCT revealed loss of outer retinal structures, thinning of the hyperreflective 
band corresponding to RPE/Bruch’s membrane and a coarse lamination 
pattern (figure 3-23B). The distorted retinal microanatomy in an area of the 
fundus in which cell-death was not evident may suggest that the early 
development of the human neurosensory retina is disturbed. 
 
Other sequence alterations identified in the studied patient cohort included 
three previously unreported (EVS, dbSNP135 and 1000 genomes) missense 
variants in the heterozygous state. A p.Gln117Arg change was found in an 
individual of white European ancestry with early-onset retinal dystrophy and 
heavily pigmented fundi. Gln117 is located in an evolutionarily conserved 
region of the protein that corresponds to the pore-forming loop; this glutamine 
is also conserved among the majority of other Kir family members [538]. A 
p.Arg162Gln was identified in heterozygous state in each of two unrelated 
male affected individuals of Turkish ancestry (aged 33 and 42). Interestingly, 
this change occurs in the same amino acid as the dominant mutation causing 
snowflake vitreoretinal degeneration (p.Arg162Trp) [543]. Both patients 
carrying heterozygous p.Arg162Gln have been diagnosed with adult-onset RP, 
are night blind and have field of vision reduced to less than 10°. Notably, one 
of the two (42-year-old) is the product of a first cousin marriage; he is the only 
affected family member and fundoscopy on his parents was unremarkable. 
The identification of a heterozygous KCNJ13 variant in this proband suggests 
that the region is not homozygous by descent and therefore less likely to be 
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the disease locus [105]. Moreover, the phenotype is very different to that seen 
in families A and B, suggesting a different causative gene. A third missense 
variant (p.Glu276Ala), altering a highly conserved amino acid in the cytosolic 
COOH-terminus, was identified in an individual of South Asian origin with 
adult-onset RP.  
 
In order to study the effect of the p.Arg166X and p.Leu241Pro mutations in the 
heterozygous state, additional family members from families A and B were 
ascertained. For family A, the parents were not available for examination but it 
was possible to examine two siblings. Subject A-1 (V:1, family A in figure 3-
22), a 39-year-old female, was found to carry the mutation in heterozygous 
state. She was asymptomatic and fundus examination, 55° fundus 
autofluorescence imaging and SD OCT were normal. Importantly, there were 
no signs of snowflake vitreoretinal degeneration. In family B, Sanger 
sequencing confirmed heterozygosity for the p.Leu241Pro change in maternal 
(B-1; II:4, family B in figure 3-22) and paternal (B-2; II:5, family B in figure 3-
22) DNA. The 64-year-old father is a high myope, had cataract operations in 
his 50s and is treated for glaucoma. He was diagnosed with benign prostatic 
hyperplasia and unilateral acoustic neuroma, but was otherwise well. The 62-
year-old mother reports no symptoms and no history of disease. Fundoscopy, 
55° fundus autofluorescence imaging and SD OCT were normal in both and 
there were no signs of snowflake vitreoretinal degeneration. These results 
suggest that haploinsufficiency in KCNJ13 does not cause ocular disease. In 
vitro patch clamp studies have demonstrated that the snowflake vitreoretinal 
degeneration-associated mutation, p.Arg162Trp, produces a nonselective 
cation current, unlike its wild-type counterpart, when overexpressed in CHO-
K1 cells [543]. However, it remains to be determined how this mutant protein 
behaves in the presence of wild-type Kir7.1. It can be speculated that, 
p.Arg162Trp, is unlikely to exert a dominant negative effect on Kir7.1 channel 
function; this would be inconsistent with the LCA phenotype in families A and 
B, which presumably represents the null Kir7.1 phenotype in humans. The 
electrophysiological effects of p.Arg162Trp and p.Leu241Pro on Kir7.1 
channel with and without the presence of wild-type Kir7.1 merits further 
investigation. It seems likely that the different snowflake vitreoretinal 
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degeneration ocular phenotype is explained by a novel function of the mutant 
p.Arg162Trp allele in the heterozygous state (gain of function). 
 
Retinal disease caused by KCNJ13 mutations adds to a small group of 
disorders caused by reduced or abrogated expression of genes encoding 
inward-rectifying potassium channel subunits. These diseases involve glucose 
homeostasis (familial hyperinsulinaemia hypoglycaemia type II, KCNJ11) 
[554], renal sodium and potassium reabsorption (Bartter syndrome type II, 
KCNJ1) [555], the glial cell membrane resting potential (SeSAME/EAST 
syndrome, KCNJ10) [556] and the excitability of the cardiac and skeletal 
muscle (Andersen-Tawil syndrome, KCNJ2) [557]. 
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Table 3-17. Summary of DNA variants in the KCNJ13 coding region reported here and elsewhere 
Coding DNA Variants  SIFT PolyPhen-2 Frequency (chromosomes) 
Reference 
Nucleotide Protein Prediction 
Tolerance 
Index  
(0 to 1) 
Prediction 
HumVar 
score  
(0 to 1) 
in individuals 
with recessive 
retinal disease  
(n= 666+4) 
in European 
controls 
(n=382) 
c.17G>C p.Cys6Ser tolerated 1.00 Benign 0.001 0/670 0/382 EVS (MAF 0.02%) 
c.27T>A p.(=) not applicable 0/670 0/382 EVS (MAF 0.02%) 
c.53G>A p.Arg18Gln tolerated 0.77 Benign 0.004 0/670 0/382 EVS (MAF 0.02%) 
c.208G>T p.Val70Phe tolerated 0.50 Benign 0.043 0/670 0/382 dbSNP132 [rs79005659] 
c.214G>T p.Ala72Ser intolerant 0.02 POD 0.978 0/670 0/382 dbSNP132 [rs77818131] 
c.344A>G p.Glu115Gly intolerant 0.00 POD 0.991 0/670 0/382 dbSNP132 [rs112079468] 
c.350A>G p.Gln117Arg intolerant 0.00 POD 0.945 1/670 0/382 this study [LCA panel] 
c.438C>T p.(=) not applicable 0/670 0/382 EVS (MAF 0.02%) 
c.484C>T p.Arg162Trp intolerant 0.00 POD 0.972 0/670 0/382 Hejtmancik et al.[543] 
c.485G>A p.Arg162Gln tolerated 0.20 POD 0.937 2/670 0/382 this study [RP panel] 
c.496C>T p.Arg166X not applicable 4/670 0/382 this study [family A] 
c.511C>T p.(=) not applicable 0/670 0/382 EVS (MAF 0.02%) 
c.524C>T p.Thr175Ile tolerated 0.38 Benign 0.001 212/670 109/382 dbSNP132 [rs1801251], EVS 
c.528A>G p.(=) not applicable 0/670 0/382 EVS (MAF 0.02%) 
c.607C>T p.(=) not applicable 0/670 0/382 EVS (MAF 0.02%) 
c.652T>C p.Tyr218His tolerated 0.74 Benign 0.001 0/670 0/382 1000 genomes, EVS  
c.722T>A p.Leu241Gln tolerated 0.07 Benign 0.001 0/670 0/382 EVS (MAF 0.02%) 
c.722T>C p.Leu241Pro intolerant 0.02 POD 0.997 2/670 0/382 this study [LCA panel; family B] 
c.725C>T p.Thr242Met intolerant 0.03 POD 0.998 0/670 0/382 EVS (MAF 0.02%) 
c.807A>G p.(=) not applicable 0/670 0/382 EVS (MAF 0.02%) 
c.827A>C p.Glu276Ala intolerant 0.03 POD 0.987 1/670 0/382 this study [RP panel] 
c.869C>A p.Pro290Gln intolerant 0.02 POD 0.945 0/670 0/382 dbSNP132 [rs17853727] 
c.925G>T p.Gly309Cys intolerant 0.00 POD 0.998 0/670 0/382 dbSNP132 [rs17857137] 
c.980C>T p.Thr327Ile intolerant 0.01 Benign 0.113 0/670 0/382 EVS (MAF 0.02%) 
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3.2.5 Recessive Mutations in PLA2G5 Cause Benign Fleck Retina 
 
Benign fleck retina is a term used to refer to an autosomal recessive condition 
associated with a distinctive retinal appearance and no apparent visual or 
electrophysiological deficits [558]. Affected individuals are asymptomatic but 
fundus examination reveals a striking pattern of diffuse, yellow-white, fleck-like 
lesions extending to the far periphery but sparing the foveal region [559-562]. 
The benign fleck retina phenotype was first described in 1980 in seven 
affected siblings born to consanguineous parents [559]. A similar clinical 
appearance was subsequently reported in three unrelated individuals 
originating from diverse ethnic backgrounds [560-562]. 
 
A consanguineous family of South Asian origin is the basis of this section 
(family J, figure 3-26). Initially, subject J-4, a healthy, asymptomatic 10-year-
old girl (IV-2, family J in figure 3-26), was referred after abnormal retinal 
appearance was noticed on a routine eye test. No family history of retinal 
disease was reported. Visual acuity was normal. Fundus examination revealed 
multiple, discrete, polymorphous, yellow-white flecks at the level of the RPE; 
the flecks affected both fundi in a symmetrical pattern, spread peripherally, 
beyond the major vascular arcades and spared the maculae (figure 3-27). 
Other family members including three siblings and both parents were also 
examined. Similar findings to the proband were obtained in subjects J-5 (aged 
9; IV-3, family J in figure 3-26) and J-6 (aged 7; IV-4, family J in 3-26); normal 
retinal appearance was observed in subject J-3 (IV-1, family J in figure 3-26) 
and parents J-1 (III-6, family J in figure 3-26) and J-2 (III-7, family J in figure 3-
26). Electrophysiological assessment was performed. Full field ERGs, pERGs 
and EOGs were normal in all three affected subjects and a diagnosis of benign 
fleck retina was confirmed. The clinical findings are summarised in table 3-18. 
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Figure 3-26. Identification of PLA2G5 mutations in individuals from two families with benign 
fleck retina  
Pedigrees of families J and K are shown. Homozygosity mapping using DNA from subject K-2 
revealed a 12 cM region on 1p (flanked by rs10796459 and rs12407356). DNA samples from 
subjects J-1, J-2, J-3, J-4, J-5 and J-6 were also genotyped and a 5 cM region (flanked by 
rs3738122 and rs1832047) was found to be homozygous in all affected and consistent with 
disease segregation. Refseq genes contained in this shared region between families K and J 
are shown. Exome sequencing using DNA from subject J-6 revealed a rare homozygous 
missense change, c.133G>T, p.Gly45Cys in PLA2G5. Gene structure of PLA2G5, coverage 
depth distribution of the mapped reads along its five exons (Savant Genome Browser) and 
sequencing reads corresponding to this variant are presented (IGV viewer; 34 reads total: 10 
forward and 24 reverse,100% thymine). Subsequently, bidirectional Sanger sequencing 
confirmed segregation of the p.Gly45Cys change in family J and identified a homozygous 
nonsense mutation in K-2 (c.185G>A, p.Trp62X). Electropherograms of DNA sequences 
surrounding these two variants are shown. Both sequences are displayed in the forward 
orientation. 
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Figure 3-27. 
[A] Colour photographs and corresponding fundus autofluorescence images of the left fundi of 
subjects K-2 (aged 12), J-4 (aged 12) and M-1 (aged 39). On fundus photography, multiple 
yellow-white flecks of various sizes are observed. Fundus autofluorescence imaging reveals 
hyperautofluorescent lesions corresponding in location with the flecks. The macula is relatively 
spared in subjects J-3 and M-1 but not in K-2 where only the fovea appears not to be affected. 
This might reflect a more detrimental effect of the c p.Trp62X mutation in homozygous state 
(subject K-2) as opposed to homozygous missense (p.Gly45Cys in subject J-3), compound 
heterozygous missense and frameshift (p.Gly45Cys and c.383delA, p.Gln128ArgfsX88 in M-1) 
mutations.  
[B] Fundus autofluorescence imaging and linear SD OCT scan of the left retina of subject K-2. 
Deep, discrete hyperreflective deposits, more obvious at the edge of the foveal scan are 
observed. Panel with enlarged image of boxed region shows outer retina and RPE in detail. 
The lesions are located posterior to the hyperreflective band corresponding to the 
photoreceptor IS/OS junction and do not disrupt it. An overlay of SD OCT with fundus 
autofluorescence image is also presented. Deposits are spatially associated with the 
hyperautofluorescent lesions thus, corresponding to the flecks.  
[C] Functional assessment of the central retina in subject K-2. Static perimetry testing 
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(threshold sensitivities from 0 to 20 dB, test spot size Goldmann III) results overlaid with 
fundus autofluorescence imaging are presented. Retinal sensitivity was normal. 
[D] Longitudinal data showing evolution of fleck-like lesions over time. Magnified view of 
fundus photographs from the left eye (vascular arcades) of subject K-2 at ages six and 12. 
Flecks increase in number and size and become more confluent. 
 
DNA samples from the three affected siblings (subjects J-4, J-5 and J-6), their 
unaffected sister (subject J-3) and parents (subjects J-1 and J-2) were 
genotyped with the use of GeneChip Human Mapping 50K Xba Arrays 
(experiment conducted by Dr Zheng Li; section 2.4.18.2.1). The BRLMM 
genotype calling algorithm was used; CEL files were input and the threshold 
was set at 0.01 (section 2.5.4). The pedigree was consistent with the 
propagation of a single mutant allele from a recent ancestor such that affected 
individuals were autozygous for this allele and the unaffected sibling not. A 
python script interacting with a MySQL database was used to detect regions 
obeying this rule and rank them by genetic distance (section 2.5.4.3). Three 
chromosomal segments over 1 cM were identified (table 3-19): two regions on 
1p (19 cM and 5 cM) and one region on 2q (14 cM).  
 
Exon capture and high-throughput sequencing of DNA from subject J-6 was 
undertaken (Agilent SureSelect 38 Mb exome capture, Illumina HiSeq2000 
sequencer; section 2.4.17). Reads were aligned to the hg19 human reference 
sequence (section 2.5.2.2); average sequencing depth on target was 72 with 
87% of the targeted region covered with a minimum read depth of 10. Overall, 
15,611 exonic sequence alterations with respect to the reference sequence 
were identified (table 3-20). Given the level of consanguinity in this family it 
was hypothesised that the trait is recessive and we focused on homozygous 
variants. Based on the prior belief that benign fleck retina-associated 
mutations are rare, calls with MAF over 0.5% in the 1000 genomes pilot 
dataset (20101123 release; 1094 genomes) or an internal set of 224 exomes 
(individuals with adult-onset neurodegenerative disease) were filtered. 
Subsequently, we focused on the three regions of homozygosity found by SNP 
arrays to be shared among affected family members; no loss-of-function 
variants were identified and three homozygous rare missense changes were 
detected: p.Gly45Cys in PLA2G5, p.Asn385Ser in ECE1 and p.Arg241Gln in 
NEU2 (table 3-20). 
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Simultaneously, a DNA sample was obtained from a previously reported case 
of benign fleck retina (K-2; V-3, family K in figure 3-26) [561]. There was 
evidence of parental consanguinity and homozygosity mapping using the 
Affymetrix Genome-Wide Human SNP Array 6.0 (sections 2.4.18.2.2 and 
2.5.4.3) yielded four regions of homozygosity over 10 cM (table 3-19). The 
third largest segment (12 cM) encompassed one of the loci detected in family 
J. Thus, we focused on the PLA2G5:p.Gly45Cys and ECE1:p.Asn385Ser 
variants found within this shared region. On the basis of physiological 
relevance (Unigene and OMIM), the PLA2G5 change appeared to be more 
likely to cause disease and Sanger sequencing of the open reading frame 
(exons 2 to 5, 138 amino acids, Ensembl transcript ENST00000375108) and 
intron-exon boundaries was undertaken in four unrelated individuals with 
benign fleck retina. Clinical and electrophysiological characteristics of two of 
these cases (K-2 and L-1) have been detailed in previous reports [560-561]. 
 
Biallelic PLA2G5 variants were identified in three of four cases; all changes 
were novel (figure 3-26 and table 3-21). Notably, seven nonsynonymous 
sequence alterations (all with MAF <0.05%) and no loss-of-function PLA2G5 
variants have been previously reported (EVS, dbSNP135, 1000 genomes) or 
were identified in an internal set of 224 exomes (table 3-21). Subject K-2, a 
12-year-old boy [561], was found to be homozygous for a p.Trp62X change, 
altering the last base of exon 3. Subject L-1, a 28-year-old female [560], was 
found to carry two changes in heterozygous state (p.Gly49Ser and p.Arg53X). 
PCR amplification and subsequent TA cloning of exon 3 (pGEM-T Easy 
Vector, Promega; sections 2.3, 2.4.7 and 2.4.13) demonstrated that these 
variants were present on different alleles. Two heterozygous changes were 
also identified in subject M-1, a 39-year-old female (p.Gly45Cys and 
c.383delA, p.Gln128ArgfsX88); these variants were also shown to be biallelic 
using a similar approach (long-range PCR and TA cloning of the 5 kb of DNA 
encompassing exons 3 to 5; experiment conducted by Dr Alice E Davidson). 
Interestingly, the p.Gly45Cys variant was detected in a homozygous state in 
the three affected members of family J. Both missense changes identified in 
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Table 3-18. Clinical characteristics and molecular pathology of subjects with benign fleck retina  
Subject Gender 
Visual function* 
(age at examination) 
Lipid levels 
(mmol/l)^ 
Other systemic 
findings 
Molecular diagnosis, amino acid 
changes in PLA2G5 
J-4 Female Normal ERG, pERG, EOG (12) not tested  p.[Gly45Cys];[Gly45Cys] 
J-5 Female Normal ERG, pERG, EOG (12) not tested  p.[Gly45Cys];[Gly45Cys] 
J-6 Male Normal ERG, pERG, EOG (10) not tested  p.[Gly45Cys];[Gly45Cys] 
K-2 Male Normal ERG, pERG [6][561] and MP1 (12) 
LDL 3.6 mmol/l, total 
cholesterol 5.5 mmol/l 
High BMI (31), 
allergic rhinitis 
p.[Trp62X];[Trp62X] 
L-1 Female Normal ERG, EOG (12)[560] not tested High BMI p.[Gly49Ser];[Arg53X] 
M-1 Female Normal ERG, pERG (37) 
LDL 3.9 mmol/l, total 
cholesterol 6.3 mmol/l 
High BMI (26) p.[Gly45Cys];[Gln128Argfs*45] 
N-1 Female Normal ERG, pERG (10) normal LDL, cholesterol Normal BMI [?];[?] 
Subjects J-4, J-5, J-6 and K-2 are of South Asian origin and born to consanguineous parents; subject L-1 is of mixed Australian aboriginal and white 
descent; subject M-1 is of South Asian origin; subject N-1 is white British. All patients presented with abnormal retinal appearance on a routine eye 
test, were asymptomatic, reported no night blindness and had visual acuities of 0.2 logMAR (logarithm of the minimal angle of resolution) or better. 
Colour vision was normal in all eyes [evaluated using Farnsworth D-15 test (L-2)[560], HRR (K-2, M-1 and N-1) or Ishihara test plates (J-4, J-5, J-6, 
L-2,[560] M-1 and N-1). Subjects K-2 and L-1 had mild myopic astigmatism and subject M-1 is a high myope. 
Subjects K-2 and M-1 had mild eosinophilia (0.45 and 0.64 x 10
9
/l respectively; normal levels from 0.0 to 0.4 x 10
9
/l). 
 
*Visual function was evaluated using electrophysiology or perimetry (Nidek MP1, Goldmann III stimulus size)  
^Normal levels are from 2.3 to 4.9 mmol/l for cholesterol and from 0.0 to 3.0 mmol/l for LDL. 
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Table 3-19. Segments of homozygosity yielded from homozygosity mapping in families A and B 
Chromosome From To 
Genetic Distance 
(Marshfield linkage map) 
Reference 
chr1 54,742,471 (rs590041) 64,361,979 (rs855824) 19 cM 
Family J, 
regions >1 cM chr2  232,025,284 (rs6437002) 236,731,624 (rs952608) 14 cM 
chr1  20,238,860 (rs3738122)  23,266,939 (rs1832047) 5 cM 
chr7 pter 8,546,068 (rs2189903) 15 cM 
Family K, 
regions >10 cM 
chr18 pter 4,925,739 (rs9961128) 12 cM 
chr1 18,477,450 (rs10796459) 24,578,011 (rs12407356) 12 cM 
chr1 110,701,174 (rs12118197) 144,989,739 (rs2590125) 11 cM 
Genotypes of subjects J-1, J-2, J-3, J-4, J-5 and J-6 were generated using the Affymetrix GeneChip Human Mapping 50K Array Xba (section 
2.4.18.2.1). Genotypes of subject K-2 were generated using the Affymetrix Genome-Wide Human SNP Array 6.0 (section 2.4.18.2.2).  
 
Table 3-20. Prioritization of variants identified by exome sequencing of DNA from patient J-6 
 Total 
Within regions of homozygosity  
(on the basis of exome sequencing data) 
Within regions of homozygosity shared 
among affected but not unaffected siblings  
(on the basis of SNP genotyping data) 
All variants. 15,611 1,223 81 
Only NS/SS/I, 7,247 588 40 
AND  0.5% MAF in 1000 genomes, 648 41 3 
AND  0.5% MAF in internal database 580 36 3 
AND are predicted to be loss of function 80 7 0 
Variants presented were sequentially filtered on the basis of effect on protein sequence (synonymous or intronic variants were excluded), presence in 
the 1000 genomes project dataset (with  0.5% MAF; the 20101123 sequence and alignment release including 1094 individuals was used), presence in 
exomes from an internal database (with  0.5% MAF; DNA from 224 samples processed using the same tools as J-6) and being presumed to cause loss 
of protein function (nonsense, splice site variants and frameshifting insertions-deletions). 
 
NS/SS/I, nonsynonymous, splice site or coding insertion-deletion variants. 
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Table 3-21. Summary of coding PLA2G5 sequence variants identified here and elsewhere (EVS, 1000 genomes and dbSNP134) 
Coding DNA variants SIFT PolyPhen-2 
Blosum 62 
score 
(-4 to 11) 
Reference 
(observed allele count) Nucleotide Protein Prediction 
Tolerance 
index  
(0 to 1) 
Prediction
 
HumVar 
Score  
(0 to 1) 
c.9 C>T p.(=) not applicable 6 
1000 genomes [rs2020887], 
EVS (1244/3632), this study 
c.15 C>G p.(=) not applicable 4 EVS (1/4877) 
c.48 T>C p.(=) not applicable 7 EVS (1/4877) 
c.88 G>A p.Glu30Lys tolerated 0.78 Benign 0.03 1 EVS (1/4877) 
c.102 G>T p.(=) not applicable 6 Bushman_pop [rs111762734] 
c.108 C>T p.(=) not applicable 6 
internal database (1/448), 
EVS (3/4875) 
c.110 C>G p.Ala37Gly tolerated 0.35 POD 0.97 0 EVS (1/4877) 
c.133 G>T p.Gly45Cys intolerant 0.00 POD 1.00 -3 this study [families J and M] 
c.144 C>T p.(=) not applicable 9 
1000 genomes [rs11573265], 
EVS (77/4801), this study 
c.145 G>A p.Gly49Ser intolerant 0.02 POD 1.00 0 this study [family L] 
c.157 C>T p.Arg53X not applicable -4 this study [family L] 
c.181 G>A p.Asp61Asn intolerant 0.01 POD 1.00 1 EVS (1/4877) 
c.185 G>A p.Trp62X not applicable -4 this study [family K] 
c.292 G>A p.Glu98Lys intolerant 0.04 Benign 0.47 1 EVS (1/4855) 
c.297 C>T p.(=) not applicable 6 EVS (2/4876) 
c.311 A>C p.His104Pro tolerated 0.23 Benign 0.00 -2 EVS (1/4877) 
c.312 T>C p.(=) not applicable 8 
internal database (1/448), 
EVS (7/4871) 
c.368 G>A p.Arg123Gln tolerated 0.53 Benign 0.10 1 EVS (2/4876) 
c.383delA p.Gln128ArgfsX88 not applicable -4 this study [family M] 
c.402 C>T p.(=) not applicable 6 Bushman_pop [rs112000348] 
c.406 C>T p.Leu136Phe tolerated 0.71 Benign 0.00 0 EVS (1/4877) 
Bushman_pop denotes variants identified only among the four Bushmen genomes (Schuster et al.[563]). For internal database see text 
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benign fleck retina patients (p.Gly45Cys and p.Gly49Ser) were highly 
conserved among orthologs and paralogs.  
 
PLA2G5 encodes group V PLA2, a secreted PLA2 first described in 1994 [564]. 
The PLA2 superfamily includes a broad range of enzymes defined by their 
ability to catalyze the hydrolysis of the middle (sn-2) ester bond of 
glycerophospholipids and thus release potentially bioactive lipids, namely 
lysophospholipids and free fatty acids (arachidonic acid and others) [565-566]. 
PLA2s have been subdivided into several classes, including secreted PLA2s 
[567]. These are water-soluble, Ca2+-requiring enzymes that contain Histidine 
and Aspartic acid catalytic dyads and have the ability to function during 
secretion (in the secretory compartment or in the extracellular space, in an 
autocrine or paracrine manner) or after internalization [568]. Based on 
selected structural determinants, secreted PLA2s have been classified into six 
groups. Individual secreted PLA2s exhibit unique enzymatic properties and 
show diverse tissue and cellular localizations; thus distinct physiological roles 
and nonredundant functions are likely [568]. PLA2G5 is highly expressed in 
the eye and heart and present in other tissues including placenta, lung and 
brain (eyeSAGE, Unigene, [564, 569-573]). A number of human cells including 
macrophages, neutrophils, bronchial and renal tubular epithelium, 
subendocardial cells (cardiomyocytes) and interstitial fibroblasts of gastric 
submucosa have been shown to express PLA2G5 [572, 574-578]. 
 
A variety of biological functions have been attributed to group V PLA2. These 
are often related to the enzyme’s ability to provide arachidonic acid for 
eicosanoid (prostaglandins, leukotriens and others) generation [576, 579]. 
Additional functions not directly related to lipid mediator biosynthesis have also 
been demonstrated; these include regulation of phagocytosis, foam cell 
formation and anti-bacterial activities [577, 580-581]. This combination of pro- 
and anti-inflammatory properties and the presence of cell type-specific 
functions suggest that group V PLA2 has distinct anatomical and context 
dependent roles [574, 581]. Studies employing transgenic [582] and knock-out 
[583] mice have provided important insights into the role of group V PLA2 in 
various pathophysiological events. Enzyme deficiency in Pla2g5 null mice 
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leads to marked attenuation of airway inflammation (asthma [584-585] and 
acute respiratory distress syndrome [586]) and reduced atherosclerosis [587-
588]. Conversely, as group V PLA2 modulates immune complex clearance by 
stimulating phagocytosis, knockout mice demonstrate exacerbation of 
autoantibody-induced arthritis [581]. Pla2g5 transgenic mice overexpressing 
PLA2G5 die soon after birth due to aberrant hydrolysis of lung surfactant 
phospholipids [582]. Despite the growing body of research focusing on animal 
model studies, definite evidence for an in vivo role of group V PLA2 in human 
tissues is lacking and it is likely that some biological functions are not 
conserved from mouse to human [568].  
 
None of the studied patients reported a medical history of major or chronic 
illness (table 3-18). Patient K-2 experiences symptoms of mild seasonal 
allergic rhinitis and infrequently receives antihistamine tablets. A high body 
mass index was recorded in three patients. In both mutation-positive 
individuals tested (subjects K-2 and M-1), a blood test revealed slight 
eosinophilia and mildly elevated LDL and total cholesterol levels (table 3-18). 
Notably, an association of human PLA2G5 haplotypes with total and LDL 
cholesterol has been previously reported [589]. Although there is strong in 
vitro evidence that group V PLA2 is enzymatically active in serum and 
hydrolyses LDL [590], no effect on plasma lipoproteins was observed in mice 
with enzyme deficiency [587]. It is possible that the raised LDL levels are 
unrelated to the PLA2G5 mutations and further studies would be of interest. It 
is however noteworthy that a phase II trial of varsepladib, an inhibitor of 
secreted PLA2s (selectivity against group IIA, V and X PLA2s) has 
demonstrated efficacy in reducing the concentrations of LDL cholesterol [591]. 
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Figure 3-28. Structure of the PLA2G5 gene and hypothetical model of human group V PLA2 
binding to a phospholipid membrane surface. 
[A] Exons are depicted with boxes in which the shaded areas denote coding sequence and 
the unshaded areas denote 5’ and 3’ untranslated region. The amino acid sequence of the 
signal peptide is shown in normal font; the sequence of the 118-amino-acid mature enzyme 
after cleavage of the prepeptide is shown in bold font (Uniprot, [564]). Cystine residues 
forming the six disulfide bridges maintaining the enzyme’s rigid three-dimensional structure 
are italicised (Uniprot, [564]). Amino acids responsible for interfacial binding (Tryptophan 50) 
[592] and catalytic activity(Histidine 67 and Aspartic Acid 111) [568] are underlined. 
[B] A homology model of human group V PLA2 (Protein Data Bank accession code 2ghn 
[593]) after hypothetical association with a phospholipid membrane is presented. Structural 
features of the, conserved among secreted PLA2s, active site are highlighted; those include a 
catalytic Ca
2+
 ion bound by a peptide loop (yellow) and a catalytic dyad formed by amino 
acids His67 and Asp111 (dark blue) [568]. The Ca
2+
 coordination includes carbonyl backbone 
interactions from Tyr47, Gly49 and Gly51 as well as a shared bidentate interaction from 
Asp68 (amino acids coloured in yellow; Uniprot). Trp50, a key amino acid in the enzyme’s 
interfacial binding surface (distinct from the active site) is highlighted in red; its indole chain 
contributes to the characteristic ability of group V PLA2 to bind to both zwitterionic and anionic 
phospholipid vesicles [592]. Cationic residues towards the COOH end of the protein, also 
responsible for membrane binding, are coloured in purple [594]. 
PyMOL was used to view the human group V PLA2 three-dimensional molecular structure 
(orthoscopic view, cartoon setting, cylindrical helices). 
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To gain insight into the function of group V PLA2 in the retina, clinical 
investigations were performed in patients with mutations in PLA2G5. Firstly, in 
vivo cross sectional imaging using SD OCT (Spectralis HRA+OCT, Heidelberg 
Engineering) was undertaken. Deposit accumulation within the RPE 
monolayer and/or the area between the RPE and photoreceptor cells was 
observed (subjects K-2 and M-1; figure 3-27). Secondly, fundus 
autofluorescence imaging [147] (HRA2, Heidelberg Engineering) was utilised 
to provide insight into the molecular composition of the fleck-like lesions; 
hyperautofluorescent material, i.e. rich in lipofuscin or other fluorophores was 
observed (subjects J-4, J-5, J-6, K-2 and M-1; figure 3-27). Lipofuscin 
accumulation is a hallmark of aging in metabolically active cells including 
cardiac myocytes, neurons and RPE [595]. In the latter, the main source of 
lipofuscin is the undegradable components of phagocytosed photoreceptor 
outer segment discs [147, 596]. Excessive build-up has been associated with 
various forms of photoreceptor degeneration namely retinal dystrophies and 
age-related macular degeneration [147]. In order to assess the functional 
significance of abnormalities detected by fundus autofluorescence and SD 
OCT in benign fleck retina patients, fundus-controlled perimetry 
(“microperimetry”; MP1 Microperimeter, Nidek Technologies) was performed. 
Retinal sensitivity was normal in a 10-year-old patient even when areas 
corresponding to large flecks were stimulated (subject K-2; figure 3-27). This 
suggests that the compounds of lipofuscin accumulating in this condition have 
no or minimal functional consequences; this observation is supported by 
normal electrophysiological findings (table 3-18). Finally, fundus photography 
in subject K-2 at 6 and 12 years of age has documented an increase in 
number and size of retinal flecks (figure 3-27). This is not evident from cross 
sectional analysis across four decades and a genotype-phenotype correlation 
cannot be excluded (figure 3-27). 
 
Despite Kolko et al. previously demonstrating high levels of PLA2G5 mRNA 
expression within the rat retina [570], the precise protein localization is 
currently unknown. To determine this, immunohistochemical staining of human 
retinal tissue obtained from an 87-year-old male donor eye was performed 
(experiment designed and conducted by Dr Alice E Davidson). 
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Immunoreactivity was predominantly detected in the outer and inner plexiform 
layers (figure 3-29). This result is unexpected as the data (SD OCT, fundus 
autofluorescence imaging) indicate that the primary defect in patients with 
mutated group V PLA2 is in close proximity to the RPE. More specifically, 
abnormal RPE phagocytosis could explain the level and autofluorescent 
nature of the fleck-like lesions (figure 3-27); this hypothesis is supported by 
previous reports that demonstrated the capacity of the protein to promote 
phagosome maturation in other tissues [580]. The inconsistency between 
protein localization in donor retina and site of structural change in patients is 
difficult to explain and future studies investigating group V PLA2 staining in 
younger retinae should provide further insight. 
 
No mutation was detected in the PLA2G5 coding region and intron-exon 
boundaries of patient N-1, a 10-year-old girl with a typical benign fleck retina 
phenotype (rs2020887, a previously reported SNP, was found in heterozygous 
state). This finding suggests that benign fleck retina may be a genetically 
heterogeneous condition. Interestingly, group IB PLA2, another conventional 
secretory phospholipase, has been shown to be expressed at similar levels 
and to have a comparable localization to group V PLA2 within the rat retina 
[570]. PLA2G1B was therefore selected as a candidate gene and its coding 
region and intron-exon boundaries were screened; no variants were identified 
in patient N-1. 
 
Retinal disease due to mutation in PLA2G5 adds to a small group of human 
Mendelian disorders associated with genes encoding PLA2s; these diseases 
involve neurodegeneration (mutations in PLA2G6 and PNPLA6), abnormal 
lipid storage (mutations in PNPLA2) or platelet dysfunction (mutations in 
PLA2G4A and PLA2G7). Notably, PLA2G7 encodes a lipoprotein-associated 
PLA2 and its natural deficiency (caused by a functionally validated 
p.Val279Phe null allele; MAF from 4 to 18% in East Asian and around 0.03% 
in European populations) is not detrimental to human health with carriers 
having a low risk for coronary artery disease [597-598]. 
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Figure 3-29. Localization of group V PLA2 within a control human retinal tissue 
Human retinal tissue from an 87-year-old male donor eye was obtained from the eye bank at MEH with the approval of Moorfields & Whittington 
Research Ethics Committee (06/Q0504/78) and embedded in optimal cutting temperature compound. Cryostat sections were cut at 10 µm and thaw-
mounted onto charged slides. Immunohistochemistry was performed at room temperature to reveal group V PLA2 localization using Mouse anti-Human 
PLA2G5 monoclonal antibody (LS-C11702, clone MCL-3G1, Lifespan Bioscience, Seattle, WA, USA) [586], at a dilution factor of 1 in 20. An alkaline 
phosphatase-conjugated avidin-biotin complex kit (Vectastain ABC-AP Mouse IgG kit, Vector Laboratories, Burlingame, CA, USA) was used as a 
secondary detection method according to manufacturer’s guidelines. An additional quenching step was performed for 30 minutes to reduce 
autofluorescence using 1% levamisole. 
Ch, Choroid; OS, photoreceptor outer segments; IS photoreceptor inner segment; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner 
nuclear layer; IPL, inner plexiform layer; G ganglion cell layer. Scale bar is 50 µm. 
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4 GENERAL DISCUSSION 
 
In 1977, in an address to the American Society of Human Genetics, Arno 
Motulsky highlighted that “genetics has given medicine a rich intellectual 
foundation and has made possible many practical medical applications” [599]. 
Thirty-five years later, genetic information continues to increase our 
understanding of disease mechanisms and to guide the development of novel 
therapeutic approaches. The present thesis focuses on Mendelian disorders 
(Motulsky in the same address claimed that “most data in this [monogenic trait] 
area are noncontroversial and accepted by all observers” [599]) and more 
specifically autosomal recessive retinal disease. Phenotypic data on five 
mechanistically distinct retinal disorders were collected (section 3.1) and 
defects in three molecules that have not been previously associated with 
recessive retinal disease were identified (section 3.2). 
 
In this study, DNA samples from over 500 unrelated individuals affected with 
autosomal recessive retinal disease were available (section 2.1). Initially, 
subjects with distinctive clinical (sections 3.1.3 and 3.1.7) and/or 
electrophysiological features (sections 3.1.3, 3.1.4, 3.1.5 and 3.1.6) were 
selected and screened for previously associated with retinal disease candidate 
genes. Notably, a specific function has been assigned to the proteins encoded 
by most of the genes tested (including SAG, RDH5, KCNV2, GRM6 and OAT). 
This facilitated the identification of features that have mechanistic relevance in 
individuals harbouring disease-causing mutations (for example the reduced 
fundus autofluorescence associated with RDH5 variants, section 3.1.4.2.3). 
Furthermore, it allowed a more specific diagnosis of such individuals based on 
molecular and biochemical events rather than clinical appearance (for 
example RDH5 retinopathy instead of fundus albipunctatus and GRM6 
retinopathy instead of autosomal recessive CSNB). Once a number of patients 
affected with a distinct disease subtype had been identified, additional clinical 
data were collected and an attempt to characterise the natural history of 
disease was made. This was often hindered by the cross-sectional nature of 
the study and the high degree of phenotypic variability observed. Explaining 
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this variability in symptoms and progression remains a major challenge and 
future studies should provide important insights into contributory genetic and 
environmental factors.  
 
The “phenotype-oriented” method described above and elaborated in section 
3.1 uses a robust pretest hypothesis as individuals were tested for a specific 
gene only if their clinical presentation was similar to the phenotype previously 
associated with this gene. Such an approach has important advantages and 
disadvantages. The main advantage is that the results, i.e. the observed DNA 
variation, are more likely to be meaningful and easier to place in context. The 
main disadvantage is the underestimation of the phenotypic variability 
associated with defects in a specific molecule. Furthermore, the role of a 
particular gene in human disease is not fully investigated. Approaches that are 
more unbiased and hypothesis-free are becoming increasingly available as a 
result of technological advances in microarray and sequencing technologies. 
These methods allow discoveries in previously unexplored places to be made. 
Such discoveries include:  
(a) the identification of disease-causing variants in genes not previously 
associated with disease such as TRPM1, KCNJ13 and PLA2G5 (sections 
3.2.3, 3.2.4 and 3.2.5). 
(b) the expansion of the phenotypic spectrum caused by variants in genes that 
have been previously associated with disease. Likely examples from this study 
are a homozygous change in RLBP1 detected in an individual with a mild fleck 
retina phenotype (hz18682, table 3-12, section 3.2.1; figure 4.1) as well as a 
variant, previously associated with rod monochromasy [344], identified in an 
individual with late-onset maculopathy (rs147876778; hz18502, table 3-13, 
section 3.2.2). 
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Figure 4-1. Fundus photographs and autofluorescence images from the left and right eyes of 
a 29-year-old individual. The patient reported night blindness from a very young age. Her 
parents are first cousins and she has two affected and four unaffected siblings. Colour vision 
and visual acuity were normal (0.0 logMAR and 17/17 Ishihara in each eye). 
Electrophysiological findings were in keeping with fundus albipunctatus (section 3.1.4) without 
evidence of cone system involvement. Screening of RDH5 was negative. Homozygosity 
mapping (hz18682, table 3-12, section 3.2.1) revealed a region of homozygosity around 
RLBP1, a gene previously associated with progressive rod-cone degeneration (Bothnia 
dystrophy; see section 3.1.4). Subsequently, Sanger sequencing identified a homozygous 
p.Val11Ala variant in RLBP1; this sequence alteration has not been previously reported (1000 
genomes, dbSNP, HGMD, EVS). It is likely that the p.Val11Ala change forms a hypomorphic 
allele associated with a significantly milder phenotype compared to the one associated with 
other RLBP1 mutations [150, 600]. 
 
Some unexpected results may also be observed when genome-wide 
approaches are utilised. Examples from this study include: 
(a) a proband with FEVR born to related parents in which exome sequencing 
identified compound heterozygous variants in the previously associated with 
FEVR gene LRP5 [601-602] (hz19762, table 3-13, section 3.2.2); 
(b) a pedigree with two individuals affected with FEVR (proband and her 
father’s first cousin) in which one subject was found homozygous and one 
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heterozygous for the same splice site change in TSPAN12 (hz17327, table 3-
12, section 3.2.1). Notably, heterozygous frameshift, splice site, nonsense and 
missense mutations in TSPAN12 are associated with dominantly inherited 
FEVR [603-604]; 
 (c) a pedigree with three individuals affected with rod monochromacy 
(proband and two maternal aunts; figure 4-2) in which the proband was found 
to be homozygous for a previously reported disease-causing [343] variant in 
CNGA3 (rs141386891; hz17857, table 3-12, section 3.2.1); both her aunts 
were found heterozygous for this change and homozygous for a different, also 
previously reported as disease-causing [344] variant in CNGB3 
(rs147876778). Surprisingly the proband’s unaffected sister was also found 
homozygous for the CNGA3 sequence alteration (MAF< 0.01% in EVS). 
 
Figure 4-2. Pedigree and genetic testing results from a family segregating rod monochromasy. 
CNGA3+ denotes presence of an allele harbouring a p.Arg437Cys. 
CNGB3+ denotes presence on an allele harbouring a p.Arg403Gln. 
+/+, homozygous; +/-, heterozygous 
 
(d) a pedigree with three individuals affected with RP (two siblings and their 
first cousin; figure 4-3) in which one of the two siblings and her maternal 
cousin are homozygous for a previously reported [605] frameshift mutation in 
RP1. Intriguingly, the other affected sibling was found heterozygous for the 
same change (hz18655, table 3-12, section 3.2.1). 
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Figure 4-3. Pedigree and genetic testing results from a family segregating RP  
RP1+ denotes presence on an allele harbouring a p.Glu487_Glu488delinsGluX. 
+/+, homozygous; +/-, heterozygous. 
See text for more details. 
 
The trade-off of replacing informed but biased hypotheses (section 3.1) with 
unbiased but generic ones (section 3.2) is that every result must be treated 
with the skepticism that is appropriate for an ignorant hypothesis [104]. 
Therefore, additional, convincing evidence needs to be collected. Obtaining 
sufficient data is challenging and potentially unachievable for some true 
positive results. In this thesis, despite confidently imposing an autosomal 
recessive, Mendelian model and being able to apply powerful family-based 
filtering strategies (homozygosity mapping, linkage approaches), causality 
could not be established in the majority of families studied with microarrays or 
exome sequencing (section 3.2). It can be argued that only the low-hanging 
fruit were harvested and in retrospect, TRPM1, KCNJ13 and PLA2G5 may 
appear obvious candidate genes. Robinson et al. note that “a major problem in 
studying rare disease is that one can never be entirely certain that a given 
gene is in fact the sought after disease gene until a second unrelated 
individual is described with mutation in the same gene and a comparable 
phenotype” [96]. The main strength of this study has been the availability of a 
large number of families to screen in order to robustly associate a molecular 
defect with a phenotype. Although dealing with the explosive growth in the 
quantity and complexity of genomic data is often considered the major 
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challenge for the future, involving in genetic research and collecting DNA 
samples from as many affected individuals as possible is also key. Equally if 
not more important to those is to maintain a constant flow of basic research 
discoveries. Knowledge gained from basic research has significantly benefited 
this clinical study; if information has not been previously accumulated on the 
function of TRPM1, KCNJ13 and PLA2G5, these would have probably been 
overlooked as candidate genes. 
 
It seems inevitable that genetics and genomics will transform the way 
medicine is practiced. It is clear however that a substantial amount of research 
is needed before implementing “genomic medicine”. Gaining insight into 
genetic and phenotypic heterogeneity of disease is extremely important and 
the results presented in this thesis are a minor contribution towards ophthalmic 
care that focuses on predisposition testing, early detection and targeted 
therapy. 
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6 APPENDIX 
 
6.1  Computing Probabilities for Continuous Autozygous Segments in 
Consanguineous Pedigrees 
 
6.1.1 Coefficient of Inbreeding and Consanguinity 
 
Wright’s (section 1.1.1.4) coefficient of inbreeding, f (as redefined by Malécot), 
is the probability of two alleles at any locus in an individual being autozygous 
[606-607]. Wright's equation for calculating f is [607-608]:  
f = [(1/2)m (1+fa)] 
where f is the coefficient of inbreeding for the person in question, fa is the 
coefficient of inbreeding for the common ancestor, m is the total number of 
zygotes in the path and  represents the sum for all common ancestor alleles. 
Common ancestors are assumed to be non-inbred and unrelated; therefore, fa 
= 0. 
 
Consanguineous marriage is most commonly defined as a union between a 
couple related as second cousins or closer, equivalent to a coefficient of 
inbreeding in their progeny of f ≥ 0.0156 [609]. 
 
6.1.2 Crossing Over 
 
In diploid eukaryotes, during meiosis, each of the two (paternal and maternal) 
homologous chromosome copies duplicates to form two pairs of strands 
(chromatids). All four resulting strands line up together forming a very tight 
bundle. During the prophase of meiosis I, homologs separate from each other 
at most places but maintain one or more zones of physical contact known as 
chiasmata (figure 6-1). Chiasmata reflect the occurrence of crossover between 
chromatids, i.e. breakage of the double helix in one paternal and one maternal 
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chromatid and joining of maternal and paternal ends. While chiasmata can be 
observed cytogenetically, crossovers are a feature of genetic marker maps 
[610]. Correspondence between cytological chiasmata and genetic crossing-
over is assumed although this assumption is not absolutely accurate [611]. It is 
also assumed that the two chromatids involved in any particular crossover 
cannot be the two copies of a single homologous chromosome (sister 
chromatids) [612]. The fact that chiasmata are more frequent in female 
meioses [613-615] is ignored in this analysis. 
 
 
 
Figure 6-1. The five stages of prophase in meiosis. 
Two pairs of homologs are shown (chromosomes 1 and 17) [134]. 
 
It is known that the locations of multiple crossovers on a chromosome at 
meiosis are not independent but exhibit crossover interference, operating 
whenever crossover events fail to occur completely "at random" [616]. 
Crossover interference may be of two types: (a) chiasma interference (positive 
or negative) which reflects the influence on formation of a new chiasma by an 
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existing chiasma and (b) chromatidal interference which refers to the 
correlation of the two chromatides of the next crossover event to those that 
participated in the preceding or neighboring crossover [617]. There is little 
consistent evidence of chromatid interference [618] and it is assumed to be 
zero. 
 
6.1.3 Map Distance 
 
For simplicity purposes this section mainly focuses on two-point analysis. 
Crossovers may lead to what is known as “homologous recombination” and 
the following relation holds between crossover and recombination: an odd 
number of crossover points between two loci on a gamete leads to 
recombination whereas an even point leads to nonrecombination [610]. 
Recombination fraction (θ; see also section 1.1.1.2) expresses the probability 
that an odd number of crossovers (recombination) will take place between two 
loci during meiosis. By definition, however far apart the loci are, θ cannot 
exceed 0.5; therefore, it is not an additive distance measure. The major 
reason for this nonadditivity is the occurrence of multiple crossovers between 
the loci making them either linked (recombination fraction 0  θ < 0.5) or not 
linked (θ = 0.5). It is the average number of crossovers between loci that 
serves as a stochastic measure of distance between loci. The nonadditive 
recombination fraction θ can be converted into an additive map distance x = 
f(θ) using transformations called mapping functions. The map distance (in 
Morgans) between two chromosomal points a and b is denoted by xab and is 
defined as the expected (average) number of crossovers per meiosis 
occurring in a gamete in [a, b] [611]. Another definition is: genetic map length 
equals one half of the expected number of chiasmata in the given region of the 
germ plasm. This can be explained by the fact that an offspring receives one 
of the four chromatids; hence, assuming no interference, each chiasma 
resolves as a crossover in the offspring with probability one half, independent 
of the resolution of other chiasmata [616, 619]. 
The main method for constructing map functions is the differential equation 
method introduced by Haldane in 1919; this makes two assumptions: (a) any 
APPENDIX 
 
245 
 
recombination frequency θ can be regarded as a function θ = θ(x) of the map 
distance x of the segment in question; (b) the recombination frequency is 
approximately equal to map distance for short intervals, i.e., θ(x)  x for x small 
[29, 611, 617]. 
 
Using these assumptions many different map functions have been developed, 
each one assuming different mechanisms of crossover interference and 
generated by various specifications of a parameter called coefficient of 
coincidence C(x) [620]. 
 
 
Figure 6-2. Map distance schematic. 
 
To understand C(x), consider three loci as shown in figure 6-2 and let the 
corresponding recombination frequencies between the loci be θ12 = θ(x), θ13 = 
θ(x+Δx), θ23 = θ(Δx). If C(x, Δx) is the coefficient of coincidence between the 
interval (0, x) and the increment (x, x+Δx), then C(x, Δx) is given by the 
following equation [617]: 
 
θ(x+Δx) = θ(x) + θ(Δx) - 2C(x, Δx) θ(x) θ(Δx). 
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The most commonly used functions are found in table 6-1. 
 
Table 6-1. Main map functions 
Source Coefficient of coincidence 
(interference) 
Map function 
Haldane [29] 1 θ = (1-e-2x)/2 
Morgan [621] 0 θ = x 
Kosambi [622] 2 θ(x) θ = (e4x-1)/(e4x+1) 
Haldane’s function represents the case of no interference [C(x) = 1], whereas Morgan’s 
function θ(x) = x represents complete interference [C(x) = 0] such that a crossover event 
occurring in one interval precludes its occurrence in any subsequent small interval. Coefficient 
of coincidence in Kosambi’s function [C(x) = 2 θ(x)] assumes that for long segments with θ  
1/2 interference vanishes (C  1), whereas for short segments (θ  0) the degree of 
interference becomes complete (C  0) [617]. 
 
 
Figure 6-3. Graphs of Morgan (θ = x), Haldane and Kosambi functions (modified from 
[610]). For small distances (with θ  0.05), any map function is appropriate. 
 
6.1.4 Probability Distribution of Autozygous Fragments 
 
Let a length x cM of a chromosome be considered as divided into a very large 
number N of small equal portions Δx (x = N Δx). As Δx is very small, the map 
distance Δx equals the recombination frequency θ(Δx) (see figure 6-3). 
 
A random variable is a variable whose value is a numerical outcome. As map 
distance x  (0; +) is a continuous random variable, its relative likelihood to 
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occur at a given point in the observation space is described by its probability 
density function [623]. Let f(x) be the probability density function of x with f(x)  
0 and  = 1. The probability P(X) of X having a value between a and 
b is given by the integral of its probability density function from a to b: 
P (a < X < b) =  
 
In a similar fashion, the probability of X being between x and x + Δx is:  
P (x  X  x+Δx) =   
 
From the geometric interpretation of the definite integral, for small Δx, we 
have: 
 
P (x  X  x+Δx) = = f(x) Δx            (equation 1) 
 
Let the following functions of x  (0; +) be defined as follows: 
P0 (x) as the probability of no recombination in an interval of genetic distance 
x; P1 (x) as the probability of at least one crossover in an interval of genetic 
distance x. 
 
From figure 6-3 and as Δx is small (with the probability of over two crossovers 
being close to 0) we have: 
P0 (Δx) = 1 – P1 (Δx) = 1 – θ(Δx) = 1 – Δx 
 
As x = N Δx, assuming no interference (Haldane’s model), the probability of no 
recombination in x equals the probability of no recombination in each of the N 
Δx-sized intervals making  
 
P0 (x) = [P0 (Δx)]
N = (1 – Δx)N              (equation 2) 
 
Let #1 in figure 6-2 be a heterozygous marker at the q tip (point 0 of the 
genetic distance) of a chromosome in a noninbred individual (common 
ancestor). The probability that #1 will be identical by descent along two distinct 
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paths (paternal and maternal) involving in total m meioses from this single 
ancestor is f = (1/2)m 
For m meioses, the probability of observing a continuous identical by descent 
segment of size X (from locus #1 to locus #3) equals the probability of no 
crossover between #1 and #2 in m meioses [P0m(x)] and at least one 
crossover in the very small interval between #2 and #3 [P1m(Δx)]. 
 
P (x  X  x+Δx) = P0m (x) P1m (Δx)             (equation 3) 
 
Using equation 2, P0m (x) and P1m (Δx) are calculated as follows: 
 
P0m (x) = [P0 (x)]
m = {[P0 (Δx)]
N}m = (1–Δx)Nm 
 
As N=  
P0m (x) =                (equation 4) 
P1m (Δx) = 1 - P0m(Δx) = 1 – [P0(Δx)]
m = 1 – (1–Δx)m           (equation 5) 
 
Applying the formula an-bn = (a-b)(an-1 +an-2 b +an-3 b2 + … +bn-1) for a=1, b=1-
Δx and n=m in equation 5, we get: 
P1m (Δx) = 1
m – (1 – Δx)m = (equation 6) 
 
Combining equations 1, 3, 4 and 6 we have: 
f(x) Δx =  Δx  → 
f(x) =       (equation 7) 
 
For Δx0 we have: 
 = e-mx  (from the definition of the number e) and 
  m. 
 
Therefore equation 7 becomes: 
f(x)= m e-mx                 (equation 8) 
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The probability density function of equation 8 is for a spot x cM from point 0. 
For an arbitrary point in the genome were autozygosity is observed, let x and 
y, both in the interval (0, +), be the genetic distances to its left and right side 
till the next crossover. If fx  and fy are the probability density functions for these 
two variables, we have shown that  
fx(x) = fy(x) = m e
-mx 
 
For z = x + y we have [624]:  
fz (z) =  = =  m
2  →  
fz (z) =                 (equation 9) 
 
This is an Erlang-2 (k=2) distribution [625-626] of z  (0; +) with a mean μ = 
 =  and a variance var(z) =  =  where m being the total number of 
meioses from the founder.  
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6.2 Python Code for Homozygosity Mapping 
 
The program is running on a Ubuntu 10.04 Linux machine (144.82.133.7) with python 2.6.5, MySQL 5.1 and a python-mysqldb 1.2.2-
7ubuntu1 module. After connecting to mysql ($mysql –u username –p), two databases (“panos2” [ mysql> CREATE DATABASE panos2;] 
and “panos3” [ mysql> CREATE DATABASE panos3; ] should be created. To use type plum or, preferably, plum --rs. 
 
Input files are comma-separated values (CSV) files containing either annotation information (downloaded from http://www.affymetrix.com; 
for Genome-Wide Human SNP Array 6.0, relevant file can be downloaded from 
http://www.affymetrix.com/support/technical/byproduct.affx?product=genomewidesnp_6]) or genotyping data from an individual (typically 
output from the Affymetrix Genotyping Console Software [http://www.affymetrix.com/browse/level_seven_software_products_only.jsp? 
productId=131535&categoryId=35625#1_1]. The latter CSV file should be arranged so that the first column corresponds to ProbeSetID, 
the second to Code (AA, AB, BB, NoCall) and the fourth to DbSnpRsID. 
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#!/usr/bin/env python 
# encoding: utf-8 
 
import sys 
import os 
import MySQLdb 
 
 
def printOptions(): 
 
        print "\n2010B PLUM\n" 
        print "Make a choice:" 
        print "1. Import new family member to database" 
        print "2. Generate the input data for a family" 
        print "3. Run the script for a family" 
        print "4. Make a csv file from a table" 
        print "5. Find common areas between families" 
        print "6. Import new annotation file" 
        print "7. Delete data" 
        print "8. Quit" 
        print "Your Choice: ", 
        answer = sys.stdin.readline() 
        if answer.split('\n')[0] == '1': 
                return 1 
        elif answer.split('\n')[0] == '2': 
                return 2 
        elif answer.split('\n')[0] == '3': 
                return 3 
        elif answer.split('\n')[0] == '4': 
                return 4 
        elif answer.split('\n')[0] == '5': 
                return 5 
        elif answer.split('\n')[0] == '6': 
                return 6 
        elif answer.split('\n')[0] == '7': 
                return 7 
        elif answer.split('\n')[0] == '8': 
                return 8 
        else: 
                print "Please chose one of the available choices" 
                printOptions() 
 
 
def checkTable(db,tableName): 
        sqlQuery = 'SHOW TABLES' 
        cursor = db.cursor() 
        cursor.execute(sqlQuery) 
        result = cursor.fetchall() 
        exists = 0 
        for table in result: 
                if table[0] == tableName: 
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                        exists = 1 
        cursor.close() 
        return exists 
 
 
def initialDBSetup(db,DBchoice): 
        cursor = db.cursor() 
         
        create_families_query = 'CREATE TABLE families ( \ 
        FamilyID varchar(50) NOT NULL,\ 
        FatherID varchar(50) DEFAULT NULL, \ 
        MotherID varchar(50) DEFAULT NULL, \ 
        IndividualID1 varchar(50) DEFAULT NULL, \ 
        IndividualID2 varchar(50) DEFAULT NULL, \ 
        IndividualID3 varchar(50) DEFAULT NULL, \ 
        IndividualID4 varchar(50) DEFAULT NULL, \ 
        IndividualID5 varchar(50) DEFAULT NULL, \ 
        IndividualID6 varchar(50) DEFAULT NULL, \ 
        IndividualID7 varchar(50) DEFAULT NULL, \ 
        IndividualID8 varchar(50) DEFAULT NULL, \ 
        IndividualID9 varchar(50) DEFAULT NULL, \ 
        IndividualID10 varchar(50) DEFAULT NULL, \ 
        PRIMARY KEY (FamilyID) \ 
        ) ENGINE=MyISAM DEFAULT CHARSET=utf8' 
        cursor.execute(create_families_query) 
         
        if DBchoice == 0: 
                create_annotation_query = 'CREATE TABLE annotation ( \ 
                ProbeSetID varchar(20) NOT NULL, \ 
                DbSnpRsID varchar(20) NOT NULL, \ 
                Chromosome varchar(2) NOT NULL, \ 
                ChromosomeStart varchar(7) NOT NULL, \ 
                CytoBand varchar(10) NOT NULL, \ 
                GeneticMap varchar(255) NOT NULL, \ 
                PRIMARY KEY (ProbeSetID) \ 
                ) ENGINE=MyISAM DEFAULT CHARSET=utf8' 
        else: 
                create_annotation_query = 'CREATE TABLE annotation ( \ 
                ProbeSetID varchar(20) NOT NULL, \ 
                DbSnpRsID varchar(20) NOT NULL, \ 
                Chromosome varchar(2) NOT NULL, \ 
                ChromosomeStart varchar(7) NOT NULL, \ 
                CytoBand varchar(10) NOT NULL, \ 
                GeneticMap varchar(255) NOT NULL, \ 
                PRIMARY KEY (DbSnpRsID) \ 
                ) ENGINE=MyISAM DEFAULT CHARSET=utf8' 
        cursor.execute(create_annotation_query) 
         
        create_families_status_query = 'CREATE TABLE families_status ( \ 
        FamilyID varchar(50) NOT NULL,\ 
        IndividualID1 varchar(5) DEFAULT NULL, \ 
        IndividualID2 varchar(5) DEFAULT NULL, \ 
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        IndividualID3 varchar(5) DEFAULT NULL, \ 
        IndividualID4 varchar(5) DEFAULT NULL, \ 
        IndividualID5 varchar(5) DEFAULT NULL, \ 
        IndividualID6 varchar(5) DEFAULT NULL, \ 
        IndividualID7 varchar(5) DEFAULT NULL, \ 
        IndividualID8 varchar(5) DEFAULT NULL, \ 
        IndividualID9 varchar(5) DEFAULT NULL, \ 
        IndividualID10 varchar(5) DEFAULT NULL, \ 
        PRIMARY KEY (FamilyID) \ 
        ) ENGINE=MyISAM DEFAULT CHARSET=utf8' 
        cursor.execute(create_families_status_query) 
         
        db.commit() 
        cursor.close() 
 
 
def importFamilyMember(db,DBchoice): 
        # read the id of the individual and check for correct input 
        while 1: 
                print "Individual ID: ", 
                individualID = sys.stdin.readline() 
                try: 
                        individualID = int(individualID.split('\n')[0]) 
                        print 'Numeric values not allowed' 
                except Exception, e: 
                        individualID = individualID.split('\n')[0] 
                        break 
         
        # read the type of the individual father/mother/child 
        exit = False 
        while not exit: 
                print "Individual Type ('f' for father/'m' for mother/'c' for child): ", 
                individualType = sys.stdin.readline() 
                individualType = individualType.split('\n')[0] 
                if individualType == "f" or individualType == "m": 
                        break 
                # if it is a child check if it is affected or unaffected 
                if  individualType == "c": 
                        while 1: 
                                print "Status ('aff' for affected/'unaff' for unaffected): ", 
                                status = sys.stdin.readline() 
                                status = status.split('\n')[0] 
                                if status == "aff" or status == "unaff": 
                                        exit = True 
                                        break 
         
        # read the family ID; all individuals of the same family need to have the same family ID, otherwise a new family will be created 
 
        while 1: 
                print "Enter the family ID of the individual.\nThe family ID needs to be the SAME\nfor all family members otherwise\na new family will 
be created\nFamily ID: ", 
                familyID = sys.stdin.readline() 
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                try: 
                        familyID = int(familyID.split('\n')[0]) 
                        print 'Numeric values not allowed' 
                except Exception, e: 
                        familyID = familyID.split('\n')[0] 
                        break 
        # read the path of the data file of the individual 
        fileNameOK = False 
        while not fileNameOK: 
                print "Full path of text file: ", 
                filePath = sys.stdin.readline() 
                filePath = filePath.split('\n')[0] 
                if os.path.isfile(filePath): 
                        fileNameOK = True 
                else: 
                        print 'File does not exist' 
         
        # check if individual exists; if not import it 
 
        if checkTable(db,individualID) == 0: 
                cursor = db.cursor() 
                # check if the family with the given ID exists or not 
                check_family_query = 'SELECT * FROM families WHERE familyID=\''+familyID+'\'' 
                cursor.execute(check_family_query) 
                results = cursor.fetchall() 
                nrows = int(cursor.rowcount) 
                check = 1 
                column_number = -1 
                if nrows == 0: # family does not exist insert a row in the families table 
                        insert_families_query = 'INSERT INTO families VALUES ("%s", null, null, null, null, null, null, null, null, null, null, null, 
null)'%(familyID) 
                        cursor.execute(insert_families_query) 
                         
                        insert_families_status_query = 'INSERT INTO families_status VALUES ("%s", null, null, null, null, null, null, null, null, null, 
null)'%(familyID) 
                        cursor.execute(insert_families_status_query) 
                 
                if individualType == "f": # individual is the father 
                        update_families_father_query = 'UPDATE families SET FatherID=\''+individualID+'\' WHERE familyID=\''+familyID+'\'' 
                        cursor.execute(update_families_father_query) 
                        column_number = 1 
                 
                elif individualType == "m": # individual is the mother 
                        update_families_mother_query = 'UPDATE families SET MotherID=\''+individualID+'\' WHERE familyID=\''+familyID+'\'' 
                        cursor.execute(update_families_mother_query) 
                        column_number = 2 
                 
                else: # individual is a child 
                        if nrows == 0: # no other children exist till now because the family was just created 
                                update_families_child_query = 'UPDATE families SET IndividualID1=\''+individualID+'\' WHERE familyID=\''+familyID+'\'' 
                                cursor.execute(update_families_child_query) 
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                                update_families_status_child_status_query = 'UPDATE families_status SET IndividualID1=\''+status+'\' WHERE 
familyID=\''+familyID+'\'' 
                                cursor.execute(update_families_status_child_status_query) 
                        else: 
                                # other children already exist and we need to find the first individualID{number} available 
                                # scan all columns to see the first empty individual and update the entry 
                                column_number = 3 
                                while column_number < 12: 
                                        if results[0][column_number] == None: 
                                                update_families_individualID_query = 'UPDATE families SET IndividualID'+str(column_number-
2)+'=\''+individualID+'\' WHERE familyID=\''+familyID+'\'' 
                                                cursor.execute(update_families_individualID_query) 
                                                update_families_status_individualID_status_query = 'UPDATE families_status SET 
IndividualID'+str(column_number-2)+'=\''+status+'\' WHERE familyID=\''+familyID+'\'' 
                                                cursor.execute(update_families_status_individualID_status_query) 
                                                break 
                                        column_number += 1 
                                # there is a limit that allows only families with maximum 10 children. tough luck 
                                if column_number == 12: 
                                        print 'Individual not imported. Already 10 children exist in the database.' 
                                        check = 0 
                if check == 1: # create table for the individual 
                         
                        if DBchoice == 0: 
                                create_individual_query = 'CREATE TABLE '+individualID+' ( \ 
                                ProbeSetID varchar(20) NOT NULL, \ 
                                Code varchar(7) NOT NULL, \ 
                                Confidence varchar(10) NOT NULL, \ 
                                DbSnpRsID varchar(20) NOT NULL, \ 
                                PRIMARY KEY (ProbeSetID) \ 
                                ) ENGINE=MyISAM DEFAULT CHARSET=utf8' 
                        else: 
                                create_individual_query = 'CREATE TABLE '+individualID+' ( \ 
                                ProbeSetID varchar(20) NOT NULL, \ 
                                Code varchar(7) NOT NULL, \ 
                                Confidence varchar(10) NOT NULL, \ 
                                DbSnpRsID varchar(20) NOT NULL, \ 
                                PRIMARY KEY (DbSnpRsID) \ 
                                ) ENGINE=MyISAM DEFAULT CHARSET=utf8' 
                        cursor.execute(create_individual_query) 
                        try: 
                                load_data_query = 'LOAD DATA LOCAL INFILE \''+filePath+'\' INTO TABLE '+individualID+' FIELDS TERMINATED BY \'\t\' 
LINES TERMINATED BY \'\r\n\' IGNORE 6 LINES' 
                                cursor.execute(load_data_query) 
                        except Exception, e: 
                                print 'File could not be imported...' 
                                drop_table_query = 'DROP TABLE '+individualID 
                                cursor.execute(drop_table_query) 
                                if column_number == 1: 
                                        update_families_father_query = 'UPDATE families SET FatherID=NULL WHERE familyID=\''+familyID+'\'' 
                                        cursor.execute(update_families_father_query) 
                                elif column_number == 2: 
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                                        update_families_mother_query = 'UPDATE families SET MotherID=NULL WHERE familyID=\''+familyID+'\'' 
                                        cursor.execute(update_families_mother_query) 
                                else: 
                                         
                                        update_families_individualID_query = 'UPDATE families SET IndividualID'+str(column_number-2)+'=NULL WHERE 
familyID=\''+familyID+'\'' 
                                        cursor.execute(update_families_individualID_query) 
                                        update_families_status_individualID_status_query = 'UPDATE families_status SET IndividualID'+str(column_number-
2)+'=NULL WHERE familyID=\''+familyID+'\'' 
                                        cursor.execute(update_families_status_individualID_status_query) 
                 
                db.commit() 
                cursor.close() 
        # if member exists print message 
        else: 
                print 'Individual '+individualID+' already exists in the database' 
 
 
def generateInputData(db,DBchoice): 
        cursor = db.cursor() 
        drop_children_query = 'DROP TABLE IF EXISTS children' 
        cursor.execute(drop_children_query) 
        familiesID_query = 'SELECT familyID from families' 
        cursor.execute(familiesID_query) 
        families = cursor.fetchall() 
        exit = False 
        while not exit: 
                for f in families: 
                        print f[0] 
                exit2 = False 
                while not exit2: 
                        print "Family ID: ", 
                        familyID = sys.stdin.readline() 
                        try: 
                                familyID = int(familyID.split('\n')[0]) 
                                print 'Numeric values not allowed' 
                        except Exception, e: 
                                familyID = familyID.split('\n')[0] 
                                for f in families: 
                                        if f[0] == familyID: 
                                                exit = True 
                                                exit2 = True 
                                                break 
        aff = [] # list with all the affected Individual IDs 
        unaff = [] # list with all the unaffected Individual IDs 
        sqlQuery3 = 'SELECT * from families_status WHERE familyID=\''+familyID+'\'' 
        cursor.execute(sqlQuery3) 
        results = cursor.fetchall() 
        print results[0] 
        i = 1 
        while i < 11: 
                if results[0][i] == "aff": 
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                        aff.append(i) 
                if results[0][i] == "unaff": 
                        unaff.append(i) 
                i += 1 
        print aff 
        print unaff 
         
        # if affected children exist 
        if aff.__len__() > 0: 
                sqlQuery4 = 'SELECT ' 
                for a in aff: 
                        sqlQuery4 += 'IndividualID'+str(a)+',' 
                sqlQuery4 = sqlQuery4.strip(',') 
                sqlQuery4 += ' FROM families WHERE familyID=\''+familyID+'\'' 
                cursor.execute(sqlQuery4) 
                aff = cursor.fetchall()[0] 
                # create a temporary table called affected to join all the affected individuals to 
                if DBchoice == 0: 
                        sqlQuery6 = 'CREATE TABLE affected ( ProbeSetID varchar(20) NOT NULL, ' 
                        sqlQuery7 = 'INSERT INTO affected SELECT '+aff[0]+'.ProbeSetID,' 
                else: 
                        sqlQuery6 = 'CREATE TABLE affected ( DbSnpRsID varchar(20) NOT NULL, ' 
                        sqlQuery7 = 'INSERT INTO affected SELECT '+aff[0]+'.DbSnpRsID,' 
                i = 0 
                while i < aff.__len__(): 
                        sqlQuery6 += 'Code'+str(i+1)+' varchar(7) DEFAULT NULL, Confidence'+str(i+1)+' varchar(10) DEFAULT NULL, ' 
                        sqlQuery7 += aff[i]+'.Code,'+aff[i]+'.Confidence,' 
                        i += 1 
                if DBchoice == 0: 
                        sqlQuery6 += 'PRIMARY KEY (ProbeSetID) ) ENGINE=MyISAM DEFAULT CHARSET=utf8' 
                else: 
                        sqlQuery6 += 'PRIMARY KEY (DbSnpRsID) ) ENGINE=MyISAM DEFAULT CHARSET=utf8' 
                print sqlQuery6+'\n' 
                cursor.execute(sqlQuery6) 
                 
                sqlQuery7 = sqlQuery7.strip(',') 
                sqlQuery7 += ' FROM '+aff[0] 
                i = 1 
                while i < aff.__len__(): 
                        if DBchoice == 0: 
                                sqlQuery7 += ' INNER JOIN '+aff[i]+' ON '+aff[i-1]+'.ProbeSetID = '+aff[i]+'.ProbeSetID' 
                        else: 
                                sqlQuery7 += ' INNER JOIN '+aff[i]+' ON '+aff[i-1]+'.DbSnpRsID = '+aff[i]+'.DbSnpRsID' 
                        i += 1 
                print sqlQuery7+'\n' 
                cursor.execute(sqlQuery7) 
         
        # if unaffected children exist 
        if unaff.__len__() > 0: 
                sqlQuery5 = 'SELECT ' 
                for u in unaff: 
                        sqlQuery5 += 'IndividualID'+str(u)+',' 
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                sqlQuery5 = sqlQuery5.strip(',') 
                sqlQuery5 += ' FROM families WHERE familyID=\''+familyID+'\'' 
                cursor.execute(sqlQuery5) 
                unaff = cursor.fetchall()[0] 
                 
                # create a temporary table called unaffected to join all the affected individuals to 
                if DBchoice == 0: 
                        sqlQuery8 = 'CREATE TABLE unaffected ( ProbeSetID varchar(20) NOT NULL, ' 
                        sqlQuery9 = 'INSERT INTO unaffected SELECT '+unaff[0]+'.ProbeSetID,' 
                else: 
                        sqlQuery8 = 'CREATE TABLE unaffected ( DbSnpRsID varchar(20) NOT NULL, ' 
                        sqlQuery9 = 'INSERT INTO unaffected SELECT '+unaff[0]+'.DbSnpRsID,' 
                i = 0 
                while i < unaff.__len__(): 
                        sqlQuery8 += 'Code'+str(i+1)+' varchar(7) DEFAULT NULL, Confidence'+str(i+1)+' varchar(10) DEFAULT NULL, ' 
                        sqlQuery9 += unaff[i]+'.Code,'+unaff[i]+'.Confidence,' 
                        i += 1 
                if DBchoice == 0: 
                        sqlQuery8 += 'PRIMARY KEY (ProbeSetID) ) ENGINE=MyISAM DEFAULT CHARSET=utf8' 
                else: 
                        sqlQuery8 += 'PRIMARY KEY (DbSnpRsID) ) ENGINE=MyISAM DEFAULT CHARSET=utf8' 
                print sqlQuery8+'\n' 
                cursor.execute(sqlQuery8) 
                 
                sqlQuery9 = sqlQuery9.strip(',') 
                sqlQuery9 += ' FROM '+unaff[0] 
                i = 1 
                while i < unaff.__len__(): 
                        if DBchoice == 0: 
                                sqlQuery9 += ' INNER JOIN '+unaff[i]+' ON '+unaff[i-1]+'.ProbeSetID = '+unaff[i]+'.ProbeSetID' 
                        else: 
                                sqlQuery9 += ' INNER JOIN '+unaff[i]+' ON '+unaff[i-1]+'.DbSnpRsID = '+unaff[i]+'.DbSnpRsID' 
                        i += 1 
                print sqlQuery9+'\n' 
                cursor.execute(sqlQuery9) 
         
        # join the affected and/or unaffected children in one table called children 
        if DBchoice == 0: 
                sqlQuery10 = 'CREATE TABLE children ( ProbeSetID varchar(20) NOT NULL, ' 
        else: 
                sqlQuery10 = 'CREATE TABLE children ( DbSnpRsID varchar(20) NOT NULL, ' 
        i = 0 
        while i < aff.__len__() + unaff.__len__(): 
                sqlQuery10 += 'Code'+str(i+1)+' varchar(7) DEFAULT NULL, Confidence'+str(i+1)+' varchar(10) DEFAULT NULL, ' 
                i += 1 
        if DBchoice == 0: 
                sqlQuery10 += 'PRIMARY KEY (ProbeSetID) ) ENGINE=MyISAM DEFAULT CHARSET=utf8' 
        else: 
                sqlQuery10 += 'PRIMARY KEY (DbSnpRsID) ) ENGINE=MyISAM DEFAULT CHARSET=utf8' 
        print sqlQuery10+'\n' 
        cursor.execute(sqlQuery10) 
        sqlQuery11 = '' 
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        if aff.__len__() > 0 and unaff.__len__() > 0: 
                sqlQuery11 = 'INSERT INTO children SELECT ' 
                if DBchoice == 0: 
                        if aff.__len__() > 0: 
                                sqlQuery11 += 'affected.ProbeSetID, ' 
                        else: 
                                sqlQuery11 += 'unaffected.ProbeSetID, ' 
                else: 
                        if aff.__len__() > 0: 
                                sqlQuery11 += 'affected.DbSnpRsID, ' 
                        else: 
                                sqlQuery11 += 'unaffected.DbSnpRsID, ' 
                i = 0 
                while i < aff.__len__(): 
                        sqlQuery11 += 'affected.Code'+str(i+1)+',affected.Confidence'+str(i+1)+',' 
                        i += 1 
                i = 0 
                while i < unaff.__len__(): 
                        sqlQuery11 += 'unaffected.Code'+str(i+1)+',unaffected.Confidence'+str(i+1)+',' 
                        i += 1 
                sqlQuery11 = sqlQuery11.strip(',') 
                if DBchoice == 0: 
                        sqlQuery11 += ' from affected inner join unaffected on affected.ProbeSetID = unaffected.ProbeSetID' 
                else: 
                        sqlQuery11 += ' from affected inner join unaffected on affected.DbSnpRsID = unaffected.DbSnpRsID' 
        elif aff.__len__() > 0 and unaff.__len__() == 0: 
                sqlQuery11 = 'INSERT INTO children SELECT * from affected' 
        else: 
                sqlQuery11 = 'INSERT INTO children SELECT * from unaffected' 
                print sqlQuery11+'\n' 
        cursor.execute(sqlQuery11) 
        sqlQuery12 = 'DROP TABLE IF EXISTS affected' 
        sqlQuery13 = 'DROP TABLE IF EXISTS unaffected' 
        cursor.execute(sqlQuery12) 
        cursor.execute(sqlQuery13) 
         
        # join the parents if they exist 
        sqlQuery14 = 'SELECT FatherID,MotherID from families WHERE familyID=\''+familyID+'\'' 
        cursor.execute(sqlQuery14) 
        results = cursor.fetchall()[0] 
        sqlQuery15 = 'SELECT ' 
        fatherExists = False 
        motherExists = False 
        if results[0] != None: 
                print 'Father exists' 
                if DBchoice == 0: 
                        sqlQuery15 += results[0]+'.ProbeSetID,'+results[0]+'.Code as FatherCode,'+results[0]+'.Confidence as FatherConfidence,' 
                else: 
                        sqlQuery15 += results[0]+'.DbSnpRsID,'+results[0]+'.Code as FatherCode,'+results[0]+'.Confidence as FatherConfidence,' 
                fatherExists = True 
        if results[1] != None: 
                print 'Mother exists' 
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                motherExists = True 
                if fatherExists: 
                        sqlQuery15 += results[1]+'.Code as MotherCode,'+results[1]+'.Confidence as MotherConfidence,' 
                else: 
                        if DBchoice == 0: 
                                sqlQuery15 += results[1]+'.ProbeSetID,'+results[1]+'.Code as MotherCode,'+results[1]+'.Confidence as MotherConfidence,' 
                        else: 
                                sqlQuery15 += results[1]+'.DbSnpRsID,'+results[1]+'.Code as MotherCode,'+results[1]+'.Confidence as MotherConfidence,' 
        i = 0; 
        while i < aff.__len__() + unaff.__len__(): 
                sqlQuery15 += 'children.Code'+str(i+1)+', children.Confidence'+str(i+1)+',' 
                i += 1 
        sqlQuery15 = sqlQuery15.strip(',') 
        if DBchoice == 0: 
                if fatherExists and motherExists: 
                        sqlQuery15 += ' FROM '+results[0]+' INNER JOIN children ON '+results[0]+'.ProbeSetID = children.ProbeSetID INNER JOIN 
'+results[1]+' ON children.ProbeSetID = '+results[1]+'.ProbeSetID' 
                elif fatherExists and not motherExists: 
                        sqlQuery15 += ' FROM '+results[0]+' INNER JOIN children ON '+results[0]+'.ProbeSetID = children.ProbeSetID' 
                elif motherExists and not fatherExists: 
                        sqlQuery15 += ' FROM '+results[1]+' INNER JOIN children ON '+results[1]+'.ProbeSetID = children.ProbeSetID' 
                else: 
                        sqlQuery15 = 'SELECT * from children' 
        else: 
                if fatherExists and motherExists: 
                        sqlQuery15 += ' FROM '+results[0]+' INNER JOIN children ON '+results[0]+'.DbSnpRsID = children.DbSnpRsID INNER JOIN 
'+results[1]+' ON children.DbSnpRsID = '+results[1]+'.DbSnpRsID' 
                elif fatherExists and not motherExists: 
                        sqlQuery15 += ' FROM '+results[0]+' INNER JOIN children ON '+results[0]+'.DbSnpRsID = children.DbSnpRsID' 
                elif motherExists and not fatherExists: 
                        sqlQuery15 += ' FROM '+results[1]+' INNER JOIN children ON '+results[1]+'.DbSnpRsID = children.DbSnpRsID' 
                else: 
                        sqlQuery15 = 'SELECT * from children' 
        print sqlQuery15+'\n' 
         
        # create a table for the familyID 
        sqlQuery18 = 'DROP TABLE IF EXISTS '+familyID 
        cursor.execute(sqlQuery18) 
         
        sqlQuery2 = 'CREATE TABLE '+familyID+' ( \ 
                ProbeSetID varchar(20) NOT NULL, \ 
                DbSnpRsID varchar(20) NOT NULL, \ 
                Chromosome varchar(2) DEFAULT NULL, \ 
                ChromosomeStart varchar(7) DEFAULT NULL, \ 
                CytoBand varchar(10) DEFAULT NULL, \ 
                GeneticMap varchar(255) DEFAULT NULL,' 
         
        sqlQuery16 = 'INSERT INTO '+familyID+' SELECT annotation.ProbeSetID,\ 
        annotation.DbSnpRsID,\ 
        annotation.Chromosome,\ 
        annotation.ChromosomeStart,\ 
        annotation.Cytoband,\ 
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        annotation.GeneticMap,' 
        if fatherExists: 
                sqlQuery16 += 'temp.FatherCode,temp.FatherConfidence,' 
                sqlQuery2 += 'FatherCode varchar(7) DEFAULT NULL, FatherConfidence varchar(10) DEFAULT NULL,' 
        if motherExists: 
                sqlQuery16 += 'temp.MotherCode,temp.MotherConfidence,' 
                sqlQuery2 += 'MotherCode varchar(7) DEFAULT NULL, MotherConfidence varchar(10) DEFAULT NULL,' 
        i = 0; 
        while i < aff.__len__() + unaff.__len__(): 
                sqlQuery16 += 'temp.Code'+str(i+1)+', temp.Confidence'+str(i+1)+',' 
                sqlQuery2 += 'Code'+str(i+1)+' varchar(7) DEFAULT NULL, Confidence'+str(i+1)+' varchar(10) DEFAULT NULL,' 
                i += 1 
        sqlQuery16 += 'NULL, NULL, NULL' 
        if DBchoice == 0: 
                sqlQuery16 += ' FROM annotation INNER JOIN ('+sqlQuery15+') AS temp ON annotation.ProbeSetID = temp.ProbeSetID WHERE 
CAST(annotation.GeneticMap AS DECIMAL(20,15)) AND temp.ProbeSetID NOT LIKE \"AFFX-%\"' #ORDER BY annotation.Chromosome' 
        else: 
                sqlQuery16 += ' FROM annotation INNER JOIN ('+sqlQuery15+') AS temp ON annotation.DbSnpRsID = temp.DbSnpRsID WHERE 
CAST(annotation.GeneticMap AS DECIMAL(20,15)) #ORDER BY annotation.Chromosome' 
        sqlQuery2 += 'homoz varchar(20) DEFAULT NULL,' \ 
                'linkage varchar(20) DEFAULT NULL,' \ 
                'mendel varchar(20) DEFAULT NULL,' 
        if DBchoice == 0: 
                sqlQuery2 += ' PRIMARY KEY (ProbeSetID) \ 
                ) ENGINE=MyISAM DEFAULT CHARSET=utf8' 
        else: 
                sqlQuery2 += ' PRIMARY KEY (DbSnpRsID) \ 
                ) ENGINE=MyISAM DEFAULT CHARSET=utf8' 
        print sqlQuery2+'\n' 
        cursor.execute(sqlQuery2) 
        print sqlQuery16+'\n' 
        cursor.execute(sqlQuery16) 
         
        # sqlQuery17 = 'DROP TABLE IF EXISTS children' 
        # cursor.execute(sqlQuery17) 
        db.commit() 
        cursor.close() 
 
 
def importNewAnnotationFile(db): 
        cursor = db.cursor() 
        fileNameOK = False 
        while not fileNameOK: 
                print "Full path of text file: ", 
                filePath = sys.stdin.readline() 
                filePath = filePath.split('\n')[0] 
                if os.path.isfile(filePath): 
                        fileNameOK = True 
                else: 
                        print 'File does not exist' 
        while 1: 
                print 'Choose the Genetic Map you want to be imported (1/2/3): ', 
APPENDIX 
 
 
262 
 
                GMchoice = sys.stdin.readline() 
                GMchoice = GMchoice.split('\n')[0] 
                if GMchoice == '1' or GMchoice == '2' or GMchoice == '3': 
                        GMchoice = int(GMchoice) 
                        break 
                else: 
                        print 'Please choose 1, 2 or 3' 
        annotationFILE = open(filePath,'r') 
        outputPath = os.path.dirname(filePath) 
        if outputPath.__len__() > 0: 
                outputPath += '/'+os.path.basename(filePath).split('.csv')[0]+'_short.csv' 
        else: 
                outputPath = os.path.basename(filePath).split('.csv')[0]+'_short.csv' 
        outputFILE = open(outputPath,'w') 
        count = 0 
        sqlQuery = 'TRUNCATE TABLE annotation' 
        cursor.execute(sqlQuery) 
        for line in annotationFILE: 
                if count > 21: 
                        newline = 
line.split('\"')[1]+','+line.split('\"')[3]+','+line.split('\"')[5]+','+line.split('\"')[7]+','+line.split('\"')[13]+','+line.split('\"')[23]+'\n' 
                        outputFILE.write(newline) 
                        if count > 24 and line.split('\"')[23] != "---" and line.split('\"')[1].find('AFFX') == -1: 
                                sqlQuery2 = 'INSERT IGNORE INTO annotation VALUES ("%s", "%s", "%s", "%s", "%s", 
"%s")'%(line.split('\"')[1],line.split('\"')[3],line.split('\"')[5],line.split('\"')[7],line.split('\"')[13],line.split('\"')[23].split('///')[GMchoic
e-1].split('//')[0].strip(' ')) 
                                cursor.execute(sqlQuery2) 
                count += 1 
        outputFILE.close() 
        annotationFILE.close() 
        db.commit() 
        cursor.close() 
 
 
def makeCSVfile(db): 
        cursor = db.cursor() 
        showFamiliesQuery = 'SELECT familyID FROM families' 
        cursor.execute(showFamiliesQuery) 
        results = cursor.fetchall() 
        print "Available Families: " 
        for table in results: 
                        print table[0] 
        print "Name of Table: ", 
        tableName = sys.stdin.readline() 
        tableName = tableName.split('\n')[0] 
        found = False 
        for table in results: 
                if table[0] == tableName: 
                        found = True 
                        break 
         
        if found: 
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                fileName = tableName+'.csv' 
                outputFILE = open(fileName,'w') 
                print 'Reading from Database...' 
                sqlQuery2 = 'SELECT * from '+tableName 
                cursor.execute(sqlQuery2) 
                results = cursor.fetchall() 
                print 'Exporting Data...' 
                for row in results: 
                        # print row 
                        line = '' 
                        allNoCall = True 
                        for k in range(6,row.__len__()-3,2): 
                                if row[k] != 'NoCall': 
                                        allNoCall = False 
                                        break 
                        if not allNoCall: 
                                for field in row: 
                                        if field != None: 
                                                field = field.strip('\r') 
                                                line += field+',' 
                                        else: 
                                                line += 'NULL,' 
                                line = line.strip(',') 
                                outputFILE.write(line+'\n') 
                outputFILE.close() 
                print 'File '+fileName+' created succesfully at '+os.getcwd() 
        else: 
                print 'Table \''+tableName+'\' not found' 
        db.commit() 
        cursor.close() 
 
 
def homoz(dataList,father,mother,affected,unaffected): 
        """ 
        dataList: a list with the Codes of the family members 
        father: boolean that defines father existanse in the data 
        mother: boolean that defines mother existanse in the data 
        affected: number of affected children 
        unaffected: number of unaffected children 
        """ 
        if father and not mother: 
                dataList.insert(1,'NoCall') 
        if mother and not father: 
                dataList.insert(0,'NoCall') 
        if not mother and not father: 
                dataList.insert(0,'NoCall') 
                dataList.insert(0,'NoCall') 
        # Affected 
        callaff = 0 
        geno = '' 
        for n in range(2,2 + affected): 
                if dataList[n] != 'NoCall': 
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                        if geno == '': # first affected 
                                geno = dataList[n] 
                        elif geno != dataList[n]: 
                                return 'EXAFF' 
                        callaff += 1 
        if geno == 'AB': 
                return 'EXAUTO' 
                 
        # Parents 
        hetparent = 0 
        for n in range(0,2): 
                if dataList[n] == 'AB': 
                        hetparent += 1 
        meioses = hetparent * (callaff - 1) 
        if hetparent < 2: 
                return 'LINK_'+str(meioses) 
                 
        # Unaffected 
        callunaff = 0 
        for n in range(2 + affected,2 + affected + unaffected): 
                if dataList[n] != 'NoCall': 
                        if dataList[n] == geno: 
                                return 'EXUNAFF' 
                        callunaff += 1 
        meioses = meioses + 2 * callunaff 
        return 'LINK_'+str(meioses) 
 
 
def linkage(dataList,father,mother,affected,unaffected): 
        """ 
        dataList: a list with the Codes of the family members 
        father: boolean that defines father existanse in the data 
        mother: boolean that defines mother existanse in the data 
        affected: number of affected children 
        unaffected: number of unaffected children 
        """ 
        if father and not mother: 
                dataList.insert(1,'NoCall') 
        if mother and not father: 
                dataList.insert(0,'NoCall') 
        if not mother and not father: 
                dataList.insert(0,'NoCall') 
                dataList.insert(0,'NoCall') 
         
        # Affected 
        geno = '' 
        callaff = 0 
        for n in range(2,2 + affected): 
                if dataList[n] != 'NoCall': 
                        if geno == '': 
                                geno = dataList[n] 
                        elif geno != dataList[n]: 
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                                return 'EXAFF' 
                        callaff += 1 
         
        # Parents 
        hetparent = 0 
        for n in range(0,2): 
                if dataList[n] == 'AB': 
                        hetparent += 1 
         
        meioses = hetparent * (callaff - 1) 
        if hetparent < 2: 
                return 'LINK_'+str(meioses) 
         
        # Unaffected 
        callunaff = 0 
        for n in range(2 + affected,2 + affected + unaffected): 
                if dataList[n] != 'NoCall': 
                        if dataList[n] == geno and geno != 'AB': 
                                return 'EXUNAFF' 
                        callunaff += 1 
        meioses = meioses + 2 * callunaff 
        return 'LINK_'+str(meioses) 
 
 
def mendel(dataList,father,mother): 
        if father and not mother: 
                dataList.insert(1,'NoCall') 
        if mother and not father: 
                dataList.insert(0,'NoCall') 
        if not mother and not father: 
                dataList.insert(0,'NoCall') 
                dataList.insert(0,'NoCall') 
                 
        dad1 = '' 
        mom1 = '' 
        dad2 = '' 
        mom2 = '' 
         
        if dataList[0] == 'NoCall': 
                dad1 = 'NoCall' 
        else: 
                dad1 = dataList[0][0:1] 
                dad2 = dataList[0][1:2] 
        if dataList[1] == 'NoCall': 
                mom1 = 'NoCall' 
        else: 
                mom1 = dataList[1][0:1] 
                mom2 = dataList[1][1:2] 
         
        # loop through children 
        errors = 0 
        a1 = '' 
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        a2 = '' 
        flag = '' 
        for n in range(2,dataList.__len__()): 
                if dataList[n] != 'NoCall': 
                        a1 = dataList[n][0:1] 
                        a2 = dataList[n][1:2] 
                        flag = 'Error' 
                        # trial one a1 from dad, a2 from mom 
                        if dad1 == 'NoCall' or a1 == dad1 or a1 == dad2: 
                                if mom1 == 'NoCall' or a2 == mom1 or a2 == mom2: 
                                        flag = 'OK' 
                        # trial two a2 from dad and a1 from mom 
                        if dad1 == 'NoCall' or a2 == dad1 or a2 == dad2: 
                                if mom1 == 'NoCall' or a1 == mom1 or a1 == mom2: 
                                        flag = 'OK' 
                        if flag == 'Error': 
                                errors += 1 
        if errors == 0: 
                return 'MenOK' 
        else: 
                return 'Error_'+str(errors) 
 
 
def runFunction(db,func,DBchoice,famID=-1): 
        cursor = db.cursor() 
        familyID = '' 
        if famID == -1: 
                sqlQuery = 'SELECT familyID FROM families' 
                cursor.execute(sqlQuery) 
                results = cursor.fetchall() 
                print 'Available families: ' 
                found = False 
                while not found: 
                        for table in results: 
                                print table[0] 
                        while 1: 
                                print "Select Family ID: ", 
                                familyID = sys.stdin.readline() 
                                try: 
                                        familyID = int(familyID.split('\n')[0]) 
                                        print 'Numeric values not allowed' 
                                except Exception, e: 
                                        familyID = familyID.split('\n')[0] 
                                        break 
                        for table in results: 
                                if table[0] == familyID: 
                                        found = True 
                                        break 
                        if not found: 
                                print 'Not a valid Family ID:' 
        else: 
                familyID = famID 
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        if func != 3: 
                while 1: 
                        print "Threshold: ", 
                        Threshold = sys.stdin.readline() 
                        try: 
                                Threshold = float(Threshold.split('\n')[0]) 
                                break 
                        except Exception, e: 
                                print 'Needs to be numeric' 
        print 'Loading data from the database...' 
        affected = 0 
        unaffected = 0 
        father = False 
        mother = False 
        sqlQuery2 = 'SELECT * FROM families_status WHERE familyID=\''+familyID+'\'' 
        cursor.execute(sqlQuery2) 
        results = cursor.fetchall()[0] 
        affected = results.count('aff') 
        unaffected = results.count('unaff') 
        sqlQuery3 = 'SELECT * FROM families WHERE familyID=\''+familyID+'\'' 
        cursor.execute(sqlQuery3) 
        results = cursor.fetchall()[0] 
        if results[1] != None: 
                father = True 
        if results[2] != None: 
                mother = True 
        sqlQuery5 = 'SELECT DISTINCT Chromosome FROM '+familyID+' WHERE Chromosome <> \"--\" AND Chromosome <> \"MT\" ORDER BY Chromosome' 
        cursor.execute(sqlQuery5) 
        chromosomeList = cursor.fetchall() 
        summaryFileName = familyID 
        resultTableName = familyID 
        countMembers = 0 
        if father: 
                countMembers += 1 
        if mother: 
                countMembers += 1 
        countMembers += affected + unaffected 
        countMembers *= 2 
        if func == 1: 
                summaryFileName += '_homoz_summary.csv' 
                resultTableName += '_homoz' 
        else: 
                summaryFileName += '_linkage_summary.csv' 
                resultTableName += '_linkage' 
        summaryFILE = open(summaryFileName,'w') 
        dropTableQuery = 'DROP TABLE IF EXISTS '+resultTableName 
        cursor.execute(dropTableQuery) 
        createResultTableQuery = 'CREATE TABLE '+resultTableName+' ( \ 
                  id int(11) NOT NULL AUTO_INCREMENT,\ 
                  ProbeSetID varchar(20) NOT NULL,\ 
                  DbSnpRsID varchar(20) NOT NULL,\ 
                  Chromosome varchar(2) NOT NULL,\ 
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                  GeneticMap varchar(255) NOT NULL,\ 
                  GeneticDifference varchar(255) DEFAULT NULL,\ 
                  PRIMARY KEY (id)\ 
                ) ENGINE=MyISAM DEFAULT CHARSET=utf8' 
        cursor.execute(createResultTableQuery) 
        if func == 3: 
                print 'Running mendel...' 
        for chromosome in chromosomeList: 
                GeneticDifference = 0 
                countRowsInbetween = 0 
                chromosome = chromosome[0] 
                if func == 1: 
                        print 'Running homoz for chromosome '+chromosome+'...' 
                if func == 2: 
                        print 'Running linkage for chromosome '+chromosome+'...' 
                sqlQuery6 = 'SELECT * FROM '+familyID+' WHERE Chromosome=\''+chromosome+'\' ORDER BY CAST(GeneticMap AS DECIMAL(20,15))' 
                cursor.execute(sqlQuery6) 
                results = cursor.fetchall() 
                firstGMValue = 5000000.0 
                isFirstLINK = False 
                lastGMValue = 5000000.0 
                countRow = -1 
                firstRow = -1 
                notAllLINK = False 
                for row in results: 
                        countRow += 1 
                        i = 6 
                        dataList = [] 
                        while i < 6 + countMembers: 
                                dataList.append(row[i]) 
                                i += 2 
                        func_result = '-89778' 
                        if func == 1: 
                                func_result = homoz(dataList,father,mother,affected,unaffected) 
                                if DBchoice == 0: 
                                        sqlQuery7 = 'UPDATE '+familyID+' SET homoz=\''+func_result+'\' WHERE ProbeSetID=\''+row[0]+'\'' 
                                else: 
                                        sqlQuery7 = 'UPDATE '+familyID+' SET homoz=\''+func_result+'\' WHERE DbSnpRsID=\''+row[1]+'\'' 
                                cursor.execute(sqlQuery7) 
                        elif func == 2: 
                                func_result = linkage(dataList,father,mother,affected,unaffected) 
                                if DBchoice == 0: 
                                        sqlQuery7 = 'UPDATE '+familyID+' SET linkage=\''+func_result+'\' WHERE ProbeSetID=\''+row[0]+'\'' 
                                else: 
                                        sqlQuery7 = 'UPDATE '+familyID+' SET linkage=\''+func_result+'\' WHERE DbSnpRsID=\''+row[1]+'\'' 
                                cursor.execute(sqlQuery7) 
                        else: 
                                func_result = mendel(dataList,father,mother) 
                                if DBchoice == 0: 
                                        sqlQuery7 = 'UPDATE '+familyID+' SET mendel=\''+func_result+'\' WHERE ProbeSetID=\''+row[0]+'\'' 
                                else: 
                                        sqlQuery7 = 'UPDATE '+familyID+' SET mendel=\''+func_result+'\' WHERE DbSnpRsID=\''+row[1]+'\'' 
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                                cursor.execute(sqlQuery7) 
                        if func == 1 or func == 2: 
                                if func_result.find('LINK_') > -1: 
                                        currentGMValue = float(row[5]) 
                                        if isFirstLINK == False: 
                                                firstGMValue = currentGMValue 
                                                firstRow = countRow 
                                                isFirstLINK = True 
                                        lastGMValue = currentGMValue 
                                        countRowsInbetween += 1 
                                else: 
                                        notAllLINK = True 
                                        GeneticDifference = lastGMValue - firstGMValue 
                                        firstGMValue = 5000000.0 
                                        lastGMValue = 5000000.0 
                                        if GeneticDifference >= Threshold: 
                                                sqlQuery7 = 'SELECT * FROM '+familyID+' WHERE Chromosome=\''+chromosome+'\' ORDER BY CAST(GeneticMap AS 
DECIMAL(20,15)) LIMIT '+str(firstRow)+','+str(countRowsInbetween) 
                                                print 'Found one area with '+str(countRowsInbetween)+' rows and Genetic difference: 
'+str(GeneticDifference) 
                                                cursor.execute(sqlQuery7) 
                                                interestingRows = cursor.fetchall() 
                                                line = '' 
                                                for field in interestingRows[0]: 
                                                        if field != None: 
                                                                field = field.strip('\r') 
                                                                line += field+',' 
                                                line = line.strip(',') 
                                                summaryFILE.write(line+'\n') 
                                                line = line.split(',') 
                                                insertResultsQuery = 'INSERT INTO '+resultTableName+' VALUES (null, \"'+line[0]+'\", \"'+line[1]+'\", 
\"'+line[2]+'\", \"'+line[5]+'\", null)' 
                                                cursor.execute(insertResultsQuery) 
                                                line = '' 
                                                for field in interestingRows[-1]: 
                                                        if field != None: 
                                                                field = field.strip('\r') 
                                                                line += field+',' 
                                                line += str(GeneticDifference) 
                                                summaryFILE.write(line+'\n\n') 
                                                line = line.split(',') 
                                                insertResultsQuery = 'INSERT INTO '+resultTableName+' VALUES (null, \"'+line[0]+'\", \"'+line[1]+'\", 
\"'+line[2]+'\", \"'+line[5]+'\", \"'+str(GeneticDifference)+'\")' 
                                                cursor.execute(insertResultsQuery) 
                                        isFirstLINK = False 
                                        firstRow = -1 
                                        GeneticDifference = 0 
                                        countRowsInbetween = 0 
                # check in case there is an interesting area ending at the end of the chromosome 
                if func_result.find('LINK_') > -1: 
                        if not notAllLINK: 
                                GeneticDifference = float(results[-1][5]) - float(results[0][5]) 
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                                firstRow = 0 
                        if GeneticDifference >= Threshold: 
                                sqlQuery7 = 'SELECT * FROM '+familyID+' WHERE Chromosome=\''+chromosome+'\' ORDER BY CAST(GeneticMap AS DECIMAL(20,15)) 
LIMIT '+str(firstRow)+','+str(countRowsInbetween) 
                                print 'Found one area with '+str(countRowsInbetween)+' rows and Genetic difference: '+str(GeneticDifference) 
                                cursor.execute(sqlQuery7) 
                                interestingRows = cursor.fetchall() 
                                line = '' 
                                for field in interestingRows[0]: 
                                        if field != None: 
                                                field = field.strip('\r') 
                                                line += field+',' 
                                line = line.strip(',') 
                                summaryFILE.write(line+'\n') 
                                line = line.split(',') 
                                insertResultsQuery = 'INSERT INTO '+resultTableName+' VALUES (null, \"'+line[0]+'\", \"'+line[1]+'\", \"'+line[2]+'\", 
\"'+line[5]+'\", null)' 
                                cursor.execute(insertResultsQuery) 
                                line = '' 
                                for field in interestingRows[-1]: 
                                        if field != None: 
                                                field = field.strip('\r') 
                                                line += field+',' 
                                line += str(GeneticDifference) 
                                summaryFILE.write(line+'\n\n') 
                                line = line.split(',') 
                                insertResultsQuery = 'INSERT INTO '+resultTableName+' VALUES (null, \"'+line[0]+'\", \"'+line[1]+'\", \"'+line[2]+'\", 
\"'+line[5]+'\", \"'+str(GeneticDifference)+'\")' 
                                cursor.execute(insertResultsQuery) 
        summaryFILE.close() 
        print 'File '+summaryFileName+' created succesfully at '+os.getcwd() 
        db.commit() 
        cursor.close() 
 
 
def deleteIndividual(db): 
        cursor = db.cursor() 
        getAllFamiliesQuery = 'SELECT * from families' 
        cursor.execute(getAllFamiliesQuery) 
        families = cursor.fetchall() 
        for family in families: 
                for member in range(1,13): 
                        if family[member] != None: 
                                print family[member] 
        while 1: 
                print "Individual ID: ", 
                individualID = sys.stdin.readline() 
                try: 
                        individualID = int(individualID.split('\n')[0]) 
                        print 'Numeric values not allowed' 
                except Exception, e: 
                        individualID = individualID.split('\n')[0] 
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                        if checkTable(db,individualID) == 1: 
                                break 
                        else: 
                                print 'Individual does not exist' 
        deleteTableQuery = 'DROP TABLE '+individualID 
        cursor.execute(deleteTableQuery) 
        column_name  = '' 
        child = False 
        familyID = '' 
        member = 0 
        for family in families: 
                for member in range(1,13): 
                        if family[member] == individualID: 
                                familyID = family[0] 
                                if member == 1: 
                                        column_name = 'FatherID' 
                                elif member == 2: 
                                        column_name = 'MotherID' 
                                else: 
                                        column_name = 'IndividualID'+str(member-2) 
                                        child = True 
                                break 
        if child: 
                familyList = [] 
                for i in range(0,member): 
                        familyList.append(family[i]) 
                for i in range(member+1,family.__len__()): 
                        familyList.append(family[i]) 
                familyList.append(None) 
                deleteFamilyQuery = 'DELETE FROM families WHERE FamilyID=\"'+familyID+'\"' 
                cursor.execute(deleteFamilyQuery) 
                insertFamilyQuery = 'INSERT INTO families VALUES (' 
                for f in familyList: 
                        if f == None: 
                                insertFamilyQuery+='null,' 
                        else: 
                                insertFamilyQuery+='\"'+str(f)+'\"' 
                                insertFamilyQuery+=',' 
                insertFamilyQuery = insertFamilyQuery.strip(',') 
                insertFamilyQuery+=')' 
                cursor.execute(insertFamilyQuery) 
                member-=2 
                getFamilyStatusQuery = 'SELECT * from families_status WHERE FamilyID=\"'+familyID+'\"' 
                cursor.execute(getFamilyStatusQuery) 
                family = cursor.fetchall()[0] 
                familyList = [] 
                for i in range(0,member): 
                        familyList.append(family[i]) 
                for i in range(member+1,family.__len__()): 
                        familyList.append(family[i]) 
                familyList.append(None) 
                deleteFamilyQuery = 'DELETE FROM families_status WHERE FamilyID=\"'+familyID+'\"' 
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                cursor.execute(deleteFamilyQuery) 
                insertFamilyQuery = 'INSERT INTO families_status VALUES (' 
                for f in familyList: 
                        if f == None: 
                                insertFamilyQuery+='null,' 
                        else: 
                                insertFamilyQuery+='\"'+str(f)+'\"' 
                                insertFamilyQuery+=',' 
                insertFamilyQuery = insertFamilyQuery.strip(',') 
                insertFamilyQuery+=')' 
                cursor.execute(insertFamilyQuery) 
        else: 
                updateParentQuery = 'UPDATE families SET '+column_name+'=null WHERE FamilyID=\"'+familyID+'\"' 
                cursor.execute(updateParentQuery) 
        db.commit() 
        cursor.close() 
 
 
def deleteFamily(db): 
        cursor = db.cursor() 
        sqlQuery = 'SELECT familyID FROM families' 
        cursor.execute(sqlQuery) 
        results = cursor.fetchall() 
        print 'Available families: ' 
        found = False 
        while not found: 
                for table in results: 
                        print table[0] 
                while 1: 
                        print "Select Family ID: ", 
                        familyID = sys.stdin.readline() 
                        try: 
                                familyID = int(familyID.split('\n')[0]) 
                                print 'Numeric values not allowed' 
                        except Exception, e: 
                                familyID = familyID.split('\n')[0] 
                                break 
                for table in results: 
                        if table[0] == familyID: 
                                found = True 
                                break 
                if not found: 
                        print 'Not a valid Family ID:' 
        getAllIndividuals = 'SELECT * FROM families WHERE FamilyID=\"'+familyID+'\"' 
        cursor.execute(getAllIndividuals) 
        family = cursor.fetchall()[0] 
        for i in range(1,family.__len__()): 
                if family[i] != None: 
                        deleteTableQuery = 'DROP TABLE '+family[i] 
                        cursor.execute(deleteTableQuery) 
        deleteFamilyEntry = 'DELETE FROM families WHERE FamilyID=\"'+familyID+'\"' 
        cursor.execute(deleteFamilyEntry) 
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        deleteFamilyStatusEntry = 'DELETE FROM families_status WHERE FamilyID=\"'+familyID+'\"' 
        cursor.execute(deleteFamilyStatusEntry) 
        deleteTableQuery = 'DROP TABLE '+familyID 
        cursor.execute(deleteTableQuery) 
        db.commit() 
        cursor.close() 
 
 
def compareFamilies(db,DBchoice): 
        cursor = db.cursor() 
        sqlQuery = 'SELECT familyID FROM families' 
        cursor.execute(sqlQuery) 
        results = cursor.fetchall() 
        print 'Available families: ' 
        found = False 
        while not found: 
                for table in results: 
                        print table[0] 
                while 1: 
                        print "Select the first Family ID: ", 
                        familyID1 = sys.stdin.readline() 
                        try: 
                                familyID1 = int(familyID.split('\n')[0]) 
                                print 'Numeric values not allowed' 
                        except Exception, e: 
                                familyID1 = familyID1.split('\n')[0] 
                                break 
                for table in results: 
                        if table[0] == familyID1: 
                                found = True 
                                break 
                if not found: 
                        print 'Not a valid Family ID:' 
        found = False 
        fList = [] 
        for table in results: 
                fList.append(table[0]) 
        fList.remove(familyID1) 
        while not found: 
                for table in fList: 
                        print table 
                while 1: 
                        print "Select the second Family ID: ", 
                        familyID2 = sys.stdin.readline() 
                        try: 
                                familyID2 = int(familyID.split('\n')[0]) 
                                print 'Numeric values not allowed' 
                        except Exception, e: 
                                familyID2 = familyID2.split('\n')[0] 
                                break 
                for table in fList: 
                        if table == familyID2: 
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                                found = True 
                                break 
                if not found: 
                        print 'Not a valid Family ID:' 
        while 1: 
                print "Compare them based on: " 
                print "1. homoz" 
                print "2. linkage" 
                print "Your Choice: ", 
                choice = sys.stdin.readline() 
                choice = choice.split('\n')[0] 
                choiceS = '' 
                if choice == '1': 
                        choiceS = 'homoz' 
                        break 
                elif choice == '2': 
                        choiceS = 'linkage' 
                        break 
                else: 
                        print "Please chose one of the following" 
        family1R = familyID1+'_'+choiceS 
        family2R = familyID2+'_'+choiceS 
        if checkTable(db,family1R) == 0: 
                print choiceS+' has not run for family '+familyID1+'. Run now?' 
                while 1: 
                        print '1. Run '+choiceS+' for family '+familyID1 
                        print '2. Exit' 
                        print "Your Choice: ", 
                        yc = sys.stdin.readline() 
                        yc = yc.split('\n')[0] 
                        if yc == '1': 
                                runFunction(db,int(choice),DBchoice,familyID1) 
                                break 
                        elif yc == '2': 
                                sys.exit(0) 
                                break 
                        else: 
                                print "Please chose one of the following" 
        if checkTable(db,family2R) == 0: 
                print choiceS+' has not run for family '+familyID2+'. Run now?' 
                while 1: 
                        print '1. Run '+choiceS+' for family '+familyID2 
                        print '2. Exit' 
                        print "Your Choice: ", 
                        yc = sys.stdin.readline() 
                        yc = yc.split('\n')[0] 
                        if yc == '1': 
                                runFunction(db,int(choice),DBchoice,familyID2) 
                                break 
                        elif yc == '2': 
                                sys.exit(0) 
                                break 
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                        else: 
                                print "Please chose one of the following" 
        print 'About to compare family '+familyID1+' with family '+familyID2+' based on '+choiceS 
        sqlQuery5 = 'SELECT DISTINCT Chromosome FROM '+family1R+' WHERE Chromosome IN (SELECT DISTINCT Chromosome FROM '+family2R+')' 
        cursor.execute(sqlQuery5) 
        chromosomeList = cursor.fetchall() 
        resultsFile = 'results_'+familyID1+'_'+familyID2+'_'+choiceS+'.csv' 
        resultsFILE = open(resultsFile, 'w') 
        line = 'Chromosome,GeneticMap Start,GeneticMap End,Genetic Difference\n' 
        resultsFILE.write(line) 
        for chromosome in chromosomeList: 
                chromosome = chromosome[0] 
                fam1ResultsQuery = 'SELECT ProbeSetID,DbSnpRsID,Chromosome,GeneticMap FROM '+family1R+' WHERE Chromosome=\"'+chromosome+'\" ORDER BY 
CAST(GeneticMap AS DECIMAL(20,15))' 
                cursor.execute(fam1ResultsQuery) 
                fam1Results = cursor.fetchall() 
                fam2ResultsQuery = 'SELECT ProbeSetID,DbSnpRsID,Chromosome,GeneticMap FROM '+family2R+' WHERE Chromosome=\"'+chromosome+'\" ORDER BY 
CAST(GeneticMap AS DECIMAL(20,15))' 
                cursor.execute(fam2ResultsQuery) 
                fam2Results = cursor.fetchall() 
                # print fam1Results 
                i = 0 
                fam1R = [] 
                fam2R = [] 
                while i < fam1Results.__len__() - 1: 
                        fam1R.append((fam1Results[i],fam1Results[i+1])) 
                        i+=2 
                i = 0 
                while i < fam2Results.__len__() - 1: 
                        fam2R.append((fam2Results[i],fam2Results[i+1])) 
                        i+=2 
                fam = fam1R 
                fam.extend(fam2R) 
                def compareThem(a,b): 
                        return int(float(a[0][3]) - float(b[0][3])) 
                 
                fam = sorted(fam,cmp=compareThem) 
                j = 0 
                while j < fam.__len__() - 1: 
                        highEnd = float(fam[j][1][3]) 
                        nextLow = float(fam[j+1][0][3]) 
                        nextHigh = float(fam[j+1][1][3]) 
                        count = 0 
                        while highEnd >= nextLow: 
                                if highEnd >= nextHigh: 
                                        print 'Found Common: '+str(nextLow)+' - '+str(nextHigh)+' for Chromosome '+chromosome+' with Genetic 
Difference: '+str(nextHigh - nextLow) 
                                        line = chromosome+','+str(nextLow)+','+str(nextHigh)+','+str(nextHigh - nextLow)+'\n' 
                                        resultsFILE.write(line) 
                                else: 
                                        print 'Found Common: '+str(nextLow)+' - '+str(highEnd)+' for Chromosome '+chromosome+' with Genetic Difference: 
'+str(highEnd - nextLow) 
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                                        line = chromosome+','+str(nextLow)+','+str(nextHigh)+','+str(nextHigh - nextLow)+'\n' 
                                        resultsFILE.write(line) 
                                j += 1 
                                count += 1 
                                try: 
                                        nextLow = float(fam[j+1][0][3]) 
                                        nextHigh = float(fam[j+1][1][3]) 
                                except Exception, e: 
                                        break 
                        j = j + 1 - count 
        resultsFILE.close() 
        print 'Comparison Results file '+resultsFile+' created succesfully at '+os.getcwd() 
        db.commit() 
        cursor.close() 
 
 
def main(): 
        # database credentials and information  
        try: 
                db = MySQLdb.connect(host="localhost", user="root", passwd="root", db="panos2", local_infile=1) 
        except Exception, e: 
                print 'Cannot connect to MYSQL server. Make sure its running and check your settings.' 
                sys.exit(-1) 
        DBchoice = 0 
        if sys.argv.__len__() == 2: 
                if sys.argv[1] == '--rs': 
                        try: 
                                db = MySQLdb.connect(host="localhost", user="root", passwd="root", db="panos3", local_infile=1) 
                        except Exception, e: 
                                print 'Cannot connect to MYSQL server. Make sure its running and check your settings.' 
                                sys.exit(-1) 
                        DBchoice = 1 
        # if the basic tables dont exist in the database initialize the database by creating them 
        if checkTable(db,'families') == 0 and checkTable(db,'families_status') == 0 and checkTable(db,'annotation') == 0: 
                print "Initializing database..." 
                initialDBSetup(db,DBchoice) 
                print "Done" 
        else: 
                print "Database already initialized" 
         
        # print the menu and get the user's choice 
        choice = printOptions() 
        if choice == 1: 
                # import new family member 
                importFamilyMember(db,DBchoice) 
        elif choice == 2: 
                # generate input data for a family 
                generateInputData(db,DBchoice) 
        elif choice == 3: 
                # run homoz or linkage or mendel for a family 
                while 1: 
                        print "Which function do you want to run?: " 
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                        print "1. homoz" 
                        print "2. linkage" 
                        print "3. mendel" 
                        print "4. homoz and linkage" 
                        print "Your Choice: ", 
                        choice = sys.stdin.readline() 
                        choice = choice.split('\n')[0] 
                        if choice == '1' or choice == '2' or choice == '3': 
                                runFunction(db,int(choice),DBchoice) 
                                break 
                        elif choice == '4': 
                                runFunction(db,1,DBchoice) 
                                runFunction(db,2,DBchoice) 
                                break 
                        else: 
                                print "Please chose one of the following" 
        elif choice == 4: 
                # dump the data to a CSV file 
                makeCSVfile(db) 
        elif choice == 5: 
                compareFamilies(db,DBchoice) 
        elif choice == 6: 
                # import a new annotation file 
                importNewAnnotationFile(db) 
        elif choice == 7: 
                while 1: 
                        print "What do you want to delete?: " 
                        print "1. individual" 
                        print "2. whole family" 
                        print "Your Choice: ", 
                        choice = sys.stdin.readline() 
                        choice = choice.split('\n')[0] 
                        if choice == '1': 
                                deleteIndividual(db) 
                                break 
                        elif choice == '2': 
                                deleteFamily(db) 
                                break 
                        else: 
                                print "Please chose one of the following" 
        elif choice == 8: 
                print 'Quiting...' 
                sys.exit(0) 
        else: 
                print "WRONG INPUT" 
        db.close() 
 
 
if __name__ == '__main__': 
        main() 
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